<?xml version="1.0" encoding="UTF-8"?>
<!-- This is a template for a FHIR resource, and needs items (marked with "${}") replacing to make a real instance -->
<!-- The resulting instance is a Bundle of Bundles, each of which is a document (having a Composition, and supporting resources) -->
<!-- 2020-02-22 -->
<!-- This is for FHIR version R5 Preview 2 (May 2020) -->
<Bundle xmlns="http://hl7.org/fhir">
	<type value="collection"/>
	<!-- Repeat at this level per document -->
	<entry>
		<fullUrl value="urn:uuid:f05f046d-ad74-4533-8456-63aa097ac0a0"/>
		<!-- Top level of each document is a also FHIR Bundle, of type "document"
		 see http://hl7.org/fhir/documents.html, http://hl7.org/fhir/bundle.html
	 	 All the other resources for this document are within this. -->
		<resource>
            <Bundle>
            	<!-- When PUTing, some servers mandate an id here to match the existing id -->
            	<id value="091d05f4-f7e7-49c2-afc4-96462659c729"/>
				<!-- document bundles must have an identifier (bdl-9) -->
				<identifier>
					<!-- possibly different identifier types may be needed here -->
					<system value="http://ema.europa.eu/fhir/identifier/documentid"/>
					<value value="${instance.bundle[n].Identifier}"/>
				</identifier>
				<!-- fixed code -->
				<type value="document" /> 
            	<!-- document bundles must have a date (bdl-10) -->
            	<timestamp value="2021-05-11T00:32:01Z"/>
				<!-- a repeating set of entry elements, each with a FHIR resource inside -->
				<entry>
					<!-- fullUrl is mandatory for each entry in document Bundle. It is a random uuid. http://build.fhir.org/bundle.html#bundle-unique -->
					<fullUrl value="urn:uuid:e75083ce-72e1-4e30-bc4a-bee9e570df61"/>
					<resource>
						<!-- the first resource must be Composition (bdl-11) -->
						<!-- This is the overall document structure. -->
						<!-- see definition http://hl7.org/fhir/composition.html, and similar for other resources -->
                        <Composition>
                        	<!-- images if requied within html text of this document -->
							
              
              <contained>
                          <Binary>
                            <id value="stylesheet0"/>
                            <!-- example format -->
                            <contentType value="stylesheet/css"/>
                            <!-- data is base 64 encoded, actual bytes of the image png file -->
                            <data value="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"/>
                          </Binary>
                        </contained>
                        <!-- this exension is necessary per image -->
                        <extension url="http://ema.europa.eu/fhir/extension/dummyValidationReference">
                          <valueReference>
                            <reference value="#stylesheet0"/>
                          </valueReference>
                        </extension>
              
              <status value="final"/>
							<!-- document type -->
							<type>
								<coding>
									<system value="http://spor.ema.europa.eu/v1/lists/100000155531"/>
									<code value="${document[n].documentTypeCode}"/>
									<display value="${document[n].documentTypeDisplay}"/>
								</coding>
							</type>
							<subject>
								<!-- links to the List resource in this bundle - local url format -->
								<reference value="[]"/> <!-- local url format -->
								<!--reference value="${instance.bundle[n].listUuid}"/--> <!-- uuid url format. Possible alternate format may be neeed -->
							</subject>
                        	<!-- mandatory date of the document -->
                        	<date value="2021-02-01"/>
							<author>
								<identifier>
									<system value="http://spor.ema.europa.eu/v1/locations" />
									<value value="" />
								</identifier>
							</author>
                        	<title value="${document[n].title}"/>
							<relatesTo>
								<code value="appends"/>
								<targetReference>
									<!-- reference to another Composition -->
									<reference value="${document[n].relatesTo}"/>
								</targetReference>
							</relatesTo>
							<!-- main sections of the document, to follow the QRD template -->
	               			
<section>
	
		
			<title value="КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="center" class="MsoNormal" style="text-align:center"><span lang="BG"> </span></p><p align="center" class="MsoNormal" style="text-align:center"><b><span lang="BG"> </span></b></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG"> </span></p><p align="center" class="MsoNormal" style="text-align:center"><span lang="BG"> </span></p><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:green'><br clear="all" style="page-break-before:always"/> </span><br clear="all" style="page-break-before:always"/>
			</div>
		</text>
		
		
    	    
				
			    
						
		               
<section>
			<title value="1.       ИМЕ НА ЛЕКАРСТВЕНИЯ ПРОДУКТ"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Kalydeco </span><span lang="EN-GB">7</span><span lang="BG">5 mg филмирани таблетки</span></p><p class="MsoNormal"><span lang="BG">Kalydeco 150 mg филмирани таблетки</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="2.       КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Kalydeco </span><span lang="EN-GB">7</span><span lang="BG">5 mg филмирани таблетки</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Всяка филмирана таблетка съдържа </span><span lang="EN-GB">7</span><span lang="BG">5 mg ивакафтор (ivacaftor). </span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG">Помощно вещество с известно действие</span></i></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Всяка филмирана таблетка съдържа </span><span lang="EN-GB">83</span><span lang="BG">,</span><span lang="EN-GB">6</span><span lang="BG"> mg лактоза монохидрат.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Kalydeco 150 mg филмирани таблетки</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Всяка филмирана таблетка съдържа 150 mg ивакафтор (ivacaftor). </span></p><p class="MsoNormal"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG">Помощно вещество с известно действие</span></i></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Всяка филмирана таблетка съдържа 167,2 mg лактоза монохидрат.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">За пълния списък на помощните вещества вижте точка 6.1.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="3.       ЛЕКАРСТВЕНА ФОРМА"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><span lang="BG"> </span></p><p class="MsoNormal" style="text-autospace:none"><span lang="BG">Филмирана таблетка (таблетка)</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Kalydeco </span><span lang="EN-GB">7</span><span lang="BG">5 mg филмирани таблетки</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Светлосини, филмирани таблетки с формата на капсула, с отпечатано „V 75” с черно мастило от едната страна и без надпис от другата страна </span><span lang="BG" style="color:black">(1</span><span lang="EN-GB" style="color:black">2</span><span lang="BG" style="color:black">,</span><span lang="EN-GB" style="color:black">7</span><span lang="BG" style="color:black"> mm x </span><span lang="EN-GB" style="color:black">6</span><span lang="BG" style="color:black">,</span><span lang="EN-GB" style="color:black">8</span><span lang="BG" style="color:black"> mm таблетка с модифицирана форма)</span><span lang="BG">.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Kalydeco 150 mg филмирани таблетки</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Светлосини, филмирани таблетки с формата на капсула, с отпечатано „V 150” с черно мастило от едната страна и без надпис от другата страна </span><span lang="BG" style="color:black">(16,5 mm x 8,4 mm таблетка с модифицирана форма)</span><span lang="BG">.</span></p><p class="MsoNormal" style="text-autospace:none"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="4.       КЛИНИЧНИ ДАННИ"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="4.1     Терапевтични показания"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Таблетките Kalydeco са показани:</span></p><p class="labeltext" style="margin-left:.5in;text-indent:-.25in"><span lang="BG">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG" style='font-family:"Times New Roman",serif'>Като монотерапия за лечение на </span><span lang="BG" style='font-family:"Times New Roman",serif'>възрастни, юноши и деца на възраст 6 и повече години и с тегло 25</span><span style='font-family:"Times New Roman",serif'> kg</span><span lang="BG" style='font-family:"Times New Roman",serif'> или повече с кистозна фиброза (КФ), които имат<i> </i></span><i><span style='font-family:"Times New Roman",serif'>R117H CFTR</span></i><i><span style='font-family:"Times New Roman",serif'> </span></i><span lang="BG" style='font-family:"Times New Roman",serif'>мутация</span><span lang="BG" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>или една от следните водещи до каналопатии мутации (клас III) в гена на трансмембранния регулатор на проводимостта при кистозна фиброза (</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>cystic fibrosis transmembrane conductance regulator</span><span lang="BG" style='font-family:"Times New Roman",serif'>,</span><span lang="BG" style='font-family:"Times New Roman",serif'> </span><i><span lang="BG" style='font-family:"Times New Roman",serif'>CFTR</span></i><span lang="BG" style='font-family:"Times New Roman",serif'>): <i>G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N </i>или<i> S549R</i> (вж. точка 4.4 и 5.1).</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoListParagraph" style="text-indent:-.25in"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">В</span><span lang="BG"> комбинирана схема с тезакафтор/ивакафтор таблетки за лечението на </span><span lang="BG">възрастни,</span><span lang="BG"> </span><span lang="BG">юноши и деца </span><span lang="BG">на възраст 6 и повече години с кистозна фиброза (КФ), които са хомозиготни за мутацията </span><i><span lang="EN-GB">F</span></i><i><span lang="BG">508</span></i><i><span lang="EN-GB">del</span></i><span lang="BG"> или които са хетерозиготни за мутацията </span><i><span lang="EN-GB">F</span></i><i><span lang="BG">508</span></i><i><span lang="EN-GB">del</span></i><span lang="BG">, и имат една от следните мутации в </span><i><span lang="EN-GB">CFTR</span></i><span lang="BG"> гена: </span><i><span lang="EN-GB">P</span></i><i><span lang="BG">67</span></i><i><span lang="EN-GB">L</span></i><i><span lang="BG">, </span></i><i><span lang="EN-GB">R</span></i><i><span lang="BG">117</span></i><i><span lang="EN-GB">C</span></i><i><span lang="BG">, </span></i><i><span lang="EN-GB">L</span></i><i><span lang="BG">206</span></i><i><span lang="EN-GB">W</span></i><i><span lang="BG">, </span></i><i><span lang="EN-GB">R</span></i><i><span lang="BG">352</span></i><i><span lang="EN-GB">Q</span></i><i><span lang="BG">, </span></i><i><span lang="EN-GB">A</span></i><i><span lang="BG">455</span></i><i><span lang="EN-GB">E</span></i><i><span lang="BG">, </span></i><i><span lang="EN-GB">D</span></i><i><span lang="BG">579</span></i><i><span lang="EN-GB">G</span></i><i><span lang="BG">, 711+3</span></i><i><span lang="EN-GB">A</span></i><i><span lang="BG">→</span></i><i><span lang="EN-GB">G</span></i><i><span lang="BG">, </span></i><i><span lang="EN-GB">S</span></i><i><span lang="BG">945</span></i><i><span lang="EN-GB">L</span></i><i><span lang="BG">, </span></i><i><span lang="EN-GB">S</span></i><i><span lang="BG">977</span></i><i><span lang="EN-GB">F</span></i><i><span lang="BG">, </span></i><i><span lang="EN-GB">R</span></i><i><span lang="BG">1070</span></i><i><span lang="EN-GB">W</span></i><i><span lang="BG">, </span></i><i><span lang="EN-GB">D</span></i><i><span lang="BG">1152</span></i><i><span lang="EN-GB">H</span></i><i><span lang="BG">, 2789+5</span></i><i><span lang="EN-GB">G</span></i><i><span lang="BG">→</span></i><i><span lang="EN-GB">A</span></i><i><span lang="BG">, 3272‑26</span></i><i><span lang="EN-GB">A</span></i><i><span lang="BG">→</span></i><i><span lang="EN-GB">G</span></i><i><span lang="EN-GB"> </span></i><span lang="BG">и <i>3849+10</i></span><i><span lang="EN-GB">kbC</span></i><i><span lang="BG">→</span></i><i><span lang="EN-GB">T</span></i><span lang="BG">.</span></p><p class="MsoListParagraph" style="text-indent:-.25in"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">В</span><span lang="BG"> комбинирана схема с ивакафтор/тезакафтор/елексакафтор</span><span lang="BG"> </span><span lang="BG">таблетки за лечението на </span><span lang="BG">възрастни</span><span lang="BG"> и </span><span lang="BG">юноши </span><span lang="BG">на възраст 12 и повече години</span><span lang="BG"> с кистозна фиброза (КФ),</span><span lang="BG"> които са хомозиготни за мутацията </span><i><span lang="EN-GB">F</span></i><i><span lang="BG">508</span></i><i><span lang="EN-GB">del</span></i><span lang="BG"> в </span><i><span lang="EN-GB">CFTR</span></i><span lang="BG"> гена или хетерозиготни за </span><i><span lang="EN-GB">F</span></i><i><span lang="BG">508</span></i><i><span lang="EN-GB">del</span></i><i><span lang="EN-GB"> </span></i><span lang="BG">и имат мутация с минимална функция (МФ) в </span><i><span lang="EN-GB">CFTR</span></i><span lang="BG"> гена (вж. точка 5.1).</span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.2     Дозировка и начин на приложение"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Kalydeco трябва да се предписва само от лекари с опит в лечението на кистозна фиброза. Ако генотипът на пациента не е известен, преди започване на лечението трябва да се приложи точен и валидиран метод за генотипизиране, за да се потвърди наличието на една показана мутация в <i>CFTR</i> гена (вж. точка 4.1). Фазата на поли‑</span><span lang="EN-GB">T</span><span lang="BG"> варианта, идентифициран с </span><i><span lang="EN-GB">R</span></i><i><span lang="BG">117H</span></i><span lang="BG"> мутацията, трябва да се определи в съответствие с местните клинични препоръки.</span></p><p class="MsoNormal"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Дозировка"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB"><span style="text-decoration:none"> </span></span></u></p><p class="labeltext" style="page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>При възрастни, юноши и деца на възраст 6 и повече години трябва да се прилагат дози в съответствие с Таблица 1.</span></p><p class="labeltext" style="page-break-after:avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'> </span></b></p><p class="labeltext" style="margin-bottom:6.0pt;page-break-after:avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'>Таблица 1. Препоръки за дозиране</span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoTableGrid" style="width:469.6pt;margin-left:-.25pt;border-collapse:collapse;border:none" width="626"> <thead> <tr style="page-break-inside:avoid;height:16.25pt"> <td style="width:106.35pt;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:16.25pt" width="142"> <p class="labeltext" style="page-break-after:avoid"><b><span style='font-family:    "Times New Roman",serif'> </span></b></p> </td> <td style="width:234.2pt;border:solid windowtext 1.0pt;border-left:    none;padding:0in 5.4pt 0in 5.4pt;height:16.25pt" width="312"> <p align="center" class="labeltext" style="text-align:center;page-break-after:    avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'>Сутрин</span></b></p> </td> <td style="width:129.05pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.25pt" width="172"> <p align="center" class="labeltext" style="text-align:center;page-break-after:    avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'>Вечер</span></b></p> </td> </tr> </thead> <tr style="page-break-inside:avoid;height:15.3pt"> <td colspan="3" style="width:469.6pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt" width="626"> <p class="labeltext" style="page-break-after:avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'>Ивакафтор   като   монотерапия</span></b></p> </td> </tr> <tr style="page-break-inside:avoid;height:16.25pt"> <td style="width:106.35pt;border:solid windowtext 1.0pt;border-top:   none;padding:0in 5.4pt 0in 5.4pt;height:16.25pt" width="142"> <p class="labeltext" style="page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>6 и   повече   години, </span><span style='font-family:   "Times New Roman",serif'>≥25</span><span lang="BG" style='font-family:   "Times New Roman",serif'> </span><span lang="FR" style='font-family:"Times New Roman",serif'>kg</span></p> </td> <td style="width:234.2pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.25pt" width="312"> <p class="labeltext" style="page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>Една   таблетка   ивакафтор 150 mg</span></p> </td> <td style="width:129.05pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.25pt" width="172"> <p class="labeltext" style="page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>Една   таблетка   ивакафтор 150 mg</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:15.3pt"> <td colspan="3" style="width:469.6pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt" width="626"> <p class="labeltext" style="page-break-after:avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'>Ивакафтор   в   комбинация   с тезакафтор/ивакафтор</span></b></p> </td> </tr> <tr style="page-break-inside:avoid;height:15.3pt"> <td style="width:106.35pt;border:solid windowtext 1.0pt;border-top:   none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt" width="142"> <p class="labeltext" style="page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>От   6 до &lt;12 години,   &lt;</span><span style='font-family:"Times New Roman",serif'>30</span><span lang="BG" style='font-family:"Times New Roman",serif'> </span><span lang="FR" style='font-family:"Times New Roman",serif'>kg</span></p> </td> <td style="width:234.2pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.3pt" width="312"> <p class="labeltext" style="page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>Една   таблетка   тезакафтор   50 mg/   ивакафтор 75 mg</span></p> </td> <td style="width:129.05pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.3pt" width="172"> <p class="labeltext" style="page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>Една   таблетка   ивакафтор 75 mg</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:15.3pt"> <td style="width:106.35pt;border:solid windowtext 1.0pt;border-top:   none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt" width="142"> <p class="labeltext" style="page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>От   6 до &lt;12 години,   </span><span style='font-family:"Times New Roman",serif'>≥30</span><span lang="BG" style='font-family:"Times New Roman",serif'> </span><span lang="FR" style='font-family:"Times New Roman",serif'>kg</span></p> </td> <td style="width:234.2pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.3pt" width="312"> <p class="labeltext" style="page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>Една   таблетка   тезакафтор   100 mg/   ивакафтор 150 mg</span></p> </td> <td style="width:129.05pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.3pt" width="172"> <p class="labeltext" style="page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>Една   таблетка   ивакафтор 150 mg</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:15.3pt"> <td style="width:106.35pt;border:solid windowtext 1.0pt;border-top:   none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt" width="142"> <p class="labeltext" style="page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>12 и   повече години</span></p> </td> <td style="width:234.2pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.3pt" width="312"> <p class="labeltext" style="page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>Една   таблетка   тезакафтор 100 mg/ивакафтор 150 mg</span></p> </td> <td style="width:129.05pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.3pt" width="172"> <p class="labeltext" style="page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>Една   таблетка   ивакафтор 150 mg</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:15.3pt"> <td colspan="3" style="width:469.6pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt" width="626"> <p class="labeltext" style="page-break-after:avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'>Ивакафтор   в   комбинация   с ивакафтор/тезакафтор/елексакафтор</span></b></p> </td> </tr> <tr style="page-break-inside:avoid;height:15.3pt"> <td style="width:106.35pt;border:solid windowtext 1.0pt;border-top:   none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt" width="142"> <p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>12 и   повече   години</span></p> </td> <td style="width:234.2pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.3pt" width="312"> <p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Две   таблетки   ивакафтор 75 mg/   тезакафтор 50 mg/елексакафтор 100 mg</span></p> </td> <td style="width:129.05pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.3pt" width="172"> <p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Една   таблетка   ивакафтор 150 mg</span></p> </td> </tr> </table><p class="labeltext"><span style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Сутрешната и вечерната доза трябва да се приемат приблизително през 12 часа с храна, съдържаща мазнини (вж. „Начин на приложение“). </span></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG"> </span></i></p><p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><i><span lang="BG">Пропусната доза</span></i></p><p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><i><span lang="BG"> </span></i></p><p class="MsoNormal" style="text-autospace:none"><span lang="BG">Ако са изминали 6</span> <span lang="BG">или по-малко часа от пропуснатата сутрешна или вечерна доза, пациентът трябва да бъде посъветван да я приеме веднага, щом е възможно, и след това да приеме следващата доза в обичайното време. Ако са изминали повече от 6</span> <span lang="BG">часа от обичайното време, в което се приема дозата, пациентът трябва да бъде посъветван да изчака до следващата доза по схемата.</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Пациентите, получаващи </span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>Kalydeco</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>в комбинирана схема, трябва да бъдат посъветвани да не приемат повече от една доза от всяко от лекарствата едновременно.</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="BG" style='font-family:"Times New Roman",serif'>Съпътстващо приложение на инхибитори на CYP3A</span></i></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG"> </span></i></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Когато се прилага едновременно с умерени или силни инхибитори на CYP3A, или като монотерапия, или в комбинирана схема с тезакафтор/ивакафтор или с ивакафтор/тезакафтор/елексакафтор, дозата трябва да се намали (вж. Таблица 2 за препоръчителната доза). Интервалите на прилагане трябва да се променят според клиничния отговор и поносимостта (вж. точка</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>4.4 и</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>4.5).</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext" style="margin-top:0in;margin-right:0in;margin-bottom:6.0pt; margin-left:56.7pt;text-indent:-56.7pt;page-break-after:avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'>Таблица</span></b><b><span style='font-family:"Times New Roman",serif'> </span></b><b><span lang="BG" style='font-family:"Times New Roman",serif'>2: Препоръки за прилагане при съпътстваща употреба с умерени или силни инхибитори на </span></b><b><span style='font-family:"Times New Roman",serif'>CYP</span></b><b><span lang="BG" style='font-family:"Times New Roman",serif'>3</span></b><b><span style='font-family:"Times New Roman",serif'>A</span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoTableGrid" style="width:453.75pt;border-collapse:collapse;border:none" width="605"> <thead> <tr style="page-break-inside:avoid"> <td style="width:91.9pt;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB"> </span></p> </td> <td style="width:182.35pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="243"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><b><span lang="BG">Умерени    инхибитори    на</span></b><b><span lang="EN-GB"> CYP3A </span></b></p> </td> <td style="width:179.5pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="239"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><b><span lang="BG">Силни    инхибитори    на </span></b><b><span lang="EN-GB">CYP3A </span></b></p> </td> </tr> </thead> <tr style="page-break-inside:avoid"> <td colspan="3" style="width:453.75pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="605"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Ивакафтор</span></b><b><span lang="BG"> </span></b><b><span lang="BG">като   монотерапия</span></b></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:91.9pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal"><span lang="EN-GB">6 и   повече   години,<br/> </span><span lang="EN-GB" style="font-family:SimSun">≥</span><span lang="EN-GB">25</span><span lang="BG"> </span><span lang="EN-GB">kg</span></p> </td> <td style="width:182.35pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="243"> <p class="MsoNormal"><span lang="EN-GB">Сутрин   една   таблетка   ивакафтор 150 mg веднъж   дневно. </span></p> <p class="MsoNormal"><span lang="EN-GB"> </span></p> <p class="MsoNormal"><span lang="EN-GB">Без   вечерна   доза.</span></p> </td> <td style="width:179.5pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="239"> <p class="MsoNormal"><span lang="EN-GB">Сутрин   една   таблетка   ивакафтор 150 mg два   пъти   седмично, </span><span lang="BG">приблизително   през </span><span lang="EN-GB">3 </span><span lang="BG">до </span><span lang="EN-GB">4</span><span lang="BG"> дни</span><span lang="EN-GB">.</span></p> <p class="MsoNormal"><span lang="EN-GB"> </span></p> <p class="MsoNormal"><span lang="EN-GB">Без   вечерна   доза.</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td colspan="3" style="width:453.75pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="605"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Ивакафтор</span></b><b><span lang="BG"> </span></b><b><span lang="BG">в   комбинирана   схема с   тезакафтор/ивакафтор</span></b></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:91.9pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal"><span lang="BG">От 6 до &lt;</span><span lang="EN-GB">12  години</span><span lang="BG">,<br/>   &lt;</span><span lang="EN-GB">30</span><span lang="BG"> </span><span lang="EN-GB">kg</span></p> </td> <td style="width:182.35pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="243"> <p class="MsoNormal"><span lang="BG">Редувайте   всяка   сутрин:</span></p> <p class="MsoListParagraph" style="margin-left:20.5pt;text-indent:-.25in"><span lang="EN-GB">-<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="EN-GB">една   таблетка </span><span lang="BG">тезакафтор</span><span lang="EN-GB"> </span><span lang="BG">5</span><span lang="EN-GB">0 mg/</span><span lang="BG">ивакафтор </span><span lang="EN-GB">75 mg </span><span lang="BG">първия   ден</span></p> <p class="MsoListParagraph" style="margin-left:20.5pt;text-indent:-.25in"><span lang="EN-GB">-<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="EN-GB">една   таблетка </span><span lang="BG">ивакафтор </span><span lang="EN-GB">75 mg <br/> </span><span lang="BG">на   следващия   ден</span></p> <p class="MsoNormal" style="margin-left:2.5pt"><span lang="BG">Продължете   да редувате   таблетките   всеки ден</span><span lang="EN-GB">.</span></p> <p class="MsoNormal" style="margin-left:2.5pt"><span lang="EN-GB"> </span></p> <p class="MsoNormal"><span lang="EN-GB">Без   вечерна   доза.</span></p> </td> <td style="width:179.5pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="239"> <p class="MsoNormal"><span lang="BG">Сутрин   една   таблетка   тезакафтор</span><span lang="EN-GB"> 50 mg/</span><span lang="BG">ивакафтор 7</span><span lang="EN-GB">5 mg два пъти   седмично, </span><span lang="BG">приблизително   през </span><span lang="EN-GB">3 </span><span lang="BG">до </span><span lang="EN-GB">4</span><span lang="BG"> дни</span><span lang="EN-GB">.</span></p> <p class="MsoNormal"><span lang="EN-GB"> </span></p> <p class="MsoNormal"><span lang="EN-GB">Без   вечерна   доза.</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:91.9pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal"><span lang="BG">От 6 до &lt;</span><span lang="EN-GB">12  години</span><span lang="BG">,<br/> </span><span lang="EN-GB" style="font-family:SimSun">≥</span><span lang="EN-GB">30</span><span lang="BG"> </span><span lang="EN-GB">kg</span></p> </td> <td style="width:182.35pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="243"> <p class="MsoNormal"><span lang="BG">Редувайте   всяка   сутрин:</span></p> <p class="MsoListParagraph" style="margin-left:20.5pt;text-indent:-.25in"><span lang="EN-GB">-<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="EN-GB">една   таблетка </span><span lang="BG">тезакафтор</span><span lang="EN-GB"> </span><span lang="BG">10</span><span lang="EN-GB">0 mg/<br/> </span><span lang="BG">ивакафтор 150</span><span lang="EN-GB"> mg </span><span lang="BG">веднъж   дневно първия   ден</span></p> <p class="MsoListParagraph" style="margin-left:20.5pt;text-indent:-.25in"><span lang="EN-GB">-<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="EN-GB">една   таблетка </span><span lang="BG">ивакафтор </span><span lang="EN-GB">15</span><span lang="BG">0</span><span lang="EN-GB"> mg <br/> </span><span lang="BG">на   следващия   ден</span></p> <p class="MsoNormal" style="margin-left:2.5pt"><span lang="BG">Продължете   да редувате   таблетките   всеки ден</span><span lang="EN-GB">.</span></p> <p class="MsoNormal" style="margin-left:2.5pt"><span lang="EN-GB"> </span></p> <p class="MsoNormal"><span lang="EN-GB">Без   вечерна   доза.</span></p> </td> <td style="width:179.5pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="239"> <p class="MsoNormal"><span lang="BG">Сутрин   една   таблетка тезакафтор</span><span lang="BG"> </span><span lang="EN-GB">100 mg/</span><span lang="BG">ивакафтор 1</span><span lang="EN-GB">5</span><span lang="BG">0</span><span lang="EN-GB"> mg   два пъти   седмично, </span><span lang="BG">приблизително   през </span><span lang="EN-GB">3 </span><span lang="BG">до </span><span lang="EN-GB">4</span><span lang="BG"> дни</span><span lang="EN-GB">.</span></p> <p class="MsoNormal"><span lang="EN-GB"> </span></p> <p class="MsoNormal"><span lang="EN-GB">Без   вечерна   доза.</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:91.9pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal"><span lang="EN-GB">12 и   повече   години</span></p> </td> <td style="width:182.35pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="243"> <p class="MsoNormal"><span lang="BG">Редувайте   всяка   сутрин:</span></p> <p class="MsoListParagraph" style="margin-left:20.5pt;text-indent:-.25in"><span lang="EN-GB">-<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="EN-GB">една   таблетка </span><span lang="BG">тезакафтор</span><span lang="EN-GB"> 100 mg/</span><span lang="BG">ивакафтор </span><span lang="EN-GB">150 mg </span><span lang="BG">първия   ден</span></p> <p class="MsoListParagraph" style="margin-left:20.5pt;text-indent:-.25in"><span lang="EN-GB">-<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="EN-GB">една   таблетка </span><span lang="BG">ивакафтор </span><span lang="EN-GB">150 mg </span><span lang="BG">на следващия   ден</span></p> <p class="MsoNormal" style="margin-left:2.5pt"><span lang="BG">Продължете   да редувате   таблетките   всеки ден</span><span lang="EN-GB">.</span></p> <p class="MsoNormal" style="margin-left:2.5pt"><span lang="EN-GB"> </span></p> <p class="MsoNormal" style="margin-left:2.5pt"><span lang="EN-GB">Без   вечерна   доза.</span></p> </td> <td style="width:179.5pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="239"> <p class="MsoNormal"><span lang="BG">Сутрин   една   таблетка   тезакафтор</span><span lang="EN-GB"> 100 mg/</span><span lang="BG">ивакафтор </span><span lang="EN-GB">150 mg два пъти   седмично, </span><span lang="BG">приблизително   през </span><span lang="EN-GB">3 </span><span lang="BG">до </span><span lang="EN-GB">4</span><span lang="BG"> дни</span><span lang="EN-GB">.</span></p> <p class="MsoNormal"><span lang="EN-GB"> </span></p> <p class="MsoNormal"><span lang="EN-GB">Без   вечерна   доза.</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td colspan="3" style="width:453.75pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="605"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Ивакафтор</span></b><b><span lang="BG"> </span></b><b><span lang="BG">в   комбинирана   схема с ивакафтор/тезакафтор/елексакаф</span></b><b><span lang="EN-GB">тор</span></b></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:91.9pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="123"> <p class="MsoNormal"><span lang="EN-GB">12 и   повече   години</span></p> </td> <td style="width:182.35pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="243"> <p class="MsoNormal"><span lang="BG">Редувайте   всяка   сутрин</span><span lang="EN-GB">: </span></p> <p class="MsoListParagraph" style="margin-left:20.5pt;text-indent:-.25in"><span lang="EN-GB">-<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="EN-GB"> </span><span lang="BG">две   таблетки   ивакафтор </span><span lang="EN-GB">75 mg/</span><span lang="BG">тезакафтор</span><span lang="EN-GB"> 50 mg/</span><span lang="BG">елексакафтор </span><span lang="EN-GB">100 mg</span><span lang="BG">   първия ден</span></p> <p class="MsoListParagraph" style="margin-left:20.5pt;text-indent:-.25in"><span lang="EN-GB">-<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="EN-GB">една   таблетка </span><span lang="BG">ивакафтор </span><span lang="EN-GB">150 mg </span><span lang="BG">на   следващия   ден</span></p> <p class="MsoNormal" style="margin-left:2.5pt"><span lang="BG">Продължете   да редувате   таблетките   всеки ден</span><span lang="EN-GB">.</span></p> <p class="MsoNormal" style="margin-left:2.5pt"><span lang="EN-GB"> </span></p> <p class="MsoNormal" style="margin-left:2.5pt"><span lang="EN-GB">Без   вечерна   доза.</span></p> </td> <td style="width:179.5pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="239"> <p class="MsoNormal"><span lang="EN-GB">Сутрин   </span><span lang="BG">две </span><span lang="EN-GB">таблетк</span><span lang="BG">и   ивакафтор </span><span lang="EN-GB">75 mg/</span><span lang="BG">тезакафтор</span><span lang="EN-GB"> 50 mg/</span><span lang="BG">елексакафтор</span><span lang="EN-GB"> 100 mg два пъти   седмично, </span><span lang="BG">приблизително   през </span><span lang="EN-GB">3 </span><span lang="BG">до </span><span lang="EN-GB">4</span><span lang="BG"> дни</span><span lang="EN-GB">.</span></p> <p class="MsoNormal"><span lang="EN-GB"> </span></p> <p class="MsoNormal"><span lang="EN-GB">Без   вечерна   доза.</span></p> </td> </tr> </table><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG">Специални популации</span></u></p><p class="labeltext" style="page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG">Старческа възраст </span></i></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Наличните данни за пациенти в старческа възраст, лекувани с ивакафтор (прилаган като монотерапия или в комбинирана схема</span><span lang="RU">),</span><span lang="RU"> </span><span lang="BG">са много ограничени. Не се изисква корекция на дозата специално за тази популация пациенти (вж. точка 5.2). </span></p><p class="labeltext"><i><span lang="BG" style='font-family:"Times New Roman",serif'> </span></i></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG">Бъбречно увреждане</span></i></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG"> </span></i></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Не се налага корекция на дозата при пациенти с леко до умерено бъбречно увреждане. Препоръчва се повишено внимание при пациенти с тежко бъбречно увреждане (креатининов клирънс по-нисък или равен на 30 ml/min) или терминална бъбречна недостатъчност (вж. точка</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>4.4 и</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>5.2.)</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltextheading"><span lang="BG" style='font-family:"Times New Roman",serif'>Чернодробно увреждане</span></p><p class="labeltextheading"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Не се налага корекция на дозата за ивакафтор като монотерапия или в комбинирана схема при пациенти с леко чернодробно увреждане (клас</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>А по Child-Pugh). </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>При пациенти с умерено чернодробно увреждане (клас</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>В по </span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>Child</span><span lang="BG" style='font-family:"Times New Roman",serif'>-</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>Pugh</span><span lang="BG" style='font-family:"Times New Roman",serif'>) дозата ивакафтор като монотерапия трябва да се намали до 150 </span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>mg</span><span lang="BG" style='font-family:"Times New Roman",serif'> веднъж дневно. </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>При пациенти с тежко </span><span lang="BG" style='font-family:"Times New Roman",serif'>чернодробно увреждане (клас</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>С по </span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>Child</span><span lang="BG" style='font-family:"Times New Roman",serif'>-</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>Pugh</span><span lang="BG" style='font-family:"Times New Roman",serif'>) дозата ивакафтор като монотерапия трябва да се намали до 150 </span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>mg</span><span lang="BG" style='font-family:"Times New Roman",serif'> през ден или по-рядко. </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>При употреба като вечерна доза в комбинирана схема с тезакафтор/ивакафтор или ивакафтор/тезакафтор/елексакафтор вижте Таблица 3 относно препоръки за схемата на прилагане.</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext" style="margin-top:0in;margin-right:0in;margin-bottom:6.0pt; margin-left:56.7pt;text-indent:-56.7pt;page-break-after:avoid"><b><span lang="RU" style='font-family:"Times New Roman",serif'>Таблица</span></b><b><span style='font-family:"Times New Roman",serif'> </span></b><b><span lang="RU" style='font-family:"Times New Roman",serif'>3: Препоръки за </span></b><b><span lang="BG" style='font-family:"Times New Roman",serif'>прилагане</span></b><b><span lang="RU" style='font-family:"Times New Roman",serif'> при пациенти с умерено или тежко чернодробно увреждане </span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoTableGrid" style="width:481.7pt;border-collapse:collapse;border:none" width="642"> <thead> <tr style="page-break-inside:avoid"> <td style="width:113.15pt;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="151"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG"> </span></b></p> </td> <td style="width:177.2pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="236"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><b><span lang="BG">Умерено</span></b><b><span lang="EN-GB"> (</span></b><b><span lang="BG">Клас </span></b><b><span lang="EN-GB">B</span></b><b><span lang="BG"> по </span></b><b><span lang="EN-GB">Child-Pugh)</span></b></p> </td> <td style="width:191.35pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="255"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><b><span lang="BG">Тежко</span></b><b><span lang="EN-GB"> (</span></b><b><span lang="BG">Клас С    по</span></b><b><span lang="EN-GB"> Child-Pugh)</span></b></p> </td> </tr> </thead> <tr style="page-break-inside:avoid"> <td colspan="3" style="width:481.7pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="642"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Ивакафтор</span></b><b><span lang="BG"> </span></b><b><span lang="BG">като   монотерапия</span></b></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:113.15pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="151"> <p class="MsoNormal"><span lang="EN-GB">6 и   повече   години,<br/> </span><span lang="EN-GB" style="font-family:SimSun">≥</span><span lang="EN-GB">25 kg</span></p> </td> <td style="width:177.2pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="236"> <p class="MsoNormal"><span lang="EN-GB">Сутрин   една   таблетка   ивакафтор 150 mg   веднъж дневно.   </span></p> <p class="MsoNormal"><span lang="EN-GB"> </span></p> <p class="MsoNormal"><span lang="EN-GB">Без   вечерна   доза.</span></p> </td> <td style="width:191.35pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="255"> <p class="MsoNormal"><span lang="BG">Препоръчва   се да не се   използва,   освен ако не   се очаква   ползите да   превишават   рисковете</span><span lang="EN-GB">. </span></p> <p class="MsoNormal"><span lang="EN-GB"> </span></p> <p class="MsoNormal"><span lang="BG">Ако се   използва: </span><span lang="EN-GB">сутрин   една   таблетка   ивакафтор 150 mg   </span><span lang="BG">през ден   или по-рядко</span><span lang="EN-GB">. </span></p> <p class="MsoNormal"><span lang="EN-GB"> </span></p> <p class="MsoNormal"><span lang="BG">Интервалът   на   прилагане   трябва да се   променя   според   клиничния   отговор и   поносимостта</span><span lang="EN-GB">. </span></p> <p class="MsoNormal"><span lang="EN-GB"> </span></p> <p class="MsoNormal"><span lang="EN-GB">Без   вечерна   доза.</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td colspan="3" style="width:481.7pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="642"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Ивакафтор</span></b><b><span lang="BG"> </span></b><b><span lang="BG">в   комбинирана   схема с   тезакафтор/ивакафтор</span></b></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:113.15pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="151"> <p class="MsoNormal"><span lang="BG">От 6 до &lt;</span><span lang="EN-GB">12  години</span><span lang="BG">,<br/>   &lt;</span><span lang="EN-GB">30</span><span lang="BG"> </span><span lang="EN-GB">kg</span></p> </td> <td style="width:177.2pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="236"> <p class="MsoNormal"><span lang="EN-GB">Су</span><span lang="BG">т</span><span lang="EN-GB">рин една   таблетка </span><span lang="BG">тезакафтор</span><span lang="EN-GB"> 50 mg/</span><span lang="BG">ивакафтор</span><span lang="EN-GB"> </span><span lang="BG">7</span><span lang="EN-GB">5 mg   веднъж   дневно.</span></p> <p class="MsoNormal"><span lang="EN-GB"> </span></p> <p class="MsoNormal"><span lang="EN-GB">Без   вечерна   доза.</span></p> </td> <td style="width:191.35pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="255"> <p class="MsoNormal"><span lang="BG">Препоръчва   се да не се   използва,   освен ако не   се очаква ползите   да   превишават   рисковете</span><span lang="EN-GB">. </span></p> <p class="MsoNormal"><span lang="EN-GB"> </span></p> <p class="MsoNormal"><span lang="BG">Ако се   използва: </span><span lang="EN-GB">сутрин   една   таблетка </span><span lang="BG">тезакафтор </span><span lang="EN-GB">50 mg/</span><span lang="BG">ивакафтор</span><span lang="EN-GB"> </span><span lang="BG">7</span><span lang="EN-GB">5 mg веднъж   дневно </span><span lang="BG">или   по-рядко</span><span lang="EN-GB">. </span></p> <p class="MsoNormal"><span lang="EN-GB"> </span></p> <p class="MsoNormal"><span lang="BG">Интервалът   на   прилагане   трябва да се   променя   според   клиничния   отговор и   поносимостта</span><span lang="EN-GB">. </span></p> <p class="MsoNormal"><span lang="EN-GB"> </span></p> <p class="MsoNormal"><span lang="EN-GB">Без   вечерна   доза.</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:113.15pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="151"> <p class="MsoNormal"><span lang="BG">От 6 до &lt;</span><span lang="EN-GB">12  години</span><span lang="BG">,<br/> </span><span lang="EN-GB" style="font-family:SimSun">≥</span><span lang="EN-GB">30</span><span lang="BG"> </span><span lang="EN-GB">kg</span></p> </td> <td style="width:177.2pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="236"> <p class="MsoNormal"><span lang="EN-GB">Су</span><span lang="BG">т</span><span lang="EN-GB">рин една   таблетка </span><span lang="BG">тезакафтор</span><span lang="EN-GB"> 100 mg/</span><span lang="BG">ивакафтор</span><span lang="EN-GB"> 150 mg веднъж   дневно.</span></p> <p class="MsoNormal"><span lang="EN-GB"> </span></p> <p class="MsoNormal"><span lang="EN-GB">Без   вечерна доза.</span></p> </td> <td style="width:191.35pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="255"> <p class="MsoNormal"><span lang="BG">Препоръчва   се да не се   използва,   освен ако не   се очаква ползите   да   превишават   рисковете</span><span lang="EN-GB">. </span></p> <p class="MsoNormal"><span lang="EN-GB"> </span></p> <p class="MsoNormal"><span lang="BG">Ако се   използва: </span><span lang="EN-GB">сутрин   една   таблетка </span><span lang="BG">тезакафтор </span><span lang="EN-GB">100 mg/</span><span lang="BG">ивакафтор</span><span lang="EN-GB"> 150 mg веднъж   дневно </span><span lang="BG">или   по-рядко</span><span lang="EN-GB">. </span></p> <p class="MsoNormal"><span lang="EN-GB"> </span></p> <p class="MsoNormal"><span lang="BG">Интервалът   на   прилагане   трябва да се   променя   според клиничния   отговор и   поносимостта</span><span lang="EN-GB">. </span></p> <p class="MsoNormal"><span lang="EN-GB"> </span></p> <p class="MsoNormal"><span lang="EN-GB">Без   вечерна   доза.</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:113.15pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="151"> <p class="MsoNormal"><span lang="EN-GB">12 и   повече   години</span></p> </td> <td style="width:177.2pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="236"> <p class="MsoNormal"><span lang="EN-GB">Су</span><span lang="BG">т</span><span lang="EN-GB">рин една   таблетка </span><span lang="BG">тезакафтор</span><span lang="EN-GB"> 100 mg/</span><span lang="BG">ивакафтор</span><span lang="EN-GB"> 150 mg веднъж   дневно.</span></p> <p class="MsoNormal"><span lang="EN-GB"> </span></p> <p class="MsoNormal"><span lang="EN-GB">Без   вечерна   доза.</span></p> </td> <td style="width:191.35pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="255"> <p class="MsoNormal"><span lang="BG">Препоръчва   се да не се   използва,   освен ако не   се очаква   ползите да   превишават   рисковете</span><span lang="EN-GB">. </span></p> <p class="MsoNormal"><span lang="EN-GB"> </span></p> <p class="MsoNormal"><span lang="BG">Ако се   използва: </span><span lang="EN-GB">сутрин   една   таблетка </span><span lang="BG">тезакафтор </span><span lang="EN-GB">100 mg/</span><span lang="BG">ивакафтор</span><span lang="EN-GB"> 150 mg веднъж   дневно </span><span lang="BG">или   по-рядко</span><span lang="EN-GB">. </span></p> <p class="MsoNormal"><span lang="EN-GB"> </span></p> <p class="MsoNormal"><span lang="BG">Интервалът   на   прилагане   трябва да се   променя   според   клиничния   отговор и   поносимостта</span><span lang="EN-GB">. </span></p> <p class="MsoNormal"><span lang="EN-GB"> </span></p> <p class="MsoNormal"><span lang="EN-GB">Без   вечерна   доза.</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td colspan="3" style="width:481.7pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="642"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Ивакафтор</span></b><b><span lang="BG"> </span></b><b><span lang="BG">в   комбинирана   схема с ивакафтор/тезакафтор/елексакаф</span></b><b><span lang="EN-GB">тор</span></b></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:113.15pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="151"> <p class="MsoNormal"><span lang="EN-GB">12 и   повече   години</span></p> </td> <td style="width:177.2pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="236"> <p class="MsoNormal"><span lang="BG">Препоръчва   се да не се   използва</span><span lang="EN-GB">.</span></p> <p class="MsoNormal"><span lang="BG">Употребата   трябва да се   обмисля   само когато   има   категорична   медицинска   необходимост   и се очаква   ползите да   превишават   рисковете</span><span lang="EN-GB">.</span></p> <p class="MsoNormal"><span lang="EN-GB"> </span></p> <p class="MsoNormal"><span lang="BG">Ако се   използва</span><span lang="EN-GB">: </span><span lang="BG">редувайте   всеки ден между   две   таблетки   ивакафтор </span><span lang="EN-GB">75 mg/</span><span lang="BG">тезакафтор </span><span lang="EN-GB">50 mg/</span><span lang="BG">елексакафтор </span><span lang="EN-GB">100 mg </span><span lang="BG">и   една   таблетка   ивакафтор </span><span lang="EN-GB">75 mg/</span><span lang="BG">тезакафтор </span><span lang="EN-GB">50 mg/</span><span lang="BG">елексакафтор </span><span lang="EN-GB">100 mg.</span></p> <p class="MsoNormal"><span lang="EN-GB"> </span></p> <p class="MsoNormal"><span lang="EN-GB">Без   вечерна   доза.</span></p> </td> <td style="width:191.35pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="255"> <p class="MsoNormal"><span lang="BG">Не   трябва да се   използва</span><span lang="EN-GB">.</span></p> <p class="MsoNormal"><span lang="BG"> </span></p> </td> </tr> </table><p class="labeltext"><i><span lang="BG" style='font-family:"Times New Roman",serif'> </span></i></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Педиатрична популация"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Безопасността и ефикасността на ивакафтор не са установени при деца под </span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>4</span><span lang="BG" style='font-family:"Times New Roman",serif'>‑месечна възраст като монотерапия, нито в комбинация с тезакафтор/ивакафтор при деца под 6‑годишна възраст, нито в комбинация с ивакафтор/тезакафтор/елексакафтор при деца под 12‑годишна възраст.</span><span lang="BG" style='font-family:"Times New Roman",serif'> Липсват данни.</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Наличните данни са ограничени при пациенти под 6-годишна възраст с </span><i><span lang="EN-GB" style='font-family:"Times New Roman",serif'>R</span></i><i><span lang="BG" style='font-family:"Times New Roman",serif'>117</span></i><i><span lang="EN-GB" style='font-family:"Times New Roman",serif'>H</span></i><i><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span></i><span lang="BG" style='font-family:"Times New Roman",serif'>мутация на </span><i><span lang="EN-GB" style='font-family:"Times New Roman",serif'>CFTR</span></i><i><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span></i><span lang="BG" style='font-family:"Times New Roman",serif'>гена</span><span lang="BG" style='font-family:"Times New Roman",serif'>. Наличните данни при пациенти на възраст 6 и повече години са описани в точка</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>4.8,</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>5.1 и</span><span style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>5.2.</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Начин на приложение"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><span lang="BG">За перорално приложение. </span></p><p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><span lang="BG"> </span></p><p class="MsoNormal" style="text-autospace:none"><span lang="BG">Пациентите трябва да бъдат инструктирани да поглъщат таблетките цели. Таблетките не трябва да се дъвчат, раздробяват или разчупват преди поглъщане, тъй като за момента липсват клинични данни в подкрепа на други начини на приложение.</span></p><p class="MsoNormal" style="text-autospace:none"><span lang="BG"> </span></p><p class="MsoNormal" style="text-autospace:none"><span lang="BG">Таблетките ивакафтор трябва да се приемат с храна, съдържаща мазнини. </span></p><p class="MsoNormal" style="text-autospace:none"><span lang="BG"> </span></p><p class="MsoNormal" style="text-autospace:none"><span lang="BG">По време на лечението трябва да се избягват храни или напитки, съдържащи грейпфрут (вж. точка 4.5).</span></p><p class="MsoNormal" style="text-autospace:none"><span lang="BG" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.3     Противопоказания"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormalIndent" style="margin:0in"><span lang="BG">Свръхчувствителност към активното вещество или към някое от помощните вещества, изброени в точка 6.1.</span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.4     Специални предупреждения и предпазни мерки при употреба"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;page-break-after: avoid"><i><span lang="BG"> </span></i></p><p class="MsoNormal"><span lang="BG">Само пациентите с КФ, които имат <i>G551D</i></span><i><span lang="BG">, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N,</span></i><span lang="BG"> <i>S549R</i> </span><span lang="BG">водеща до каналопатия (клас III), </span><i><span lang="EN-GB">G970R</span></i><i><span lang="EN-GB"> </span></i><span lang="BG">или </span><i>R</i><i><span lang="BG">117</span></i><i>H</i><i> </i><span lang="BG">мутация </span><span lang="BG">в най-малко един алел на <i>CFTR</i> гена, са включени в проучвания 1, 2, 5 и 6 (вж. точка 5.1).</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">В проучване</span><span lang="EN-GB"> </span><span lang="BG">5 са включени четирима пациенти с мутацията <i>G970R</i>. При трима от четиримата пациенти промяната в теста за хлорни йони в потта е &lt;5 mmol/</span>l<span lang="BG"> и тази група н</span><span lang="EN-GB">e</span><span lang="BG"> показва клинично значимо подобрение на ФЕО<sub>1</sub> след 8 седмици лечение. Невъзможно e да се установи клиничната ефикасност при пациенти с мутацията <i>G970R </i>на <i>CFTR</i> гена (вж. точка 5.1).</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal"><span lang="BG">Резултатите за ефикасност от проучване фаза 2 при пациенти с КФ, които са хомозиготни за <i>F508del </i>мутацията на <i>CFTR</i> гена, не показват статистически значима разлика във ФЕО<sub>1</sub> след 16 седмици лечение с ивакафтор в сравнение с плацебо (вж. точка 5.1). Затова не се препоръчва употребата на ивакафтор като монотерапия при тези пациенти.</span></p><p class="labeltextheading" style="page-break-after:auto"><u><span lang="BG" style='font-family:"Times New Roman",serif;font-style:normal'><span style="text-decoration:none"> </span></span></u></p><p class="labeltextheading" style="page-break-after:auto"><span lang="BG" style='font-family:"Times New Roman",serif;font-style:normal'>По-малко данни за положителен ефект на ивакафтор са налични за пациенти с </span><span lang="BG" style='font-family:"Times New Roman",serif'>R117H-7T</span><span lang="BG" style='font-family:"Times New Roman",serif;font-style:normal'> мутация, свързана с не толкова тежко заболяване в проучване 6 (вж. точка 5.1). </span></p><p class="labeltextheading" style="page-break-after:auto"><span lang="BG" style='font-family:"Times New Roman",serif;font-style:normal'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Ивакафтор </span><span lang="BG" style='font-family:"Times New Roman",serif'>в комбинирана схема с тезакафтор/ивакафтор не трябва да се предписва на пациенти с КФ, </span><span lang="BG" style='font-family:"Times New Roman",serif'>които са хетерозиготни за мутацията </span><i><span style='font-family:"Times New Roman",serif'>F</span></i><i><span lang="BG" style='font-family:"Times New Roman",serif'>508</span></i><i><span style='font-family:"Times New Roman",serif'>del</span></i><span style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>и имат втора мутация </span><i><span style='font-family:"Times New Roman",serif'>CFTR</span></i><span lang="BG" style='font-family:"Times New Roman",serif'>, която не е посочена в точка 4.1</span><span lang="BG" style='font-family:"Times New Roman",serif'>.</span></p><p class="MsoNormal"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="labeltextheading"><u><span lang="BG" style='font-family:"Times New Roman",serif; font-style:normal'>Ефект върху чернодробните функционални показатели</span></u></p><p class="labeltextheading"><u><span lang="BG" style='font-family:"Times New Roman",serif; font-style:normal'><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormalIndent" style="margin:0in"><span lang="BG">Умерено повишение на трансаминазите (аланин трансаминазата [</span><span lang="EN-GB">alanine</span><span lang="EN-GB"> </span><span lang="EN-GB">transaminase</span><span lang="BG"> - ALT] или аспартат трансаминазата [</span><span lang="EN-GB">aspartate</span><span lang="EN-GB"> </span><span lang="EN-GB">transaminase</span><span lang="BG"> - AST]) е често срещано при лица с КФ. </span><span lang="BG">При някои пациенти, лекувани с ивакафтор като </span><span lang="BG">монотерапия </span><span lang="BG">и с комбинирани схеми с тезакафтор/ивакафтор или ивакафтор/тезакафтор/елексакафтор, се наблюдават повишени трансаминази. </span><span lang="BG">Затова за всички пациенти се препоръчва измерване на чернодробните функционални показатели преди започване на ивакафтор, на всеки 3 месеца през първата година на лечение и ежегодно след това. За всички пациенти с анамнеза за повишения на<i> </i>трансаминазите трябва да се помисли за по-често наблюдение на чернодробните функционални показатели. </span><span lang="BG">В случай на значителни повишения на трансаминазите (напр. пациенти с </span><span lang="EN-GB">ALT</span><span lang="EN-GB"> </span><span lang="BG">или </span><span lang="EN-GB">AST</span><span lang="BG"> &gt;5</span><span lang="EN-GB"> x </span><span lang="BG">горната граница на нормата (</span><i><span lang="EN-GB">upper</span></i><i><span lang="EN-GB"> </span></i><i><span lang="EN-GB">limit</span></i><i><span lang="EN-GB"> </span></i><i><span lang="EN-GB">of</span></i><i><span lang="EN-GB"> </span></i><i><span lang="EN-GB">normal</span></i><span lang="BG"> – </span><span lang="EN-GB">ULN</span><span lang="BG">), или </span><span lang="EN-GB">ALT</span><span lang="EN-GB"> </span><span lang="BG">или </span><span lang="EN-GB">AST</span><span lang="BG"> &gt;3</span><span lang="EN-GB"> x ULN</span><span lang="EN-GB"> </span><span lang="BG">с билирубин &gt;2</span><span lang="EN-GB"> x ULN</span><span lang="EN-GB"> </span><span lang="BG">приложението трябва да бъде прекъснато и внимателно да се проследят лабораторните изследвания, докато отклоненията се нормализират. След изчезване на повишенията на трансаминазите трябва да се обмислят ползите и рисковете от възобновяване на лечението (вж. точка 4.8).</span></p><p class="MsoNormalIndent" style="margin:0in"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG">Чернодробно увреждане</span></u></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal"><span lang="BG">Не се препоръчва употреба на ивакафтор или като монотерапия, или в комбинирана схема с тезакафтор/ивакафтор при пациенти с тежко чернодробно увреждане, освен ако не се очаква ползите да надвишават рисковете. </span><span lang="BG">Пациентите с тежко чернодробно увреждане не трябва да се лекуват с</span><span lang="BG"> ивакафтор</span><span lang="BG"> в комбинирана схема с </span><span lang="BG">ивакафтор/тезакафтор/елексакафтор</span><span lang="BG"> </span><span lang="BG">(вж. Таблица 3 и точка 4.2 и</span><span lang="EN-GB"> </span><span lang="BG">5.2).</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">При пациенти с </span><span lang="BG">умерено </span><span lang="BG">чернодробно увреждане </span><span lang="BG">не се препоръчва</span><span lang="BG"> употребата на ивакафтор </span><span lang="BG">в комбинирана схема с </span><span lang="BG">ивакафтор/тезакафтор/елексакафтор</span><span lang="EN-GB">. </span><span lang="BG">Лечението трябва да се обмисли само когато има ясна медицинска необходимост и се очаква </span><span lang="BG">ползите да надвишават рисковете</span><span lang="EN-GB">. </span><span lang="BG">Ако се използва, това трябва да става с повишено внимание с намалена доза</span><span lang="EN-GB"> (</span><span lang="BG">вж.</span><span lang="EN-GB"> Таблица 3 </span><span lang="BG">и точка </span><span lang="EN-GB">4.2 </span><span lang="BG">и </span><span lang="EN-GB">5.2).</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG">Бъбречно увреждане</span></u></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Повишено внимание се препоръчва при употребата на ивакафтор или като монотерапия, или в комбинирана схема с тезакафтор/ивакафтор или ивакафтор/тезакафтор/елексакафтор при пациенти с тежко бъбречно увреждане или терминална бъбречна недостатъчност (вж. точка</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>4.2 и</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>5.2). </span></p><p class="MsoNormal"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG">Пациенти след органна трансплантация</span></u></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal"><span lang="BG">Ивакафтор или като монотерапия, или в комбинирана схема с тезакафтор/ивакафтор или </span><span lang="BG">ивакафтор/тезакафтор/елексакафтор</span><span lang="BG"> </span><span lang="BG">не е проучван при пациенти с КФ, които са претърпели органна трансплантация. Затова не се препоръчва употреба при трансплантирани пациенти. Вижте точка 4.5 за взаимодействия с циклоспорин или такролимус. </span></p><p class="MsoNormal"><u><span lang="EN-GB"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG">Събития на обриви </span></u></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB"> </span></p><p class="MsoNormal"><span lang="BG">Честотата на събитията на обриви </span><span lang="EN-GB">с ивакафтор в комбинирана схема с </span><span lang="BG">ивакафтор/тезакафтор/елексакафтор</span><span lang="BG"> </span><span lang="BG">е по-висока при жените, отколкото при мъжете, особено при жените, приемащи хормонални контрацептиви. Не може да се изключи ролята на хормоналните контрацептиви</span><span lang="BG"> </span><span lang="BG">за възникването на обриви. При пациентките, приемащи хормонални контрацептиви</span><span lang="EN-GB">, които получават обриви, трябва да се обмисли прекъсване на лечението с ивакафтор в комбинирана схема с </span><span lang="BG">ивакафтор/тезакафтор/елексакафтор</span><span lang="BG"> </span><span lang="BG">и хормонални контрацептиви</span><span lang="EN-GB">. След отшумяването на обрива трябва да се обмисли </span><span lang="BG">дали е подходящо </span><span lang="EN-GB">подновяване</span><span lang="BG">то</span><span lang="EN-GB"> на ивакафтор в комбинирана схема с </span><span lang="BG">ивакафтор/тезакафтор/елексакафтор</span><span lang="BG"> </span><span lang="BG">без хормонални контрацептиви</span><span lang="EN-GB">. </span><span lang="BG">Ако не се появи обрив, може да се обмисли подновяването на хормоналните контрацептиви</span><span lang="EN-GB"> (</span><span lang="BG">вж. точка </span><span lang="EN-GB">4.8).</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG">Взаимодействия с лекарствени продукти</span></u></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="BG" style='font-family:"Times New Roman",serif'>Индуктори на CYP3A</span></i></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="BG" style='font-family:"Times New Roman",serif'> </span></i></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Експозицията на ивакафтор се понижава значително, а експозицията на елексакафтор и тезакафтор се очаква да се понижи при съпътстващо приложение с индуктори на CYP3A, което потенциално води до загуба на ефикасност на ивакафтор, ето защо не се препоръчва едновременно приложение на ивакафтор (като монотерапия или в комбинирана схема с тезакафтор/ивакафтор или </span><span lang="BG" style='font-family:"Times New Roman",serif'>ивакафтор/тезакафтор/елексакафтор</span><span lang="BG" style='font-family:"Times New Roman",serif'>) със силни индуктори на CYP3A (вж. точка 4.5).</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="BG" style='font-family:"Times New Roman",serif'>Инхибитори на CYP3A</span></i></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="BG" style='font-family:"Times New Roman",serif'> </span></i></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Експозицията на ивакафтор, </span><span lang="BG" style='font-family:"Times New Roman",serif'>тезакафтор и елексакафтор</span><span lang="BG" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>се повишава, когато се прилагат едновременно със силни или умерени инхибитори на CYP3A. Дозата </span><span lang="BG" style='font-family:"Times New Roman",serif'>ивакафтор</span><span lang="BG" style='font-family:"Times New Roman",serif'> (като монотерапия или в комбинирана схема с тезакафтор/ивакафтор или </span><span lang="BG" style='font-family:"Times New Roman",serif'>ивакафтор/тезакафтор/елексакафтор</span><span lang="BG" style='font-family:"Times New Roman",serif'>) трябва да се коригира, когато се прилага съпътстващо със силни или умерени инхибитори на CYP3A (вж. Таблица 2 и точка 4.2 и 4.5). </span></p><p class="MsoNormal"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Педиатрична популация "/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal"><span lang="BG">Случаи на невродено помътняване на лещата/катаракта без въздействие върху зрението се съобщават при педиатрични пациенти, лекувани с ивакафтор </span><span lang="BG">и със схеми, съдържащи ивакафтор. Въпреки че в някои случаи са налични други рискови фактори (като употреба на кортикостероиди и излагане на радиация), не може да се изключи възможен риск, приписван на лечението с ивакафтор. При педиатрични пациенти, започващи лечение с ивакафтор или като монотерапия, или в комбинирана схема с тезакафтор/ивакафтор или </span><span lang="BG">ивакафтор/тезакафтор/елексакафтор</span><span lang="BG">, се препоръчват офталмологични прегледи на изходно ниво и за проследяване (вж. точка 5.3).</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG">Съдържание на лактоза</span></u></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal"><span lang="EN-GB">Kalydeco</span><span lang="EN-GB"> </span><span lang="BG">съдържа лактоза. Пациенти с редки наследствени проблеми като непоносимост към галактоза, пълен лактазен дефицит или глюкозо-галактозна малабсорбция не трябва да приемат това лекарство.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG">Съдържание на натрий</span></u></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal"><span lang="BG">Това лекарство съдържа по-малко от 1 </span><span lang="EN-GB">mmol</span><span lang="EN-GB"> </span><span lang="BG">натрий (23</span><span lang="EN-GB"> mg</span><span lang="BG">) на доза, т.е. практически не съдържа натрий.</span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.5     Взаимодействие с други лекарствени продукти и други форми на взаимодействие"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoCommentText" style="page-break-after:avoid"><span lang="BG" style="font-size:11.0pt"> </span></p><p class="MsoCommentText"><span lang="BG" style="font-size:11.0pt">Ивакафтор е субстрат на CYP3A4 и CYP3A5. Той е слаб инхибитор на CYP3A и P-gp и потенциален инхибитор на CYP2C9. </span><i><span lang="EN-GB" style="font-size:11.0pt">In vitro</span></i><span lang="EN-GB" style="font-size:11.0pt"> </span><span lang="BG" style="font-size: 11.0pt">проучванията показват, че ивакафтор не е субстрат на </span><span lang="EN-GB" style="font-size:11.0pt">P</span><span lang="BG" style="font-size:11.0pt">‑</span><span lang="EN-GB" style="font-size:11.0pt">gp</span><span lang="BG" style="font-size:11.0pt">. </span></p><p class="MsoCommentText"><span lang="BG" style="font-size:11.0pt;color:black"> </span></p><p class="labeltext" style="page-break-after:avoid"><u><span lang="BG" style='font-family:"Times New Roman",serif'>Лекарствени продукти, повлияващи фармакокинетиката на ивакафтор</span></u></p><p class="labeltext" style="page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="MsoCommentText" style="page-break-after:avoid"><i><span lang="BG" style="font-size:11.0pt">Индуктори на </span></i><i><span lang="EN-GB" style="font-size:11.0pt">CYP</span></i><i><span lang="BG" style="font-size:11.0pt">3</span></i><i><span lang="EN-GB" style="font-size:11.0pt">A</span></i><i><span lang="EN-GB" style="font-size:11.0pt"> </span></i></p><p class="MsoCommentText" style="page-break-after:avoid"><i><span lang="BG" style="font-size:11.0pt"> </span></i></p><p class="MsoCommentText"><span lang="BG" style="font-size:11.0pt">Едновременното приложение на ивакафтор с рифампицин, силен индуктор на </span><span lang="EN-GB" style="font-size:11.0pt">CYP</span><span lang="BG" style="font-size: 11.0pt">3</span><span lang="EN-GB" style="font-size:11.0pt">A</span><span lang="BG" style="font-size:11.0pt">, понижава експозицията на ивакафтор (</span><span lang="EN-GB" style="font-size:11.0pt">AUC</span><span lang="BG" style="font-size:11.0pt">) с 89% и понижава хидроксиметил ивакафтор (</span><span lang="EN-GB" style="font-size:11.0pt">M</span><span lang="BG" style="font-size: 11.0pt">1) в по-малка степен, отколкото ивакафтор. Не се препоръчва едновременно приложение </span><span lang="BG" style="font-size:11.0pt">на <u>ивакафтор</u></span><span lang="BG" style="font-size:11.0pt"> </span><span lang="BG" style="font-size:11.0pt">(като монотерапия или в комбинирана схема с тезакафтор/ивакафтор</span><span lang="BG"> </span><span lang="BG" style="font-size:11.0pt">или </span><span lang="BG" style="font-size:11.0pt">ивакафтор/тезакафтор/елексакафтор</span><span lang="BG" style="font-size:11.0pt">) със силни индуктори на </span><span lang="EN-GB" style="font-size:11.0pt">CYP</span><span lang="BG" style="font-size: 11.0pt">3</span><span lang="EN-GB" style="font-size:11.0pt">A</span><span lang="BG" style="font-size:11.0pt"> като рифампицин, рифабутин, фенобарбитал, карбамазепин, фенитоин и жълт кантарион (</span><i><span lang="EN-GB" style="font-size:11.0pt">Hypericum</span></i><i><span lang="EN-GB" style="font-size:11.0pt"> </span></i><i><span lang="EN-GB" style="font-size:11.0pt">perforatum</span></i><span lang="BG" style="font-size:11.0pt">) (вж. точка</span><span lang="EN-GB" style="font-size: 11.0pt"> </span><span lang="BG" style="font-size:11.0pt">4.4).</span></p><p class="MsoCommentText"><span lang="BG" style="font-size:11.0pt"> </span></p><p class="MsoCommentText"><span lang="BG" style="font-size:11.0pt">Не се препоръчва корекция на дозата, когато ивакафтор (като монотерапия или в комбинирана схема с тезакафтор/ивакафтор</span><span lang="BG"> </span><span lang="BG" style="font-size:11.0pt">или </span><span lang="BG" style="font-size:11.0pt">ивакафтор/тезакафтор/елексакафтор</span><span lang="BG" style="font-size:11.0pt">) се използва с умерени или слаби индуктори на </span><span lang="EN-GB" style="font-size:11.0pt">CYP</span><span lang="BG" style="font-size: 11.0pt">3</span><span lang="EN-GB" style="font-size:11.0pt">A</span><span lang="BG" style="font-size:11.0pt">. </span></p><p class="labeltext"><u><span lang="BG" style='font-family:"Times New Roman",serif'><span style="text-decoration:none"> </span></span></u></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="BG" style='font-family:"Times New Roman",serif'>Инхибитори на CYP3A</span></i></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="BG" style='font-family:"Times New Roman",serif'> </span></i></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Ивакафтор е чувствителен субстрат на CYP3A. Едновременното приложение с кетоконазол, силен инхибитор на CYP3A, повишава 8,5 пъти експозицията на ивакафтор (измерена като площ под кривата [AUC]) и повишава M1 в по-малка степен, отколкото ивакафтор. Препоръчва се намаляване на дозата ивакафтор (като монотерапия или в комбинирана схема с тезакафтор/ивакафтор или </span><span lang="BG" style='font-family:"Times New Roman",serif'>ивакафтор/тезакафтор/елексакафтор</span><span lang="BG" style='font-family:"Times New Roman",serif'>) при едновременно приложение със силни инхибитори на CYP3A като кетоконазол, итраконазол, позаконазол, вориконазол, телитромицин и кларитромицин (вж. Таблица 2 и точка 4.2 и 4.4).</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><b><span lang="BG"> </span></b></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Едновременното приложение с флуконазол, умерено силен инхибитор на CYP3A, повишава експозицията на ивакафтор 3 пъти и повишава M1 в по-малка степен, отколкото ивакафтор. Препоръчва се намаляване на дозата ивакафтор (като монотерапия или в комбинирана схема с тезакафтор/ивакафтор или </span><span lang="BG" style='font-family:"Times New Roman",serif'>ивакафтор/тезакафтор/елексакафтор</span><span lang="BG" style='font-family:"Times New Roman",serif'>) при пациенти, приемащи едновременно умерено силни инхибитори на CYP3A като флуконазол, еритромицин и верапамил (вж. Таблица 2 и точка 4.2 и 4.4). </span></p><p class="labeltext"><u><span lang="BG" style='font-family:"Times New Roman",serif'><span style="text-decoration:none"> </span></span></u></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Едновременното приложение на ивакафтор със сок от грейпфрут, който съдържа една или повече съставки, които умерено инхибират CYP3A, може да повиши експозицията на ивакафтор. По време на лечението с ивакафтор (като монотерапия или в комбинирана схема с тезакафтор/ивакафтор или </span><span lang="BG" style='font-family:"Times New Roman",serif'>ивакафтор/тезакафтор/елексакафтор</span><span lang="BG" style='font-family:"Times New Roman",serif'>) трябва да се избягват храните или напитките, съдържащи грейпфрут (вж. точка 4.2).</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG">Потенциал на ивакафтор да взаимодейства с транспортери</span></i></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal"><i>In vitro</i> <span lang="BG">проучванията показват, че ивакафтор не е субстрат за </span>OATP1B1 <span lang="BG">или</span> OATP1B<span lang="BG">3. Ивакафтор и неговите метаболити са субстрати на </span>BCRP <i><span lang="EN-GB">in vitro</span></i><span lang="BG">. Поради неговия висок присъщ пермеабилитет и малката вероятност да бъде екскретиран непроменен, не се очаква едновременното приложение на инхибитори на </span>BCRP<span lang="BG"> да промени експозицията на ивакафтор и </span>M1-IVA<span lang="BG">, а евентуалните промени в експозицията на </span>M<span lang="BG">6</span>-IVA<span lang="BG"> не се очаква да бъдат клинично значими.</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG">Ципрофлоксацин</span></i></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG"> </span></i></p><p class="MsoNormal"><span lang="BG">Едновременното приложение на ципрофлоксацин с ивакафтор не повлиява експозицията на ивакафтор. Не се налага коригиране на дозата, когато </span><span lang="BG">ивакафтор</span><span lang="BG"> </span><span lang="BG">(като монотерапия или в комбинирана схема с тезакафтор/ивакафтор или </span><span lang="BG">ивакафтор/тезакафтор/елексакафтор</span><span lang="BG">) се прилага едновременно с ципрофлоксацин.</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext" style="page-break-after:avoid"><u><span lang="BG" style='font-family:"Times New Roman",serif'>Лекарствени продукти, които се повлияват от ивакафтор</span></u></p><p class="MsoCommentText" style="page-break-after:avoid"><span lang="BG" style="font-size:11.0pt"> </span></p><p class="MsoCommentText"><span lang="BG" style="font-size:11.0pt">Приложението на ивакафтор може да повиши системната експозиция на лекарствени продукти, чувствителни субстрати на </span><span lang="EN-GB" style="font-size:11.0pt">CYP</span><span lang="BG" style="font-size: 11.0pt">2</span><span lang="EN-GB" style="font-size:11.0pt">C</span><span lang="BG" style="font-size:11.0pt">9</span><span lang="BG" style="font-size:11.0pt"> </span><span lang="BG" style="font-size:11.0pt">и/или </span><span lang="EN-GB" style="font-size:11.0pt">P</span><span lang="BG" style="font-size: 11.0pt">‑</span><span lang="EN-GB" style="font-size:11.0pt">gp</span><span lang="BG" style="font-size:11.0pt">, и/или</span><span lang="BG" style="font-size:11.0pt"> </span><span lang="EN-GB" style="font-size: 11.0pt">CYP</span><span lang="BG" style="font-size:11.0pt">3</span><span lang="EN-GB" style="font-size:11.0pt">A</span><span lang="BG" style="font-size: 11.0pt">, което може да повиши или удължи техния терапевтичен ефект и нежелани реакции.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG">Субстрати на CYP2C9</span></i></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG"> </span></i></p><p class="MsoCommentText"><span lang="BG" style="font-size:11.0pt">Ивакафтор може да инхибира </span><span lang="EN-GB" style="font-size:11.0pt">CYP</span><span lang="BG" style="font-size: 11.0pt">2</span><span lang="EN-GB" style="font-size:11.0pt">C</span><span lang="BG" style="font-size:11.0pt">9. Затова се препоръчва наблюдение на международното нормализирано съотношение (</span><i><span lang="EN-GB" style="font-size:11.0pt">international</span></i><i><span lang="EN-GB" style="font-size:11.0pt"> </span></i><i><span lang="EN-GB" style="font-size:11.0pt">normalised</span></i><i><span lang="EN-GB" style="font-size:11.0pt"> </span></i><i><span lang="EN-GB" style="font-size:11.0pt">ratio</span></i><span lang="EN-GB" style="font-size:11.0pt"> </span><span lang="BG" style="font-size: 11.0pt">– </span><span lang="EN-GB" style="font-size:11.0pt">INR</span><span lang="BG" style="font-size:11.0pt">) по време на едновременното приложение на варфарин с </span><span lang="BG" style="font-size:11.0pt">ивакафтор</span><span lang="BG" style="font-size:11.0pt"> </span><span lang="BG" style="font-size:11.0pt">(като монотерапия или в комбинирана схема с тезакафтор/ивакафтор или </span><span lang="BG" style="font-size:11.0pt">ивакафтор/тезакафтор/елексакафтор</span><span lang="BG" style="font-size:11.0pt">). Другите лекарствени продукти, чиято експозиция може да се повиши, включват глимепирид и глипизид. Тези лекарствени продукти трябва да се прилагат с повишено внимание.</span></p><p class="MsoCommentText"><u><span lang="BG" style="font-size:11.0pt"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG">Дигоксин и други субстрати на </span></i><i><span lang="EN-GB">P</span></i><i><span lang="BG">-</span></i><i><span lang="EN-GB">gp</span></i></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG"> </span></i></p><p class="MsoCommentText"><span lang="BG" style="font-size:11.0pt">Едновременното приложение с </span><span lang="BG" style="font-size:11.0pt">дигоксин, чувствителен субстрат на </span><span lang="EN-GB" style="font-size:11.0pt">P</span><span lang="BG" style="font-size: 11.0pt">-</span><span lang="EN-GB" style="font-size:11.0pt">gp</span><span lang="BG" style="font-size:11.0pt">, повишава експозицията на дигоксин 1,3 пъти, което съответства на слабо инхибиране на </span><span lang="EN-GB" style="font-size:11.0pt">P</span><span lang="BG" style="font-size:11.0pt">‑</span><span lang="EN-GB" style="font-size:11.0pt">gp</span><span lang="EN-GB" style="font-size:11.0pt"> </span><span lang="BG" style="font-size:11.0pt">от ивакафтор. Приложението на </span><span lang="BG" style="font-size:11.0pt">ивакафтор</span><span lang="BG" style="font-size:11.0pt"> </span><span lang="BG" style="font-size:11.0pt">(като монотерапия или в комбинирана схема с тезакафтор/ивакафтор или </span><span lang="BG" style="font-size:11.0pt">ивакафтор/тезакафтор/елексакафтор</span><span lang="BG" style="font-size:11.0pt">) може да повиши системната експозиция на лекарствени продукти, чувствителни субстрати на </span><span lang="EN-GB" style="font-size:11.0pt">P</span><span lang="BG" style="font-size: 11.0pt">‑</span><span lang="EN-GB" style="font-size:11.0pt">gp</span><span lang="BG" style="font-size:11.0pt">, което може да повиши или удължи техния терапевтичен ефект и нежелани реакции. Когато се прилага едновременно с дигоксин или други субстрати на </span><span lang="EN-GB" style="font-size:11.0pt">P</span><span lang="BG" style="font-size: 11.0pt">‑</span><span lang="EN-GB" style="font-size:11.0pt">gp</span><span lang="BG" style="font-size:11.0pt"> с тесен терапевтичен индекс, като например циклоспорин, еверолимус, сиролимус или такролимус, трябва да се подхожда с повишено внимание и да се извършва нужното наблюдение.</span></p><p class="MsoCommentText"><span lang="BG" style="font-size:11.0pt"> </span></p><p class="MsoCommentText" style="page-break-after:avoid"><i><span lang="BG" style="font-size:11.0pt">Субстрати на </span></i><i><span lang="EN-GB" style="font-size:11.0pt">CYP</span></i><i><span lang="RU" style="font-size:11.0pt">3</span></i><i><span lang="EN-GB" style="font-size:11.0pt">A</span></i></p><p class="MsoCommentText" style="page-break-after:avoid"><i><span lang="BG" style="font-size:11.0pt"> </span></i></p><p class="MsoCommentText"><span lang="BG" style="font-size:11.0pt">Едновременното приложение с (перорален) мидазолам, който е чувствителен субстрат на CYP3A, повишава експозицията на мидазолам 1,5 пъти, което съответства на слабо инхибиране на CYP3A от ивакафтор. </span><span lang="BG" style="font-size:11.0pt">Не се налага корекция на дозата на субстрати на </span><span lang="EN-GB" style="font-size:11.0pt">CYP</span><span lang="BG" style="font-size: 11.0pt">3</span><span lang="EN-GB" style="font-size:11.0pt">A</span><span lang="EN-GB" style="font-size:11.0pt"> </span><span lang="BG" style="font-size: 11.0pt">като мидазолам, алпразолам, диазепам или триазолам, когато те се прилагат едновременно с ивакафтор (като монотерапия или в комбинирана схема с тезакафтор/ивакафтор или </span><span lang="BG" style="font-size:11.0pt">ивакафтор/тезакафтор/елексакафтор</span><span lang="BG" style="font-size:11.0pt">). </span></p><p class="MsoNormal"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="RU">Хормонални контрацептиви</span></i></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="RU"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal"><span lang="BG">Ивакафтор (като монотерапия или в комбинирана схема с тезакафтор/ивакафтор или </span><span lang="BG">ивакафтор/тезакафтор/елексакафтор</span><span lang="BG">) е проучван с естроген/прогестерон перорални контрацептиви и е доказано, че няма значим ефект върху експозицията на пероралния контрацептив. </span><span lang="BG">Затова не се налага корекция на дозата на пероралните контрацептиви</span><span lang="BG">.</span></p><p class="labeltext"><u><span lang="BG" style='font-family:"Times New Roman",serif'><span style="text-decoration:none"> </span></span></u></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Педиатрична популация"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="labeltext" style="page-break-after:avoid"><u><span lang="BG" style='font-family:"Times New Roman",serif'><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal"><span lang="BG">Проучвания за взаимодействията са провеждани само при възрастни. </span></p><p class="labeltext"><u><span lang="BG" style='font-family:"Times New Roman",serif'><span style="text-decoration:none"> </span></span></u></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.6     Фертилитет, бременност и кърмене"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG"> </span></i></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Бременност "/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="labeltext" style="page-break-after:avoid"><u><span lang="BG" style='font-family:"Times New Roman",serif'><span style="text-decoration:none"> </span></span></u></p><p class="Default"><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>Липсват или има ограничени данни (за изхода на по-малко от 300 случая на бременност) от употребата на </span><span lang="RU" style='font-size:11.0pt;font-family:"Times New Roman",serif'>ивакафтор </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>при бременни жени</span><span lang="RU" style='font-size:11.0pt; font-family:"Times New Roman",serif'>. </span><span lang="BG" style='font-size: 11.0pt;font-family:"Times New Roman",serif'>Проучванията при животни не показват преки или непреки вредни ефекти, свързани с репродуктивна токсичност</span><span lang="RU" style='font-size:11.0pt;font-family:"Times New Roman",serif'> (</span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>вж. точка</span><span lang="RU" style='font-size:11.0pt; font-family:"Times New Roman",serif'> 5.3). Като </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>предпазна мярка </span><span lang="EN-GB" style='font-size: 11.0pt;font-family:"Times New Roman",serif'>e</span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'> за предпочитане да се избягва употребата на </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>ивакафтор</span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>по време на бременност.</span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Кърмене"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Не е известно дали ивакафтор и/или неговите метаболити се екскретират в кърмата. </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>Наличните фармакокинетични данни при животни показват екскреция на </span><span lang="BG" style='font-family:"Times New Roman",serif'>ивакафтор в млякото на лактиращи женски плъхове. Поради тази причина </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>не </span><span lang="BG" style='font-family:"Times New Roman",serif'>може да се изключи риск за </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>новородените/кърмачетата</span><span lang="BG" style='font-family:"Times New Roman",serif'>. </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>Трябва да се вземе решение дали да се преустанови кърменето или да се преустанови/не се приложи терапията с </span><span lang="BG" style='font-family:"Times New Roman",serif'>ивакафтор</span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>, като се вземат предвид ползата от кърменето за детето и ползата от терапията за жената</span><span lang="BG" style='font-family:"Times New Roman",serif'>.</span></p><p class="MsoNormalIndent" style="margin:0in"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Фертилитет"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormalIndent" style="margin:0in;page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal"><span lang="BG">Липсват данни за ефекта на ивакафтор върху фертилитета при хора. Ивакафтор оказва въздействие върху фертилитета при плъхове (вж. точка 5.3).</span></p><p class="MsoNormal"><span lang="BG" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.7     Ефекти върху способността за шофиране и работа с машини"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;page-break-after: avoid"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Ивакафтор</span><span lang="BG"> </span><span lang="BG">повлиява в малка степен способността за шофиране и работа с машини. Ивакафтор може да причини замаяност </span><span lang="BG">(вж. точка 4.8), ето защо пациентите, получили замаяност, трябва да бъдат посъветвани да не шофират и да на работят с машини, докато симптомите не отзвучат.</span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.8     Нежелани лекарствени реакции"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><span lang="BG"> </span></p><p class="labeltext" style="page-break-after:avoid"><u><span lang="BG" style='font-family:"Times New Roman",serif'>Резюме на профила на безопасност</span></u></p><p class="labeltext" style="page-break-after:avoid"><u><span lang="BG" style='font-family:"Times New Roman",serif'><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal"><span lang="BG">Най-честите нежелани реакции при пациентите на възраст 6 и повече години, получаващи ивакафтор, са </span><span lang="BG">главоболие (23,9%), орофарингеална болка (22,0%), </span><span lang="BG">инфекция на горните дихателни пътища</span><span lang="BG"> (22,0%), назална конгестия (20,2%), </span><span lang="BG">коремна болка (15,6%), </span><span lang="BG">назофарингит (14,7%), </span><span lang="BG">диария (12,8%), замаяност (9,2%), обрив (12,8%) </span><span lang="BG">и бактерии в храчките (12,8%). Повишения на трансаминазите възникват при 12,8% от лекуваните с ивакафтор пациенти спрямо 11,5% от пациентите на плацебо.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">При </span><span lang="BG">пациентите на възраст от 2 до под 6</span><span lang="EN-GB"> </span><span lang="BG">години най-честите нежелани реакции са назална конгестия (26,5%),</span><span lang="BG"> инфекция на горните дихателни пътища </span><span lang="BG">(23,5%), повишения на трансаминазите (14,7%), обрив (11,8%) и бактерии</span><span lang="BG"> в </span><span lang="BG">храчките (11,8%).</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Сериозните нежелани реакции при пациентите, които са получавали ивакафтор, включват</span><span lang="BG" style='font-family:"Times New Roman",serif'> коремна болка и повишения на трансаминазите</span><span lang="BG" style='font-family:"Times New Roman",serif'> (вж. точка 4.4)</span><span lang="BG" style='font-family:"Times New Roman",serif'>.</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext" style="line-height:13.0pt;page-break-after:avoid"><u><span lang="BG" style='font-family:"Times New Roman",serif'>Табличен списък на нежеланите реакции</span></u></p><p class="labeltext" style="line-height:13.0pt;page-break-after:avoid"><u><span lang="BG" style='font-family:"Times New Roman",serif'><span style="text-decoration:  none"> </span></span></u></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Таблица </span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>4</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>отразява нежеланите реакции, наблюдавани при монотерапия с ивакафтор в клинични изпитвания (плацебо-контролирани и неконтролирани проучвания), при които продължителността на експозицията на ивакафтор варира от 16 седмици до 144 седмици. Допълнителни нежелани лекарствени реакции, наблюдавани при ивакафтор в комбинирана схема с тезакафтор/ивакафтор и/или </span><span lang="BG" style='font-family:"Times New Roman",serif'>ивакафтор/тезакафтор/елексакафтор</span><span lang="BG" style='font-family:"Times New Roman",serif'>, са дадени също в Таблица 4. Честотата на нежеланите реакции е дефинирана както следва: много чести (</span><span style='font-family:"Times New Roman",serif'>≥</span><span lang="BG" style='font-family:"Times New Roman",serif'>1/10); чести (</span><span style='font-family:"Times New Roman",serif'>≥</span><span lang="BG" style='font-family:"Times New Roman",serif'>1/100 до &lt;1/10); нечести (</span><span style='font-family:"Times New Roman",serif'>≥</span><span lang="BG" style='font-family:"Times New Roman",serif'>1/1 000 до &lt;1/100); редки (</span><span style='font-family: "Times New Roman",serif'>≥</span><span lang="BG" style='font-family:"Times New Roman",serif'>1/10 000 до &lt;1/1 000); много редки (&lt;1/10 000); с неизвестна честота (от наличните данни не може да бъде направена оценка). Във всяка от групите по честота нежеланите реакции са подредени по намаляваща сериозност.</span></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:6.0pt; margin-left:56.7pt;text-align:justify;text-justify:inter-ideograph;text-indent: -56.7pt;page-break-after:avoid"><b><span lang="BG">Таблица </span></b><b><span lang="EN-GB">4</span></b><b><span lang="BG">: Нежелани реакции</span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:100.0%;border-collapse:collapse;border:none" width="100%"> <thead> <tr style="page-break-inside:avoid;height:26.4pt"> <td style="width:33.66%;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:26.4pt" valign="top" width="33%"> <p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph;    page-break-after:avoid"><b><span lang="BG">Системо-органен    клас</span></b></p> </td> <td style="width:34.98%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:26.4pt" valign="top" width="34%"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><b><span lang="BG">Нежелани    реакции</span></b></p> </td> <td style="width:31.36%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:26.4pt" valign="top" width="31%"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><b><span lang="BG">Честота</span></b></p> </td> </tr> </thead> <tr style="page-break-inside:avoid;height:6.4pt"> <td rowspan="4" style="width:33.66%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="33%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Инфекции   и инфестации</span></p> </td> <td style="width:34.98%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="34%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Инфекция   на горните   дихателни   пътища </span></p> </td> <td style="width:31.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="31%"> <p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph;   page-break-after:avoid"><span lang="BG">много   чести</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:6.4pt"> <td style="width:34.98%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="34%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Назофарингит   </span></p> </td> <td style="width:31.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="31%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">много   чести</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:6.35pt"> <td style="width:34.98%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="34%"> <p class="MsoNormal"><span lang="BG">Грип </span><sup><span lang="EN-GB" style='font-family:"Arial",sans-serif'>†</span></sup></p> </td> <td style="width:31.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="31%"> <p class="MsoNormal"><span lang="BG">чести</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:6.35pt"> <td style="width:34.98%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="34%"> <p class="MsoNormal"><span lang="BG">Ринит</span></p> </td> <td style="width:31.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="31%"> <p class="MsoNormal"><span lang="BG">чести</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.66%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Нарушения   на   метаболизма   и храненето</span></p> </td> <td style="width:34.98%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="34%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Хипогликемия   </span><sup><span lang="EN-GB" style='font-family:"Arial",sans-serif'>†</span></sup></p> </td> <td style="width:31.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="31%"> <p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph;   page-break-after:avoid"><span lang="BG">чести</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td rowspan="2" style="width:33.66%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Нарушения   на нервната   система</span></p> </td> <td style="width:34.98%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="34%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Главоболие</span></p> </td> <td style="width:31.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="31%"> <p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph;   page-break-after:avoid"><span lang="BG">много   чести</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:34.98%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="34%"> <p class="MsoNormal"><span lang="BG">Замаяност</span></p> </td> <td style="width:31.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="31%"> <p class="MsoNormal"><span lang="BG">много чести</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:13.15pt"> <td rowspan="6" style="width:33.66%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="33%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Нарушения   на ухото и   лабиринта</span></p> </td> <td style="width:34.98%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="34%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Болка   в ухото</span></p> </td> <td style="width:31.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="31%"> <p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph;   page-break-after:avoid"><span lang="BG">чести</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:13.15pt"> <td style="width:34.98%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="34%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Ушен   дискомфорт </span></p> </td> <td style="width:31.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="31%"> <p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph;   page-break-after:avoid"><span lang="BG">чести</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:13.15pt"> <td style="width:34.98%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="34%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Тинитус</span></p> </td> <td style="width:31.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="31%"> <p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph;   page-break-after:avoid"><span lang="BG">чести</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:13.15pt"> <td style="width:34.98%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="34%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Хиперемия   на   тъпанчевата   мембрана</span></p> </td> <td style="width:31.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="31%"> <p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph;   page-break-after:avoid"><span lang="BG">чести</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:13.15pt"> <td style="width:34.98%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="34%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Вестибуларно   нарушение </span></p> </td> <td style="width:31.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="31%"> <p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph;   page-break-after:avoid"><span lang="BG">чести</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:13.15pt"> <td style="width:34.98%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="34%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Конгестия   на ухото </span></p> </td> <td style="width:31.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="31%"> <p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph;   page-break-after:avoid"><span lang="BG">нечести</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:13.15pt"> <td rowspan="6" style="width:33.66%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="33%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Респираторни,   гръдни и   медиастинални   нарушения</span></p> </td> <td style="width:34.98%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="34%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Орофарингеална   болка</span></p> </td> <td style="width:31.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="31%"> <p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph;   page-break-after:avoid"><span lang="BG">много   чести</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:6.4pt"> <td style="width:34.98%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="34%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Назална   конгестия </span></p> </td> <td style="width:31.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="31%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">много   чести</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:6.4pt"> <td style="width:34.98%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="34%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Промяна   в дишането</span><span lang="BG"> </span><sup><span lang="EN-GB" style='font-family:"Arial",sans-serif'>†</span></sup></p> </td> <td style="width:31.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="31%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">чести</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:6.4pt"> <td style="width:34.98%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="34%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Ринорея</span><span lang="BG"> </span><sup><span lang="EN-GB" style='font-family:"Arial",sans-serif'>†</span></sup></p> </td> <td style="width:31.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="31%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">чести</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:6.4pt"> <td style="width:34.98%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="34%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Конгестия   на синусите </span></p> </td> <td style="width:31.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="31%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">чести</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:6.35pt"> <td style="width:34.98%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="34%"> <p class="MsoNormal"><span lang="BG">Фарингеален   еритем</span></p> </td> <td style="width:31.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="31%"> <p class="MsoNormal"><span lang="BG">чести</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:6.35pt"> <td style="width:33.66%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="33%"> <p class="MsoNormal"><span lang="BG"> </span></p> </td> <td style="width:34.98%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="34%"> <p class="MsoNormal"><span lang="BG">Хриптене   </span><sup><span lang="EN-GB" style='font-family:"Arial",sans-serif'>†</span></sup></p> </td> <td style="width:31.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="31%"> <p class="MsoNormal"><span lang="BG">нечести</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:18.75pt"> <td rowspan="5" style="width:33.66%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.75pt" valign="top" width="33%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Стомашно-чревни   нарушения</span></p> </td> <td style="width:34.98%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.75pt" valign="top" width="34%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Коремна   болка</span></p> </td> <td style="width:31.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.75pt" valign="top" width="31%"> <p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph;   page-break-after:avoid"><span lang="BG">много   чести</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:18.75pt"> <td style="width:34.98%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.75pt" valign="top" width="34%"> <p class="MsoNormal"><span lang="BG">Диария</span></p> </td> <td style="width:31.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.75pt" valign="top" width="31%"> <p class="MsoNormal"><span lang="BG">много   чести</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:18.75pt"> <td style="width:34.98%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.75pt" valign="top" width="34%"> <p class="MsoNormal"><span lang="BG">Болка в   горната   част на   корема </span><sup><span lang="EN-GB" style='font-family:"Arial",sans-serif'>†</span></sup></p> </td> <td style="width:31.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.75pt" valign="top" width="31%"> <p class="MsoNormal"><span lang="BG">чести</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:18.75pt"> <td style="width:34.98%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.75pt" valign="top" width="34%"> <p class="MsoNormal"><span lang="BG">Флатуленция   </span><sup><span lang="EN-GB" style='font-family:"Arial",sans-serif'>†</span></sup></p> </td> <td style="width:31.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.75pt" valign="top" width="31%"> <p class="MsoNormal"><span lang="BG">чести</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:18.75pt"> <td style="width:34.98%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.75pt" valign="top" width="34%"> <p class="MsoNormal"><span lang="BG">Гадене</span><span lang="EN-GB">*</span></p> </td> <td style="width:31.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.75pt" valign="top" width="31%"> <p class="MsoNormal"><span lang="BG">чести</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:18.75pt"> <td rowspan="3" style="width:33.66%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.75pt" valign="top" width="33%"> <p class="MsoNormal"><span lang="BG">Хепатобилиарни   нарушения</span></p> </td> <td style="width:34.98%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.75pt" valign="top" width="34%"> <p class="MsoNormal"><span lang="BG">Повишения   на   трансаминазите</span></p> </td> <td style="width:31.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.75pt" valign="top" width="31%"> <p class="MsoNormal"><span lang="BG">много   чести</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:34.98%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="34%"> <p class="MsoNormal"><span lang="BG">Повишена   аланин   аминотрансфераза</span><span lang="BG"> </span><sup><span lang="EN-GB" style='font-family:"Arial",sans-serif'>†</span></sup></p> </td> <td style="width:31.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="31%"> <p class="MsoNormal"><span lang="BG">чести</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:34.98%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="34%"> <p class="MsoNormal"><span lang="BG">Повишена   аспартат   аминотрансфераза</span><span lang="BG"> </span><sup><span lang="EN-GB" style='font-family:"Arial",sans-serif'>†</span></sup></p> </td> <td style="width:31.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="31%"> <p class="MsoNormal"><span lang="BG">чести</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td rowspan="3" style="width:33.66%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal"><span lang="BG">Нарушения   на кожата и   подкожната   тъкан</span></p> </td> <td style="width:34.98%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="34%"> <p class="MsoNormal"><span lang="BG">Обрив</span></p> </td> <td style="width:31.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="31%"> <p class="MsoNormal"><span lang="BG">много   чести</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:34.98%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="34%"> <p class="MsoNormal"><span lang="BG">Акне </span><sup><span lang="EN-GB" style='font-family:"Arial",sans-serif'>†</span></sup></p> </td> <td style="width:31.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="31%"> <p class="MsoNormal"><span lang="BG">чести</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:34.98%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="34%"> <p class="MsoNormal"><span lang="BG">Пруритус   </span><sup><span lang="EN-GB" style='font-family:"Arial",sans-serif'>†</span></sup></p> </td> <td style="width:31.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="31%"> <p class="MsoNormal"><span lang="BG">чести</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td rowspan="5" style="width:33.66%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal"><span lang="BG">Нарушения   на   възпроизводителната   система и   гърдата</span></p> </td> <td style="width:34.98%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="34%"> <p class="MsoNormal"><span lang="BG">Образувание   в гърдата</span></p> </td> <td style="width:31.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="31%"> <p class="MsoNormal"><span lang="BG">чести</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:34.98%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="34%"> <p class="MsoNormal"><span lang="BG">Възпаление   на гърдата </span></p> </td> <td style="width:31.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="31%"> <p class="MsoNormal"><span lang="BG">нечести</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:34.98%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="34%"> <p class="MsoNormal"><span lang="BG">Гинекомастия</span></p> </td> <td style="width:31.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="31%"> <p class="MsoNormal"><span lang="BG">нечести</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:34.98%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="34%"> <p class="MsoNormal"><span lang="BG">Нарушение   на гръдното   зърно</span></p> </td> <td style="width:31.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="31%"> <p class="MsoNormal"><span lang="BG">нечести</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:34.98%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="34%"> <p class="MsoNormal"><span lang="BG">Болка в   гръдното   зърно</span></p> </td> <td style="width:31.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="31%"> <p class="MsoNormal"><span lang="BG">нечести</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td rowspan="3" style="width:33.66%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Изследвания</span></p> </td> <td style="width:34.98%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="34%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Бактерии   в храчките</span></p> </td> <td style="width:31.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="31%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">много   чести</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:34.98%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="34%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Повишена   креатин   фосфокиназа   в кръвта</span><span lang="BG"> </span><sup><span lang="EN-GB" style='font-family:"Arial",sans-serif'>†</span></sup></p> </td> <td style="width:31.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="31%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">чести</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:34.98%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="34%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Повишено   кръвно   налягане </span><sup><span lang="EN-GB" style='font-family:"Arial",sans-serif'>†</span></sup></p> </td> <td style="width:31.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="31%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">нечести</span></p> </td> </tr> </table><p class="MsoNormal"><sup><span lang="EN-GB" style="font-size:9.0pt">*</span></sup><span lang="EN-GB" style="font-size:9.0pt"> </span><span lang="BG" style="font-size:9.0pt">Нежелана реакция и честота, съобщени само при клинични проучвания с ивакафтор в комбинация с тезакафтор/ивакафтор</span></p><p class="MsoNormal"><sup><span lang="EN-GB" style='font-family:"Arial",sans-serif'>†</span></sup><sup><span lang="EN-GB" style='font-family:"Arial",sans-serif'> </span></sup><span lang="BG" style="font-size:9.0pt">Нежелана реакция и честота, съобщени само при клинични проучвания с ивакафтор в комбинация с ивакафтор/тезакафтор/елексакафтор<span style="color:#1F497D">.</span></span></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG">Описание на избрани нежелани реакции</span></u></p><p class="MsoNormal" style="page-break-after:avoid"><b><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></b></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG">Повишения на трансаминазите</span></i></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG"> </span></i></p><p class="MsoNormal"><span lang="BG">По време на 48-седмичните плацебо-контролирани проучвания 1 и 2 на ивакафтор като монотерапия при пациенти на възраст 6</span> <span lang="BG">и повече години честотата на максимални стойности на трансаминазите (</span><span lang="EN-GB">ALT</span><span lang="EN-GB"> </span><span lang="BG">или </span><span lang="EN-GB">AST</span><span lang="BG">) &gt;</span><span lang="EN-GB"> </span><span lang="BG">8, &gt;</span><span lang="EN-GB"> </span><span lang="BG">5 или &gt;</span><span lang="EN-GB"> </span><span lang="BG">3</span><span lang="EN-GB"> x ULN</span><span lang="EN-GB"> </span><span lang="BG">е съответно 3,7%; 3,7% и 8,3% при пациентите, лекувани с ивакафтор, и 1,0%; 1,9% и 8,7% при пациентите, третирани с плацебо. Двама пациенти, един на плацебо и един на ивакафтор, прекратяват окончателно лечението поради повишени трансаминази, всеки &gt;</span><span lang="EN-GB"> </span><span lang="BG">8</span><span lang="EN-GB"> x ULN</span><span lang="BG">. Нито един от лекуваните с ивакафтор пациенти не е получил повишение на трансаминазите &gt;</span><span lang="EN-GB"> </span><span lang="BG">3</span><span lang="EN-GB"> x ULN</span><span lang="BG">, асоциирано с повишен общ билирубин &gt;</span><span lang="EN-GB"> </span><span lang="BG">1,5</span><span lang="EN-GB"> x ULN</span><span lang="BG">. При пациентите, лекувани с ивакафтор, повечето повишения на трансаминазите до 5</span><span lang="EN-GB"> x ULN</span><span lang="EN-GB"> </span><span lang="BG">отшумяват без прекъсване на лечението. Приложението на ивакафтор е прекъснато при повечето пациенти с повишения на трансаминазите &gt;</span><span lang="EN-GB"> </span><span lang="BG">5</span><span lang="EN-GB"> x ULN</span><span lang="BG">. Във всички случаи, където приложението е прекъснато поради повишени трансаминази и впоследствие е подновено, приложението на ивакафтор е могло да бъде подновено успешно (вж. точка</span><span lang="EN-GB"> </span><span lang="BG">4.4).</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">По време на плацебо-контролираните проучвания фаза</span><span lang="EN-GB"> </span><span lang="BG">3 (до 24</span><span lang="EN-GB"> </span><span lang="BG">седмици) на тезакафтор/ивакафтор честотата на максимални стойности на трансаминазите (</span><span lang="EN-GB">ALT</span><span lang="BG"> или </span><span lang="EN-GB">AST</span><span lang="BG">) &gt;8, &gt;5 или &gt;3</span><span lang="EN-GB"> x ULN</span><span lang="BG"> е 0,2%; 1,0% и 3,4% при пациентите, лекувани с тезакафтор/ивакафтор, и 0,4%; 1,0% и 3,4% при третираните с плацебо пациенти. Един пациент (0,2%) на терапия и 2</span><span lang="EN-GB"> </span><span lang="BG">пациента (0,4%) на плацебо спират окончателно лечението поради повишени трансаминази. При нито един пациент, лекуван с тезакафтор/ивакафтор, не се получава повишение на трансаминазите &gt;</span><span lang="EN-GB"> </span><span lang="BG">3</span><span lang="EN-GB"> x ULN</span><span lang="BG">, свързвано с повишен общ билирубин &gt;</span><span lang="EN-GB"> </span><span lang="BG">2</span><span lang="EN-GB"> x ULN</span><span lang="BG">.</span></p><p class="MsoNormal" style="margin-left:40.3pt;text-indent:-40.3pt;page-break-after: avoid"><span lang="EN-GB"> </span></p><p class="MsoNormal"><span lang="BG">По време на 24</span><span lang="EN-GB"> </span><span lang="BG">седмичното плацебо-контролирано проучване фаза</span><span lang="EN-GB"> </span><span lang="BG">3</span><span lang="BG"> </span><span lang="BG">на ивакафтор/тезакафтор/елексакафтор тези показатели са </span>1<span lang="BG">,</span>5%, 2<span lang="BG">,</span>5% <span lang="BG">и </span>7<span lang="BG">,</span>9% <span lang="BG">при пациентите, лекувани с </span><span lang="BG">ивакафтор/тезакафтор/елексакафтор, и </span>1<span lang="BG">,</span>0%, 1<span lang="BG">,</span>5%<span lang="BG"> и </span>5<span lang="BG">,</span>5% <span lang="BG">при </span><span lang="BG">третираните с плацебо пациенти</span>. <span lang="BG">Честотата на нежеланите реакции на повишение на трансаминазите е</span> 10<span lang="BG">,</span>9% <span lang="BG">при пациентите, лекувани с ивакафтор </span><span lang="BG">в комбинирана схема с ивакафтор/тезакафтор/елексакафтор,</span><span lang="BG"> </span><span lang="BG">и </span>4<span lang="BG">,</span>0% <span lang="BG">при третираните с плацебо пациенти.</span></p><p class="MsoNormal"><i><span lang="EN-GB"> </span></i></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG">Събития на обриви</span></i></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB"> </span></i></p><p class="MsoNormal"><span lang="BG">При употребата на ивакафтор</span><span lang="BG"> в комбинирана схема с ивакафтор/тезакафтор/елексакафтор се наблюдават събития на обриви, общо взето леки до умерени по своята тежест, които възникват по-често при лекуваните жени (</span><span lang="EN-GB">16</span><span lang="BG">,</span><span lang="EN-GB">3%</span><span lang="BG">) и при онези от тях, които приемат </span><span lang="EN-GB">хормоналн</span><span lang="BG">и</span><span lang="EN-GB"> контрацептив</span><span lang="BG">и (20,5</span><span lang="EN-GB">%</span><span lang="BG">) </span><span lang="EN-GB">(</span><span lang="BG">вж. точка </span><span lang="EN-GB">4.4).</span></p><p class="MsoNormal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG">Повишена</span><span lang="BG"> </span><span lang="EN-GB">креатин фосфокиназа</span></i></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB"> </span></i></p><p class="MsoNormal"><span lang="BG">Общо взето преходни и асимптоматични повишения </span><span lang="BG">на </span><span lang="EN-CA">креатин фосфокиназа</span><span lang="BG">та се наблюдават при </span><span lang="BG">пациенти, лекувани с ивакафтор </span><span lang="BG">в комбинирана схема с ивакафтор/тезакафтор/елексакафтор, което не води до спиране на лечението</span><span lang="EN-CA">.</span></p><p class="MsoNormal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG">Повишено к</span><span lang="EN-GB">ръвно налягане</span></i></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB"> </span></i></p><p class="MsoNormal"><span lang="BG">Повишение от изходното ниво на средното систолно и диастолно</span><span lang="BG"> </span><span lang="EN-GB">кръвно налягане </span><span lang="BG">съответно с </span><span lang="EN-GB">3</span><span lang="BG">,</span><span lang="EN-GB">5 mmHg </span><span lang="BG">и </span><span lang="EN-GB">1</span><span lang="BG">,</span><span lang="EN-GB">9 mmHg</span><span lang="EN-GB"> </span><span lang="BG">се наблюдават при </span><span lang="BG">пациентите, лекувани с ивакафтор </span><span lang="BG">в комбинирана схема с ивакафтор/тезакафтор/елексакафтор</span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Педиатрична популация"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Данните за безопасност на ивакафтор като монотерапия са оценени при </span><span lang="EN-GB">6 </span><span lang="BG">пациенти на възраст между 4 месеца до под 6 месеца, 11 пациенти на възраст от 6 месеца до под 12 месеца, 19 пациенти на възраст от 12 месеца до под 24 месеца, 34 пациенти на възраст от 2 до под 6 години, 61 пациенти на възраст от 6 до под 12 години и 94 пациенти на възраст от 12 до под 18 години.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Профилът на безопасност на ивакафтор (като монотерапия и в комбинирана схема) в общи линии е сходен при педиатрични пациенти и също е сходен с този при възрастни пациенти.</span></p><p class="MsoNormal"><i><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></i></p><p class="MsoNormal"><span lang="BG">Честотата на повишения на трансаминазите (</span><span lang="EN-GB">ALT</span><span lang="BG"> или </span><span lang="EN-GB">AST</span><span lang="BG">), наблюдавана в проучвания 2, 5 и 6, (пациенти на възраст от 6 до под 12 години), в проучване 7 (пациенти на възраст от 2 до под 6 години) и в проучване 8 (пациенти на възраст от 6 до под 24 месеца ) е описана в Таблица 5. В плацебо-контролираните проучвания ч</span><span lang="BG">естотата на случаите на повишение на трансаминазите е подобна при лечението с ивакафтор (15,0%) и плацебо (14,6%). Пиковите повишения на чернодробните функционални показатели обикновено са по-големи при педиатричните пациенти, отколкото при по-възрастните пациенти. При всички популации пиковите повишения на чернодробните функционални показатели се връщат към стойностите от изходното ниво след прекъсване, а в почти всички случаи, в които приложението е прекъснато поради повишени трансаминази и впоследствие подновено, приложението на ивакафтор е могло да бъде подновено успешно (вж. точка 4.4). Наблюдавани са случаи, показващи повторно повишаване на трансаминазите при подновяване на лечението</span>. <span lang="BG">В проучване 7 ивакафтор е окончателно спрян при един пациент. В проучване 8 н</span><span lang="BG">яма пациенти с повишения на общия билирубин или които да са прекъснали лечението с ивакафтор поради повишаване на трансаминазите в никоя от възрастовите кохорти </span><span lang="RU">(</span><span lang="BG">вж. точка</span><span lang="EN-GB"> </span><span lang="RU">4.4 </span><span lang="BG">за овладяване на повишените трансаминази</span><span lang="RU">).</span></p><p class="MsoNormal"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="margin-bottom:12.0pt;page-break-after:avoid"><b><span lang="BG">Таблица</span><span lang="EN-GB"> 5: </span></b><b><span lang="BG">Повишения на трансаминазите при пациенти на възраст от 4</span><span lang="EN-GB"> </span></b><b><span lang="BG">месеца до </span><span lang="EN-GB">&lt;</span></b><b><span lang="BG"> </span><span lang="EN-GB">12 </span></b><b><span lang="BG">години, лекувани с ивакафтор като монотерапия</span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoTableGrid" style="margin-left:6.85pt;border-collapse:collapse;border:none"> <tr style="height:28.95pt"> <td style="width:121.1pt;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:28.95pt" valign="top" width="161"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p> </td> <td style="width:49.65pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt" valign="top" width="66"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">n</span></b></p> </td> <td style="width:80.95pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">% </span></b><b><span lang="BG">пациенти   </span><span lang="EN-GB">&gt; 3 x ULN </span></b></p> </td> <td style="width:81.0pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">% </span></b><b><span lang="BG">пациенти   </span><span lang="EN-GB">&gt;5 x ULN</span></b></p> </td> <td style="width:81.0pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">% </span></b><b><span lang="BG">пациенти   </span><span lang="EN-GB">&gt; 8 x ULN</span></b></p> </td> </tr> <tr style="height:14.35pt"> <td style="width:121.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="161"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">от   </span><span lang="EN-GB">6 </span><span lang="BG">до</span><span lang="EN-GB"> &lt;12</span><span lang="BG"> години</span></p> </td> <td style="width:49.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="66"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">40</span></p> </td> <td style="width:80.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">15</span><span lang="BG">,</span><span lang="EN-GB">0%   (6)</span></p> </td> <td style="width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">2</span><span lang="BG">,</span><span lang="EN-GB">5% (1)</span></p> </td> <td style="width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">2</span><span lang="BG">,</span><span lang="EN-GB">5% (1)</span></p> </td> </tr> <tr style="height:14.35pt"> <td style="width:121.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="161"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">от   </span><span lang="EN-GB">2 </span><span lang="BG">до</span><span lang="EN-GB"> &lt;6</span><span lang="BG"> години</span></p> </td> <td style="width:49.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="66"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">34</span></p> </td> <td style="width:80.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">14</span><span lang="BG">,</span><span lang="EN-GB">7%   (5)</span></p> </td> <td style="width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">14</span><span lang="BG">,</span><span lang="EN-GB">7%   (5)</span></p> </td> <td style="width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">14</span><span lang="BG">,</span><span lang="EN-GB">7%   (5)</span></p> </td> </tr> <tr style="height:14.35pt"> <td style="width:121.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="161"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">от   </span><span lang="EN-GB">12 </span><span lang="BG">до</span><span lang="EN-GB"> &lt;24</span><span lang="BG"> месеца</span></p> </td> <td style="width:49.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="66"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">18</span></p> </td> <td style="width:80.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">27</span><span lang="BG">,</span><span lang="EN-GB">8%   (5)</span></p> </td> <td style="width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">11</span><span lang="BG">,</span><span lang="EN-GB">1%   (2)</span></p> </td> <td style="width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">11</span><span lang="BG">,</span><span lang="EN-GB">1%   (2)</span></p> </td> </tr> <tr style="height:13.7pt"> <td style="width:121.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.7pt" valign="top" width="161"> <p class="MsoNormal"><span lang="BG">от </span><span lang="EN-GB">6 </span><span lang="BG">до</span><span lang="EN-GB"> &lt;12</span><span lang="BG"> месеца</span></p> </td> <td style="width:49.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt" valign="top" width="66"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">11</span></p> </td> <td style="width:80.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">9</span><span lang="BG">,</span><span lang="EN-GB">1% (1)</span></p> </td> <td style="width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">0</span><span lang="BG">,</span><span lang="EN-GB">0% (0)</span></p> </td> <td style="width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">0</span><span lang="BG">,</span><span lang="EN-GB">0% (0)</span></p> </td> </tr> <tr style="height:13.7pt"> <td style="width:121.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.7pt" valign="top" width="161"> <p class="MsoNormal"><span lang="BG">от 4</span><span lang="BG"> </span><span lang="BG">до</span><span lang="EN-GB"> &lt;</span><span lang="BG">6 месеца</span></p> </td> <td style="width:49.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt" valign="top" width="66"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">6</span></p> </td> <td style="width:80.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">0</span><span lang="BG">,</span><span lang="EN-GB">0% (0)</span></p> </td> <td style="width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">0</span><span lang="BG">,</span><span lang="EN-GB">0% (0)</span></p> </td> <td style="width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">0</span><span lang="BG">,</span><span lang="EN-GB">0% (0)</span></p> </td> </tr> </table><p class="MsoNormal"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Съобщаване на подозирани нежелани реакции"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal"><span lang="BG">Съобщаването на подозирани нежелани реакции след разрешаване за употреба на лекарствения продукт е важно.</span><span lang="BG"> Това позволява да продължи наблюдението на съотношението полза/риск за лекарствения продукт. От медицинските специалисти се изисква да съобщават всяка подозирана нежелана реакция чрез <span style="background:lightgrey">национална система за съобщаване, посочена в </span></span><span lang="EN-GB"><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span lang="BG" style="background:lightgrey">Приложение V</span></a></span><span lang="BG">.</span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.9     Предозиране"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="labeltext" style="page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Няма наличен специален антидот за предозирането с ивакафтор. Лечението на предозирането се състои от общи поддържащи мерки, включително проследяване на жизнените показатели, чернодробните функционални показатели и проследяване на клиничното състояние на пациента.</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="5.       ФАРМАКОЛОГИЧНИ СВОЙСТВА "/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="5.1     Фармакодинамични свойства"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG"> </span></i></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Фармакотерапевтична група: Други продукти за лечение на дихателната система,<i> <br/> </i>ATC код: </span><span lang="BG" style="color:black">R07AX02</span></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Механизъм на действие"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal"><span lang="BG">Ивакафтор е потенциатор на CFTR белтъка, т.е. <i>in vitro</i> ивакафтор повишава пропускливостта на CFTR канала, за да се увеличи транспортът на хлорните йони при специфичните мутации, водещи до каналопатии (както са изброени в точка 4.1), характеризиращи се с намалена вероятност за отваряне на канала в сравнение с нормалния </span><span lang="EN-GB">CFTR</span><span lang="BG">. Ивакафтор потенциира също</span><span lang="BG"> вероятността за отваряне на </span><span lang="EN-GB">R</span><span lang="BG">117</span><span lang="EN-GB">H</span><span lang="BG">‑</span><span lang="EN-GB">CFTR</span><span lang="BG">, който има както малка </span><span lang="BG">вероятност за отваряне на канала, така и намалена амплитуда на потока в канала (проводимост). Мутацията</span><i><span lang="EN-GB"> G970R </span></i><span lang="EN-GB">причинява сплайсинг дефект, водещ до </span><span lang="BG">наличие на</span><span lang="BG"> </span><span lang="EN-GB">малко количество CFTR </span><span lang="BG">белтък </span><span lang="EN-GB">на клетъчната повърхност</span><span lang="EN-GB"> </span><span lang="BG">или липсата му</span><span lang="EN-GB">,</span><span lang="EN-GB"> </span><span lang="BG">което може да обясни резултатите, наблюдавани при лица с тази мутация в проучване 5 </span><span lang="EN-GB">(вж. </span><span lang="BG">„</span><span lang="EN-GB">Фармакодинамични ефекти</span><span lang="BG">“</span><span lang="EN-GB"> и данни</span><span lang="BG">те</span><span lang="EN-GB"> в </span><span lang="BG">„К</span><span lang="EN-GB">линична ефикасност</span><span lang="BG">“</span><span lang="EN-GB">).</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><i><span lang="BG">In vitro</span></i><span lang="BG"> отговорите, наблюдавани при експерименти от вида „patch clamp” с един канал с използване на мембранни пачове от клетки на гризачи, експресиращи мутантни CFTR форми, не съответстват непременно на фармакодинамичния отговор <i>in vivo </i>(напр. хлорни йони в потта) или на клиничната полза. Точният механизъм, който позволява на ивакафтор да потенциира</span><span lang="BG"> активността на отваряне на нормални и някои мутантни CFTR форми в тази система, не е напълно обяснен.</span></p><p class="MsoBodyText2" style="margin-bottom:0in;line-height:normal"><span lang="BG" style="font-size:11.0pt;color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Фармакодинамични ефекти"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG">Ивакафтор като монотерапия</span></i></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG"> </span></i></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>В проучвания 1 и 2 при пациенти с <i>G551D </i>мутация в един алел на <i>CFTR</i> гена ивакафтор води до бързи (15</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>дни), съществени (средната промяна на хлорните йони в потта от изходно ниво до седмица</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>24 е съответно ‑48 mmol/</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>l</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>[95% ДИ ‑51;</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>‑45] и ‑54 mmol/</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>l</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>[95% ДИ</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>‑62;</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>‑47]) и трайни (в продължение на 48 седмици) понижения на концентрацията на хлорните йони в потта.</span></p><p class="documenttext" style="margin-bottom:0in"><u><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'><span style="text-decoration:none"> </span></span></u></p><p class="documenttext" style="margin-bottom:0in"><span lang="BG" style='font-size: 11.0pt;font-family:"Times New Roman",serif'>В проучване 5, част 1, при пациенти, които имат не-<i>G551D</i> водеща до каналопатия мутация на <i>CFTR</i> гена, лечението с ивакафтор води до бърза (15 дни) и съществена средна промяна от изходно ниво на хлорните йони в потта от ‑49 mmol/</span><span style='font-size:11.0pt; font-family:"Times New Roman",serif'>l</span><span lang="BG" style='font-size: 11.0pt;font-family:"Times New Roman",serif'> (95% ДИ -57; -41) за 8 седмици лечение. При пациенти с <i>G970R</i>-<i>CFTR</i> мутацията обаче средната (SD) абсолютна промяна на хлорните йони в потта на седмица 8 е ‑6,25 (6,55) mmol/</span><span style='font-size:11.0pt; font-family:"Times New Roman",serif'>l</span><span lang="BG" style='font-size: 11.0pt;font-family:"Times New Roman",serif'>. В част 2 на проучването се наблюдават подобни резултати като в част 1. При визитата за проследяване на 4-тата седмица (4</span><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>седмици след приключване на приложението на ивакафтор) средните стойности на хлорни йони в потта за всяка група клонят към нивата от преди лечението.</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="documenttext" style="margin-bottom:0in"><span lang="BG" style='font-size: 11.0pt;font-family:"Times New Roman",serif'>В проучване 6 при пациенти на възраст</span><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>6</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>или повече години с КФ, които имат </span><i><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'>R</span></i><i><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>117</span></i><i><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'>H</span></i><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>мутация на </span><i><span lang="EN-GB" style='font-size:11.0pt;font-family: "Times New Roman",serif'>CFTR</span></i><span lang="EN-GB" style='font-size:11.0pt; font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-size: 11.0pt;font-family:"Times New Roman",serif'>гена, разликата между леченията в средната промяна на хлорните йони в потта от изходно ниво за 24-те седмици на лечението е ‑24</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'> mmol</span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>/</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>l</span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'> (95%</span><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>ДИ</span><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>‑28;</span><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>‑20). В подгрупов анализ по възраст разликата между леченията е -21,87</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'> mmol/l (95% </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>ДИ</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>: -26,46; -17,28)</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'> <span lang="BG">при пациенти на възраст 18 или повече години и </span></span><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'>‑27,63 mmol/l (95% </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>ДИ</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>: -37,16; -18,10) </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>при пациенти на възраст</span><span style='font-size: 11.0pt;font-family:"Times New Roman",serif'> 6-11</span><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>години</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>. </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>Двама пациенти на възраст</span><span style='font-size: 11.0pt;font-family:"Times New Roman",serif'> 12 </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>до</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'> 17 </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>години са включени в това проучване.</span></p><p class="documenttext" style="margin-bottom:0in"><u><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG">Ивакафтор в комбинирана схема с тезакафтор/ивакафтор</span></i></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">При пациенти, хомозиготни за мутацията </span><i><span lang="EN-GB">F</span></i><i><span lang="BG">508</span></i><i><span lang="EN-GB">del</span></i><span lang="BG">, разликата между леченията с ивакафтор в комбинация с тезакафтор/ивакафтор<i> </i>и с плацебо в средната абсолютна промяна от изходно ниво на хлорните йони в потта до седмица</span><span lang="EN-GB"> </span><span lang="BG">24 е ‑10,1</span><span lang="EN-GB"> mmol</span><span lang="BG">/</span><span lang="EN-GB">l</span><span lang="BG"> (95%</span><span lang="EN-GB"> </span><span lang="BG">ДИ: ‑11,4; ‑8,8).</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">При пациенти, хетерозиготни за мутацията </span><i><span lang="EN-GB">F</span></i><i><span lang="BG">508</span></i><i><span lang="EN-GB">del</span></i><i><span lang="BG">, </span></i><span lang="BG">и </span><span lang="BG">втора мутация, свързана с остатъчна активност на </span><span lang="EN-GB">CFTR</span><span lang="BG">, разликата между леченията в средната абсолютна промяна от изходно ниво на хлорните йони в потта до седмица</span><span lang="EN-GB"> </span><span lang="BG">8 е ‑9,5</span><span lang="EN-GB"> mmol</span><span lang="BG">/</span><span lang="EN-GB">l</span><span lang="BG"> (95%</span><span lang="EN-GB"> </span><span lang="BG">ДИ: ‑11,7; ‑7,3) между ивакафтор в комбинация с тезакафтор/ивакафтор</span><span lang="BG"> </span><span lang="BG">и плацебо и -4,5</span><span lang="EN-GB"> mmol</span><span lang="BG">/</span><span lang="EN-GB">l</span><span lang="BG"> (95%</span><span lang="EN-GB"> </span><span lang="BG">ДИ: ‑6,7; ‑2,3) между ивакафтор и плацебо.</span><span lang="BG"> </span></p><p class="documenttext" style="margin-bottom:0in"><u><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'><span style="text-decoration:none"> </span></span></u></p><p class="documenttext" style="margin-bottom:0in"><span lang="BG" style='font-size: 11.0pt;font-family:"Times New Roman",serif'>При пациенти на възраст от 6 до под 12 години, които са хомозиготни или хетерозиготни за мутацията</span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'> </span><i><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'>F508del</span></i><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>и имат втора мутация, свързана с остатъчна активност на </span><span lang="FR" style='font-size:11.0pt;font-family:"Times New Roman",serif'>CFTR</span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>, средната абсолютна промяна от изходното ниво в рамките на групата на хлорните йони в потта на седмица 8 е -12,3 </span><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'>mmol/l </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>(95% ДИ: -15,3; -9,3) в групата на тезакафтор/ивакафтор.</span></p><p class="documenttext" style="margin-bottom:0in"><u><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG">Ивакафтор в комбинирана схема с ивакафтор/тезакафтор/елексакафтор</span></i></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB"> </span></i></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">При п</span><span lang="BG">ациенти с </span><i><span lang="EN-GB">F508del</span></i><span lang="EN-GB"> мутация </span><span lang="BG">в</span><span lang="EN-GB"> единия алел</span><span lang="EN-GB"> </span><span lang="BG">и мутация във втория алел, което прогнозира или липса на синтез на белтък </span><span lang="EN-GB">CFTR</span><span lang="BG">, или синтез на белтък </span><span lang="EN-GB">CFTR</span><span lang="BG">, който няма отговор към </span><span lang="BG">ивакафтор и </span><span lang="BG">тезакафтор</span><span lang="EN-GB">/</span><span lang="BG">ивакафтор</span><span lang="EN-GB">, </span><span lang="BG">разликата в лечението между </span><span lang="BG">ивакафтор </span><span lang="BG">в комбинирана схема с ивакафтор/тезакафтор/елексакафтор</span><span lang="BG"> </span><span lang="BG">и плацебо за средната абсолютна промяна на хлорните йони в потта от изходното ниво до седмица </span><span lang="EN-GB">24 </span><span lang="BG">е </span><span lang="EN-GB">‑41</span><span lang="BG">,</span><span lang="EN-GB">8 mmol/l (95% </span><span lang="BG">ДИ</span><span lang="EN-GB">: -44</span><span lang="BG">,</span><span lang="EN-GB">4; -39</span><span lang="BG">,</span><span lang="EN-GB">3).</span></p><p class="MsoNormal" style="text-autospace:none"><span lang="BG"> </span></p><p class="MsoNormal" style="text-autospace:none"><span lang="BG">При</span><span lang="BG"> </span><span lang="BG">пациенти, хомозиготни за </span><i><span lang="EN-GB">F508del </span></i><span lang="BG">мутацията</span><span lang="EN-GB">, </span><span lang="BG">р</span><span lang="BG">азликата в лечението между </span><span lang="BG">ивакафтор/тезакафтор/елексакафтор</span><span lang="BG"> </span><span lang="BG">и </span><span lang="BG">тезакафтор/ивакафтор</span><span lang="BG"> </span><span lang="BG">по отношение на средната абсолютна промяна на хлорните йони в потта от изходното ниво на седмица </span><span lang="EN-GB">4 </span><span lang="BG">е</span><span lang="EN-GB"> ‑45</span><span lang="BG">,</span><span lang="EN-GB">1 mmol/l (95% ДИ: -50</span><span lang="BG">,</span><span lang="EN-GB">1</span><span lang="BG">;</span><span lang="EN-GB"> -40</span><span lang="BG">,</span><span lang="EN-GB">1).</span></p><p class="documenttext" style="margin-bottom:0in;page-break-after:avoid"><u><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'><span style="text-decoration:none"> </span></span></u></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Клинична ефикасност и безопасност"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="documenttext" style="margin-bottom:0in;page-break-after:avoid"><u><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG">Ивакафтор като монотерапия</span></i></p><p class="MsoNormal" style="page-break-after:avoid"><i><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></i></p><p class="MsoNormal" style="page-break-after:avoid"><i><u><span lang="BG">Проучвания 1 и 2: проучвания при пациенти с КФ с </span></u></i><i><u><span lang="EN-GB">G</span></u></i><i><u><span lang="BG">551</span></u></i><i><u><span lang="EN-GB">D</span></u></i><i><u><span lang="EN-GB"> </span></u></i><i><u><span lang="BG">мутации, водещи до каналопатии </span></u></i></p><p class="MsoNormal" style="page-break-after:avoid"><i><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></i></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Ефикасността на ивакафтор е оценена в две рандомизирани, двойнослепи, плацебо-контролирани, многоцентрови проучвания фаза 3 на клинично стабилни пациенти с КФ, които са имали <i>G551D</i> мутация на <i>CFTR</i> гена най-малко в 1 алел и ФЕО<sub>1</sub> </span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>≥</span><span lang="BG" style='font-family:"Times New Roman",serif'>40% от прогнозираното. </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Пациентите и в двете проучвания са рандомизирани 1:1 да получават или 150 mg ивакафтор, или плацебо на всеки 12 часа с храна, съдържаща мазнини, в продължение на 48</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>седмици в допълнение към предписаната им терапия за КФ (напр. тобрамицин, дорназа алфа). Не е разрешена употребата на хипертоничен разтвор на натриев хлорид за инхалация.</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Проучване 1 оценява 161 пациенти на възраст</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>12 и повече години; 122 (75,8%) пациенти имат <i>F508del</i> мутацията във втория алел. В началото на проучването пациентите в групата на плацебо използват някои лекарствени продукти с по-висока честота, отколкото групата на ивакафтор. Тези лекарства включват дорназа алфа (73,1% спрямо 65,1%), салбутамол (53,8% спрямо 42,2%), тобрамицин (44,9% спрямо 33,7%) и салметерол/флутиказон (41,0% спрямо 27,7%). На изходното ниво средният прогнозиран ФЕО<sub>1</sub> е 63,6% (диапазон: 31,6% до 98,2%), а средната възраст е 26 години (диапазон: 12 до 53 години). </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Проучване 2 оценява 52 пациенти на възраст от 6 до 11 години при скрининга. Средното (SD) телесно тегло е 30,9 (8,63)</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>kg; 42 (80,8%) пациенти имат <i>F508del</i> мутацията във втория алел. На изходното ниво средният прогнозиран ФЕО<sub>1</sub> е 84,2% (диапазон: 44,0% до 133,8%), а средната възраст е 9 години (диапазон: 6 до 12 години); 8</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>(30,8%) пациенти в групата на плацебо и 4 (15,4%) пациенти в групата на ивакафтор имат ФЕО<sub>1</sub> по-малко от 70% от прогнозираното на изходно ниво. </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Първичната крайна точка за ефикасност при двете проучвания е средната абсолютна промяна спрямо изходното ниво в процента на прогнозирания ФЕО<sub>1</sub> за 24 седмици лечение. </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Разликата между лечението с ивакафтор и с плацебо по отношение на средната абсолютна промяна (95%</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>ДИ) в процента на прогнозирания ФЕО<sub>1</sub> от изходно ниво до седмица 24 е 10,6 процентни точки (8,6; 12,6) при проучване 1 и 12,5 процентни точки (6,6; 18,3) при проучване 2. Разликата между лечението с ивакафтор и с плацебо по отношение на средната относителна промяна (95%</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>ДИ) в процента на прогнозирания ФЕО<sub>1</sub> от изходно ниво до седмица 24 е 17,1% (13,9; 20,2) при проучване 1 и 15,8% (8,4; 23,2) при проучване 2. Средната промяна на ФЕО<sub>1</sub> от изходно ниво до седмица 24 </span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>(l</span><span lang="BG" style='font-family:"Times New Roman",serif'>) е 0,37 </span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>l</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>в групата на ивакафтор и 0,01 </span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>l</span><span lang="BG" style='font-family:"Times New Roman",serif'> в групата на плацебо при проучване 1 и 0,30 </span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>l</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>в групата на ивакафтор и 0,07 </span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>l</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>в групата на плацебо при проучване 2. И при двете проучвания подобрението на ФЕО<sub>1</sub> е с бързо начало (ден 15) и се поддържа в продължение на 48 седмици. </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Разликата в лечението между ивакафтор и плацебо за средната абсолютна промяна (95%</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>ДИ) на процента на прогнозирания ФЕО<sub>1</sub> от изходно ниво до седмица</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>24 при пациенти на възраст от 12 до 17 години в проучване 1 е 11,9 процентни точки (5,9; 17,9). Разликата в лечението между ивакафтор и плацебо за средната абсолютна промяна (95%</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>ДИ) на процента на прогнозирания ФЕО<sub>1</sub> от изходно ниво до седмица</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>24 при пациенти с прогнозирано на изходно ниво ФЕО<sub>1 </sub>по-голямо от 90% в проучване 2 е 6,9 процентни точки (‑3,8; 17,6).</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Резултатите за клинично значимите вторични крайни точки са дадени в Таблица 6.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:6.0pt; margin-left:56.7pt;text-indent:-56.7pt;page-break-after:avoid"><b><span lang="BG">Таблица 6: Ефект на ивакафтор върху други крайни точки за ефикасност в проучванията</span></b><b><span lang="EN-GB"> </span></b><b><span lang="BG">1 и</span></b><b><span lang="EN-GB"> </span></b><b><span lang="BG">2</span></b></p><table border="0" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:100.0%;border-collapse:collapse" width="100%"> <thead> <tr style="height:10.5pt"> <td style="width:27.94%;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:10.5pt" valign="top" width="27%"> <p align="left" class="tabletextcenterjustified" style="margin:0in;text-align:    left;page-break-after:avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'> </span></b></p> </td> <td colspan="2" style="width:34.38%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt" valign="top" width="34%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'>Проучване 1</span></b></p> </td> <td colspan="2" style="width:37.68%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt" valign="top" width="37%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'>Проучване 2</span></b></p> </td> </tr> <tr style="height:28.25pt"> <td style="width:27.94%;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt;height:28.25pt" valign="bottom" width="27%"> <p class="tabletextleftjustified" style="margin:0in;page-break-after:avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'>Крайна    точка</span></b></p> </td> <td style="width:19.96%;border-top:none;    border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:28.25pt" valign="bottom" width="19%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'>Разлика    в лечението<sup>a</sup></span></b></p> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'>(95% ДИ)</span></b></p> </td> <td style="width:14.42%;border-top:none;    border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:28.25pt" valign="bottom" width="14%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><b><i><span lang="BG" style='font-family:"Times New Roman",serif'>P </span></i></b><b><span lang="BG" style='font-family:"Times New Roman",serif'>стойност</span></b></p> </td> <td style="width:19.96%;border-top:none;    border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:28.25pt" valign="bottom" width="19%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'>Разлика    в лечението<sup>a</sup></span></b></p> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'>(95% ДИ)</span></b></p> </td> <td style="width:17.72%;border-top:none;    border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:28.25pt" valign="bottom" width="17%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><b><i><span lang="BG" style='font-family:"Times New Roman",serif'>P </span></i></b><b><span lang="BG" style='font-family:"Times New Roman",serif'>стойност</span></b></p> </td> </tr> </thead> <tr style="height:10.5pt"> <td colspan="5" style="width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt" valign="top" width="100%"> <p align="left" class="tabletextcenterjustified" style="margin:0in;text-align:   left;page-break-after:avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'>Средна   абсолютна   промяна спрямо   изходното   ниво в скора   на респираторния   домейн на CFQ-R<sup>б </sup>(точки)<sup>в</sup></span></b></p> </td> </tr> <tr style="height:18.3pt"> <td style="width:27.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="27%"> <p class="tabletextleftjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>До седмица</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>24</span></p> </td> <td style="width:19.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="19%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>8,1</span></p> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>(4,7</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>;</span><span lang="BG" style='font-family:"Times New Roman",serif'> 11,4)</span></p> </td> <td style="width:14.42%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="14%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>&lt;0,0001</span></p> </td> <td style="width:19.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="19%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>6,1</span></p> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>(‑1,4</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>;</span><span lang="BG" style='font-family:"Times New Roman",serif'> 13,5)</span></p> </td> <td style="width:17.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="17%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>0,1092</span></p> </td> </tr> <tr style="height:18.85pt"> <td style="width:27.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.85pt" valign="top" width="27%"> <p class="tabletextleftjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>До седмица</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>48</span></p> </td> <td style="width:19.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt" valign="top" width="19%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>8,6</span></p> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>(5,3</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>;</span><span lang="BG" style='font-family:"Times New Roman",serif'> 11,9)</span></p> </td> <td style="width:14.42%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt" valign="top" width="14%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>&lt;0,0001</span></p> </td> <td style="width:19.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt" valign="top" width="19%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>5,1</span></p> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>(-1,6</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>;</span><span lang="BG" style='font-family:"Times New Roman",serif'> 11,8)</span></p> </td> <td style="width:17.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt" valign="top" width="17%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>0,1354</span></p> </td> </tr> <tr style="height:9.95pt"> <td colspan="5" style="width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:9.95pt" valign="top" width="100%"> <p align="left" class="tabletextcenterjustified" style="margin:0in;text-align:   left;page-break-after:avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'>Относителен   риск за   пулмонална   екзацербация</span></b></p> </td> </tr> <tr style="height:10.5pt"> <td style="width:27.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt" valign="top" width="27%"> <p class="tabletextleftjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>До седмица</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>24</span></p> </td> <td style="width:19.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.5pt" valign="top" width="19%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>0,40</span><sup><span lang="BG" style='font-family:"Times New Roman",serif'>г</span></sup></p> </td> <td style="width:14.42%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.5pt" valign="top" width="14%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>0,0016</span></p> </td> <td style="width:19.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.5pt" valign="top" width="19%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>НА</span></p> </td> <td style="width:17.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.5pt" valign="top" width="17%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>НА</span></p> </td> </tr> <tr style="height:9.95pt"> <td style="width:27.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:9.95pt" valign="top" width="27%"> <p class="tabletextleftjustified" style="margin:0in"><span lang="BG" style='font-family:"Times New Roman",serif'>До седмица</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>48</span></p> </td> <td style="width:19.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:9.95pt" valign="top" width="19%"> <p class="tabletextcenterjustified" style="margin:0in"><span lang="BG" style='font-family:"Times New Roman",serif'>0,46<sup>г</sup></span></p> </td> <td style="width:14.42%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:9.95pt" valign="top" width="14%"> <p class="tabletextcenterjustified" style="margin:0in"><span lang="BG" style='font-family:"Times New Roman",serif'>0,0012</span></p> </td> <td style="width:19.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:9.95pt" valign="top" width="19%"> <p class="tabletextcenterjustified" style="margin:0in"><span lang="BG" style='font-family:"Times New Roman",serif'>НА</span></p> </td> <td style="width:17.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:9.95pt" valign="top" width="17%"> <p class="tabletextcenterjustified" style="margin:0in"><span lang="BG" style='font-family:"Times New Roman",serif'>НА</span></p> </td> </tr> <tr style="height:10.5pt"> <td colspan="5" style="width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt" valign="top" width="100%"> <p align="left" class="tabletextcenterjustified" style="margin:0in;text-align:   left;page-break-after:avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'>Средна   абсолютна   промяна   спрямо   изходното   ниво в   телесното   тегло (kg)</span></b></p> </td> </tr> <tr style="height:18.85pt"> <td style="width:27.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.85pt" valign="top" width="27%"> <p class="tabletextleftjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>На седмица</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>24</span></p> </td> <td style="width:19.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt" valign="top" width="19%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>2,8</span></p> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>(1,8</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>;</span><span lang="BG" style='font-family:"Times New Roman",serif'> 3,7)</span></p> </td> <td style="width:14.42%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt" valign="top" width="14%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>&lt;0,0001</span></p> </td> <td style="width:19.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt" valign="top" width="19%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>1,9</span></p> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>(0,9</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>;</span><span lang="BG" style='font-family:"Times New Roman",serif'> 2,9)</span></p> </td> <td style="width:17.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt" valign="top" width="17%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>0,0004</span></p> </td> </tr> <tr style="height:18.3pt"> <td style="width:27.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="27%"> <p class="tabletextleftjustified" style="margin:0in"><span lang="BG" style='font-family:"Times New Roman",serif'>На седмица</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>48</span></p> </td> <td style="width:19.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="19%"> <p class="tabletextcenterjustified" style="margin:0in"><span lang="BG" style='font-family:"Times New Roman",serif'>2,7<br/>   (1,3 4,1)</span></p> </td> <td style="width:14.42%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="14%"> <p class="tabletextcenterjustified" style="margin:0in"><span lang="BG" style='font-family:"Times New Roman",serif'>0,0001</span></p> </td> <td style="width:19.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="19%"> <p class="tabletextcenterjustified" style="margin:0in"><span lang="BG" style='font-family:"Times New Roman",serif'>2,8</span></p> <p class="tabletextcenterjustified" style="margin:0in"><span lang="BG" style='font-family:"Times New Roman",serif'>(1,3</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>;</span><span lang="BG" style='font-family:"Times New Roman",serif'> 4,2)</span></p> </td> <td style="width:17.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="17%"> <p class="tabletextcenterjustified" style="margin:0in"><span lang="BG" style='font-family:"Times New Roman",serif'>0,0002</span></p> </td> </tr> <tr style="height:13.8pt"> <td colspan="5" style="width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.8pt" valign="top" width="100%"> <p align="left" class="tabletextcenterjustified" style="margin:0in;text-align:   left;page-break-after:avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'>Средна   абсолютна   промяна   спрямо   изходното   ниво в BMI (kg/m<sup>2</sup>)</span></b></p> </td> </tr> <tr style="height:18.3pt"> <td style="width:27.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="27%"> <p class="tabletextleftjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>На седмица </span><span lang="BG" style='font-family:"Times New Roman",serif'>24</span></p> </td> <td style="width:19.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="19%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>0,94</span></p> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>(0,62</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>;</span><span lang="BG" style='font-family:"Times New Roman",serif'> 1,26)</span></p> </td> <td style="width:14.42%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="14%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>&lt;0,0001</span></p> </td> <td style="width:19.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="19%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>0,81</span></p> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>(0,34</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>;</span><span lang="BG" style='font-family:"Times New Roman",serif'> 1,28)</span></p> </td> <td style="width:17.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="17%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>0,0008</span></p> </td> </tr> <tr style="height:18.3pt"> <td style="width:27.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="27%"> <p class="tabletextleftjustified" style="margin:0in"><span lang="BG" style='font-family:"Times New Roman",serif'>На седмица </span><span lang="BG" style='font-family:"Times New Roman",serif'>48</span></p> </td> <td style="width:19.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="19%"> <p class="tabletextcenterjustified" style="margin:0in"><span lang="BG" style='font-family:"Times New Roman",serif'>0,93</span></p> <p class="tabletextcenterjustified" style="margin:0in"><span lang="BG" style='font-family:"Times New Roman",serif'>(0,48</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>;</span><span lang="BG" style='font-family:"Times New Roman",serif'> 1,38)</span></p> </td> <td style="width:14.42%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="14%"> <p class="tabletextcenterjustified" style="margin:0in"><span lang="BG" style='font-family:"Times New Roman",serif'>&lt;0,0001</span></p> </td> <td style="width:19.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="19%"> <p class="tabletextcenterjustified" style="margin:0in"><span lang="BG" style='font-family:"Times New Roman",serif'>1,09</span></p> <p class="tabletextcenterjustified" style="margin:0in"><span lang="BG" style='font-family:"Times New Roman",serif'>(0,51</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>;</span><span lang="BG" style='font-family:"Times New Roman",serif'> 1,67)</span></p> </td> <td style="width:17.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="17%"> <p class="tabletextcenterjustified" style="margin:0in"><span lang="BG" style='font-family:"Times New Roman",serif'>0,0003</span></p> </td> </tr> <tr style="height:18.3pt"> <td colspan="5" style="width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="100%"> <p align="left" class="tabletextcenterjustified" style="margin:0in;text-align:   left;page-break-after:avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'>Средна   промяна   спрямо   изходното   ниво в z-скорове   </span></b></p> </td> </tr> <tr style="height:18.3pt"> <td style="width:27.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="27%"> <p class="tabletextleftjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>Тегло-за-възрастта</span></p> <p class="tabletextleftjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'> z-скор   на седмица 48<sup>д</sup></span></p> </td> <td style="width:19.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="19%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>0,33</span></p> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>(0,04</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>;</span><span lang="BG" style='font-family:"Times New Roman",serif'> 0,62)</span></p> </td> <td style="width:14.42%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="14%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>0,0260</span></p> </td> <td style="width:19.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="19%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>0,39</span></p> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>(0,24</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>;</span><span lang="BG" style='font-family:"Times New Roman",serif'> 0,53)</span></p> </td> <td style="width:17.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="17%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>&lt;0,0001</span></p> </td> </tr> <tr style="height:29.05pt"> <td style="width:27.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:29.05pt" valign="top" width="27%"> <p class="tabletextleftjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>BMI   за-възрастта   </span></p> <p class="tabletextleftjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>z-   скор на седмица 48<sup>д</sup></span><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p> </td> <td style="width:19.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:29.05pt" valign="top" width="19%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>0,33</span></p> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>(0,002</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>;</span><span lang="BG" style='font-family:"Times New Roman",serif'> 0,65)</span></p> </td> <td style="width:14.42%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:29.05pt" valign="top" width="14%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>0,0490</span></p> </td> <td style="width:19.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:29.05pt" valign="top" width="19%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>0,45</span></p> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>(0,26</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>;</span><span lang="BG" style='font-family:"Times New Roman",serif'> 0,65)</span></p> </td> <td style="width:17.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:29.05pt" valign="top" width="17%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>&lt;0,0001</span></p> </td> </tr> </table><p class="tablefootnote" style="margin-top:6.0pt;page-break-after:avoid"><span lang="BG" style='font-size:9.0pt;font-family:"Times New Roman",serif'>ДИ: доверителен интервал; НА: не е анализирано поради ниската честота на събитията</span></p><p class="tablefootnote" style="page-break-after:avoid"><sup><span lang="BG" style='font-size:9.0pt;font-family:"Times New Roman",serif'>a        </span></sup><span lang="BG" style='font-size:9.0pt;font-family:"Times New Roman",serif'>Разлика в лечението = ефект на ивакафтор – ефект на плацебо</span></p><p class="MsoNormal" style="margin-left:13.5pt;text-indent:-13.5pt;page-break-after: avoid"><sup><span lang="BG" style="font-size:9.0pt">б</span></sup><span lang="BG" style="font-size:9.0pt">     CFQ-R: Въпросник за кистозна фиброза – актуализиран (Cystic Fibrosis Questionnaire-Revised) е специфичен за заболяването, начин за измерване на качеството на живот във връзка със здравето при КФ.</span></p><p class="tablefootnote" style="margin-left:14.2pt;text-indent:-14.2pt; page-break-after:avoid"><sup><span lang="BG" style='font-size:9.0pt;font-family: "Times New Roman",serif'>в</span></sup><span lang="BG" style='font-size: 9.0pt;font-family:"Times New Roman",serif'>     Данните от проучване 1 са събрани от CFQ-R за възрастни/юноши и CFQ-R за деца на възраст от 12 до 13</span><span lang="EN-GB" style='font-size:9.0pt;font-family: "Times New Roman",serif'> </span><span lang="BG" style='font-size:9.0pt; font-family:"Times New Roman",serif'>години; Данните от проучване 2 са получени от CFQ-R за деца от 6- до 11-годишна възраст.</span></p><p class="tablefootnote" style="page-break-after:avoid"><sup><span lang="BG" style='font-size:9.0pt;font-family:"Times New Roman",serif'>г        </span></sup><span lang="BG" style='font-size:9.0pt;font-family:"Times New Roman",serif'>Коефициент на риска за времето до първата пулмонална екзацербация</span></p><p class="tablefootnote"><sup><span lang="BG" style='font-size:9.0pt;font-family: "Times New Roman",serif'>д        </span></sup><span lang="BG" style='font-size:9.0pt;font-family:"Times New Roman",serif'>При лица под 20-годишна възраст (CDC таблици на растежа)</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><i><u><span lang="BG">Проучване 5: проучване при пациенти с КФ с не-G551D водещи до каналопатии мутации </span></u></i></p><p class="MsoNormal" style="page-break-after:avoid"><i><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></i></p><p class="MsoNormal"><span lang="BG">Проучване 5 е фаза 3, в две части, рандомизирано, двойносляпо, плацебо-контролирано, кръстосано проучване (част 1), последвано от 16-седмичен период на открито разширено проучване (част 2) за оценка на ефикасността и безопасността на ивакафтор при пациенти с КФ на възраст 6 и повече години, които имат</span><span lang="BG"> </span><i><span lang="EN-GB">G970R </span></i><span lang="BG">или не‑<i>G551D</i> водеща до каналопатия мутация на <i>CFTR</i> гена (<i>G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P</i> или <i>G1349D</i>). </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>В част 1 пациентите са рандомизирани 1:1 да получават или 150 mg ивакафтор, или плацебо на всеки 12 часа с храна, съдържаща мазнини, в продължение на 8 седмици в допълнение към тяхната предписана терапия за КФ и преминават на другото лечение за вторите 8 седмици след период на очистване</span><span lang="BG" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>от 4 до 8 седмици. Използването на хипертоничен солен разтвор за инхалиране не е разрешено. В част 2 всички пациенти получават ивакафтор, както е показано в част 1, за още 16 седмици. Продължителността на непрекъснатото лечение с ивакафтор е 24 седмици за пациентите, рандомизирани в част 1 на последователност на лечението плацебо/ивакафтор, и 16 седмици за пациентите, рандомизирани в част 1 на последователност на лечението ивакафтор/плацебо.</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Включени са </span><span lang="RU" style='font-family:"Times New Roman",serif'>39</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>пациенти (средна възраст 23 години) с прогнозиран ФЕО<sub>1</sub> на изходно ниво<sub> </sub></span><span style='font-family:"Times New Roman",serif'>≥</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>40% (среден прогнозиран ФЕО<sub>1</sub> 78% [диапазон: 43% до 119%]). Шестдесет и два процента (24/39) от тях са носители на мутацията <i>F508del</i>-<i>CFTR</i> във втория алел. Общо 36 пациенти продължават в част 2 (18 на всяка последователност на лечението).</span></p><p class="MsoNormal"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal"><span lang="BG">В част 1 на проучване 5 средният </span><span lang="BG">процент на прогнозирания ФЕО<sub>1</sub> на изходно ниво при пациентите, третирани с плацебо, е 79,3%, а за пациентите, лекувани с ивакафтор, тази стойност е 76,4%. Средната обща стойност след изходното ниво е съответно 76,0% и 83,7%. Средната абсолютна промяна от изходно ниво до седмица 8 на процента на прогнозирания ФЕО<sub>1</sub> (първична крайна точка за ефикасност) е 7,5% в периода на ивакафтор и ‑3,2% в периода на плацебо. Наблюдаваната разлика в лечението (95% ДИ) между ивакафтор и плацебо е 10,7% (7,3; 14,1) (<i>P</i> &lt; 0,0001).</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Ефектът на ивакафтор при общата популация от проучване 5 (включително вторичните крайни точки абсолютна промяна в BMI [индекс на телесната маса] на 8 -та седмица от лечението и абсолютната промяна в скора на респираторния домейн на CFQ-R през 8 -те седмици на лечение) и по индивидуална мутация (абсолютна промяна на хлорните йони в потта и в процента на прогнозирания ФЕО<sub>1</sub> на седмица 8) е показан в Таблица 7. Въз основа на клиничните (процент на прогнозирания ФЕО<sub>1</sub>) и фармакодинамичните (хлорните йони в потта) отговори на ивакафтор не е възможно да се установи ефикасността при пациенти с <i>G970R</i> мутацията.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:6.0pt; margin-left:56.7pt;text-indent:-56.7pt;page-break-after:avoid"><b><span lang="BG">Таблица 7: Ефект на ивакафтор върху променливите за ефикасност в общата популация и за специфични <i>CFTR</i> мутации</span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:465.6pt;margin-left:.5pt;border-collapse:collapse;border:none" width="621"> <tr> <td colspan="2" style="width:167.95pt;border:solid windowtext 1.0pt;   padding:0in 2.85pt 0in 2.85pt" valign="top" width="224"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="BG">Абсолютна   промяна в процента   на   прогнозирания   ФЕО<sub>1</sub></span></b></p> </td> <td colspan="3" style="width:141.75pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid;text-autospace:none"><b><span lang="BG" style="color:black">BMI</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid;text-autospace:none"><b><span lang="BG" style="color:black">(kg/m2)</span></b></p> </td> <td style="width:155.9pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="208"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="BG">Скор на   респираторния   домейн на CFQ-R   (точки)</span></b></p> </td> </tr> <tr> <td colspan="2" style="width:167.95pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="224"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="BG">През седмица</span></b><span lang="BG"> <b>8</b></span></p> </td> <td colspan="3" style="width:141.75pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid;text-autospace:none"><b><span lang="BG" style="color:black">На   седмица 8</span></b></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="208"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="BG">През седмица 8</span></b></p> </td> </tr> <tr> <td colspan="6" style="width:465.6pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="621"> <p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><span lang="BG" style="color:black">Всички   пациенти (</span><span lang="EN-GB" style="color:black">N</span><span lang="BG" style="color:black">=39)</span></p> <p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><span lang="BG" style="color:black">Резултати,   показани   като средна (95% ДИ)   промяна от   изходно   ниво за   пациентите,   лекувани с   ивакафтор,   спрямо </span><span lang="BG">третир<span style="color:black">аните с   плацебо:</span></span></p> </td> </tr> <tr> <td colspan="2" style="width:167.95pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="224"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="BG" style="color:black">10,7 (7,3</span><span lang="EN-GB" style="color:black">;</span><span lang="BG" style="color:black"> 14,1)</span></p> </td> <td colspan="2" style="width:135.3pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="180"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="BG" style="color:black">0,66 (0,34</span><span lang="EN-GB" style="color:black">;</span><span lang="BG" style="color:black"> 0,99)</span></p> </td> <td colspan="2" style="width:162.35pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="216"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="BG" style="color:black">9,6 (4,5</span><span lang="EN-GB" style="color:black">;</span><span lang="BG" style="color:black"> 14,7)</span></p> </td> </tr> <tr style="height:15.65pt"> <td colspan="6" style="width:466.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.65pt" valign="top" width="621"> <p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><b><span lang="BG" style="color:black">Пациенти,   групирани   според вида   мутация (n)</span></b></p> <p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><span lang="BG" style="color:black">Резултати,   показани като   средна   (минимум,   максимум)   промяна от   изходно   ниво за   пациентите,   лекувани с   ивакафтор,   на седмица 8<sup>*</sup>:</span></p> </td> </tr> <tr style="height:15.65pt"> <td rowspan="2" style="width:79.55pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.65pt" valign="top" width="106"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid;text-autospace:none"><b><span lang="BG" style="color:black">Мутация   (n)</span></b></p> <p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><b><span lang="BG" style="color:black"> </span></b></p> </td> <td colspan="2" style="width:173.95pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.65pt" valign="top" width="232"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid;text-autospace:none"><b><span lang="BG">Абсолютна   промяна</span></b><b><span lang="BG">   на хлорните   йони в потта <span style="color:black">(mmol/</span></span></b><b><span style="color:black">l</span></b><b><span lang="BG" style="color:black">)</span></b></p> </td> <td colspan="3" style="width:212.6pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.65pt" valign="top" width="283"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid;text-autospace:none"><b><span lang="BG">Абсолютна   промяна</span></b><b><span lang="BG">   в процента   на   прогнозирания   ФЕО<sub>1</sub> (процентни   точки)</span></b></p> </td> </tr> <tr style="height:15.65pt"> <td colspan="2" style="width:173.95pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.65pt" valign="top" width="232"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid;text-autospace:none"><b><span lang="BG" style="color:black">На   седмица 8</span></b></p> </td> <td colspan="3" style="width:212.6pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.65pt" valign="top" width="283"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid;text-autospace:none"><b><span lang="BG" style="color:black">На   седмица 8</span></b></p> </td> </tr> <tr style="height:103.5pt"> <td style="width:79.55pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:   none;padding:0in 5.4pt 0in 5.4pt;height:103.5pt" valign="top" width="106"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid;text-autospace:none"><i><span lang="BG" style="color:black">G1244E</span></i><span lang="BG" style="color:black"> (5)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><i><span lang="BG">G1349D</span></i><span lang="BG"> (2)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><i><span lang="BG">G178R</span></i><span lang="BG"> (5)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><i><span lang="BG">G551S</span></i><span lang="BG"> (2)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><i><span lang="BG">G970R</span><sup><span lang="EN-GB"></span></sup></i><span lang="BG"> (4)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><i><span lang="BG">S1251N </span></i><span lang="BG">(8)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><i><span lang="BG">S1255P</span></i><span lang="BG"> (2)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><i><span lang="BG">S549N</span></i><span lang="BG"> (6)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid;text-autospace:none"><i><span lang="BG">S549R</span></i><span lang="BG">   (4)</span></p> </td> <td colspan="2" style="width:173.95pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:103.5pt" valign="top" width="232"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">-55 (-75; -34)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">-80 (-82; -79)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">-53 (-65; -35)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">-68<sup>†</sup> </span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">-6 (-16; -2)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">-54 (-84; -7)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">-78 (-82; -74)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">-74 (-93; -53)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">-61</span><sup><span lang="EN-GB">††</span></sup><span lang="BG"> (-71; -54)</span></p> </td> <td colspan="3" style="width:212.6pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:103.5pt" valign="top" width="283"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">8 (-1</span><span lang="EN-GB">;</span><span lang="BG"> 18)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">20 (3</span><span lang="EN-GB">;</span><span lang="BG"> 36)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">8 (-1</span><span lang="EN-GB">;</span><span lang="BG"> 18)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">3<sup>†</sup></span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">3 (-1</span><span lang="EN-GB">;</span><span lang="BG"> 5)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">9 (-20</span><span lang="EN-GB">;</span><span lang="BG"> 21)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">3 (-1</span><span lang="EN-GB">;</span><span lang="BG"> 8)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">11 (-2</span><span lang="EN-GB">;</span><span lang="BG"> 20)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">5 (-3</span><span lang="EN-GB">;</span><span lang="BG"> 13)</span></p> </td> </tr> <tr height="0"> <td style="border:none" width="106"></td> <td style="border:none" width="118"></td> <td style="border:none" width="114"></td> <td style="border:none" width="66"></td> <td style="border:none" width="9"></td> <td style="border:none" width="208"></td> </tr> </table><p class="MsoNormal" style="margin-top:6.0pt;page-break-after:avoid"><sup><span lang="BG" style="font-size:9.0pt">*</span></sup><span lang="BG" style="font-size: 9.0pt">     Статистическо тестване не е извършено поради малкия брой индивидуални мутации.</span></p><p class="MsoNormal" style="margin-left:13.5pt;text-indent:-13.5pt;page-break-after: avoid"><b><sup><span lang="BG" style="font-size:9.0pt;color:black">†</span></sup></b><span lang="BG" style="font-size:9.0pt">     Отразява резултатите от един пациент с мутацията <i>G551S</i> с данни от времевата точка на 8-та седмица.</span></p><p class="MsoNormal" style="margin-left:15.65pt;text-indent:-15.45pt;page-break-after: avoid"><b><sup><span lang="BG" style="font-size:9.0pt;color:black">††</span></sup></b><b><span lang="BG" style="font-size:9.0pt;color:black"> </span></b><span lang="BG" style="font-size:9.0pt">n=3 за анализа на абсолютната промяна на хлорните йони в потта.</span></p><p class="labeltext" style="margin-left:14.2pt;text-indent:-14.2pt"><sup><span style='font-size:9.0pt;font-family:"Times New Roman",serif'>#</span></sup><span style='font-size:9.0pt;font-family:"Times New Roman",serif'>     Причинява сплайсинг дефект, водещ до</span><span lang="BG" style='font-size:9.0pt;font-family:"Times New Roman",serif'> наличие на</span><span lang="BG" style='font-size:9.0pt;font-family:"Times New Roman",serif'> </span><span style='font-size:9.0pt;font-family:"Times New Roman",serif'>малко количество CFTR белтък на клетъчната повърхност</span><span lang="BG" style='font-size:9.0pt;font-family:"Times New Roman",serif'> или липсата му</span><span lang="BG" style='font-size:9.0pt;font-family:"Times New Roman",serif'>.</span></p><p class="labeltext" style="text-align:justify;text-justify:inter-ideograph"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>В част 2 от проучване 5 средната (SD) абсолютна промяна на процента на прогнозирания ФЕО<sub>1</sub> след 16 седмици (пациенти, рандомизирани на последователността на лечението ивакафтор/плацебо в част 1) на непрекъснато лечение с ивакафтор е 10,4% (13,2%). При визитата за проследяване 4 седмици след приключване на приложението на ивакафтор средната (SD) абсолютна промяна на процента на прогнозирания ФЕО<sub>1</sub> в част 2, седмица 16, е ‑5,9% (9,4%). За пациентите, рандомизирани на последователността на лечението плацебо/ивакафтор в част 1, има допълнителна средна (</span><span style='font-family: "Times New Roman",serif'>SD</span><span lang="BG" style='font-family:"Times New Roman",serif'>) промяна от 3,3% (9,3%) на процента на прогнозирания ФЕО<sub>1</sub> след 16 допълнителни седмици лечение с ивакафтор. При визитата за проследяване 4 седмици след приключване на приложението на ивакафтор средната (SD) абсолютна промяна на процента на прогнозирания ФЕО<sub>1</sub> от част 2, седмица 16, е</span><span style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>‑7,4% (5,5%).<u> </u></span></p><p class="labeltext"><u><span lang="BG" style='font-family:"Times New Roman",serif'><span style="text-decoration:none"> </span></span></u></p><p class="labeltext" style="page-break-after:avoid"><i><u><span lang="BG" style='font-family:"Times New Roman",serif'>Проучване 3: проучване при пациенти с КФ с F508del мутацията на CFTR гена</span></u></i></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Проучване 3 (част A) е 16-седмично, с рандомизиране 4:1, двойносляпо, плацебо-контролирано, паралелно-групово проучване фаза 2 на ивакафтор (150 mg на всеки 12 часа) при 140 пациенти с КФ на възраст 12 и повече години, които са хомозиготни за мутацията <i>F508del</i> на <i>CFTR</i> гена и са имали ФЕО<sub>1</sub> </span><span lang="EN-GB">≥</span><span lang="BG">40% от прогнозирания. </span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Средната абсолютна промяна от изходно ниво до седмица 16 в процента на прогнозирания ФЕО<sub>1</sub> (първична крайна точка за ефикасност) е 1,5 процентни точки в групата на ивакафтор и</span><span lang="EN-GB"> </span><span lang="BG">‑0,2 процентни точки в групата на плацебо. Изчислената разлика в лечението за ивакафтор спрямо плацебо е 1,7 процентни точки (95%</span><span lang="EN-GB"> </span><span lang="BG">ДИ</span><span lang="EN-GB"> </span><span lang="BG">‑0,6;</span><span lang="EN-GB"> </span><span lang="BG">4,1). Тази разлика не е статистически значима (<i>P</i></span><i><span lang="EN-GB"> </span></i><span lang="BG">=</span><span lang="EN-GB"> </span><span lang="BG">0,15).</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><i><u><span lang="BG">Проучване 4: открито разширено проучване</span></u></i></p><p class="MsoNormal"><span lang="BG" style="color:black"> </span></p><p class="MsoNormal"><span lang="BG" style="color:black">В проучване 4 пациенти, които са завършили лечението в проучвания 1 и 2 с плацебо, преминават на ивакафтор, а пациентите на ивакафтор продължават да го получават за най-малко 96 седмици, т.е. продължителността на лечението с ивакафтор е най-малко 96 седмици за пациентите в групата на плацебо/ивакафтор и най-малко 144 седмици за пациентите в групата на ивакафтор/ивакафтор.</span></p><p class="MsoNormal"><span lang="BG" style="color:black"> </span></p><p class="MsoNormal"><span lang="BG" style="color:black">Сто четиридесет и четири (144) пациенти от проучване</span><span lang="EN-GB" style="color:black"> </span><span lang="BG" style="color:black">1 са прехвърлени в проучване 4, 67 в групата на плацебо/ивакафтор и 77 в групата на ивакафтор/ивакафтор. Четиридесет и осем (48) пациенти от проучване 2 са прехвърлени в проучване 4, 22 в групата на плацебо/ивакафтор и 26 в групата на ивакафтор/ивакафтор.</span></p><p class="MsoNormal"><span lang="BG" style="color:black"> </span></p><p class="MsoNormal"><span lang="BG">Таблица</span><span lang="EN-GB"> </span><span lang="BG">8 показва резултатите от средната (SD) абсолютна промяна в процента на прогнозирания ФЕО<sub>1</sub> и за двете групи пациенти. За пациентите от групата на плацебо/ивакафтор процентът на прогнозирания ФЕО<sub>1</sub> на изходно ниво е този от проучване 4, а за пациентите от групата на ивакафтор/ивакафтор стойността на изходно ниво е тази от проучвания 1 и 2.</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif; color:black'> </span></p><p class="labeltext" style="margin-bottom:6.0pt;page-break-after:avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'>Таблица 8: Ефект на ивакафтор върху процента на прогнозирания ФЕО<sub>1</sub></span></b><span lang="BG" style='font-family: "Times New Roman",serif'> </span><b><span lang="BG" style='font-family:"Times New Roman",serif'>в проучване 4</span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="border-collapse:collapse;border:none"> <tr> <td style="width:99.85pt;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="133"> <p class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;margin-bottom:   2.0pt;margin-left:0in;page-break-after:avoid"><b><span lang="BG">Първоначално   проучване и   група за   лечение</span></b></p> </td> <td style="width:143.45pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="191"> <p align="center" class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;   margin-bottom:2.0pt;margin-left:0in;text-align:center;page-break-after:avoid"><b><span lang="BG">Продължителност   на   лечението с   ивакафтор (седмици)</span></b></p> </td> <td colspan="2" style="width:209.85pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="280"> <p align="center" class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;   margin-bottom:2.0pt;margin-left:0in;text-align:center;page-break-after:avoid"><b><span lang="BG">Абсолютна   промяна от   изходно   ниво в   процента на   прогнозирания   ФЕО<sub>1 </sub>(процентни   точки)</span></b></p> </td> </tr> <tr> <td style="width:99.85pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="133"> <p class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;margin-bottom:   2.0pt;margin-left:0in;page-break-after:avoid"><b><span lang="BG"> </span></b></p> </td> <td style="width:143.45pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="191"> <p align="center" class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;   margin-bottom:2.0pt;margin-left:0in;text-align:center;page-break-after:avoid"><b><span lang="BG"> </span></b></p> </td> <td style="width:67.0pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="89"> <p align="center" class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;   margin-bottom:2.0pt;margin-left:0in;text-align:center;page-break-after:avoid"><b><span lang="BG">N</span></b></p> </td> <td style="width:142.85pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="190"> <p align="center" class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;   margin-bottom:2.0pt;margin-left:0in;text-align:center;page-break-after:avoid"><b><span lang="BG">Средно (SD)</span></b></p> </td> </tr> <tr> <td colspan="4" style="width:453.15pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="604"> <p class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;margin-bottom:   2.0pt;margin-left:0in;page-break-after:avoid"><b><span lang="BG">Проучване 1</span></b></p> </td> </tr> <tr> <td style="width:99.85pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="133"> <p class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;margin-bottom:   2.0pt;margin-left:28.35pt;page-break-after:avoid"><b><span lang="BG">Ивакафтор</span></b></p> </td> <td style="width:143.45pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" width="191"> <p align="center" class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;   margin-bottom:2.0pt;margin-left:0in;text-align:center;page-break-after:avoid"><span lang="BG">48*</span></p> </td> <td style="width:67.0pt;border-top:none;border-left:none;border-bottom:   solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt" width="89"> <p align="center" class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;   margin-bottom:2.0pt;margin-left:0in;text-align:center;page-break-after:avoid"><span lang="BG">77</span></p> </td> <td style="width:142.85pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" width="190"> <p align="center" class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;   margin-bottom:2.0pt;margin-left:0in;text-align:center;page-break-after:avoid"><span lang="BG">9,4 (8,3)</span></p> </td> </tr> <tr> <td style="width:99.85pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="133"> <p class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;margin-bottom:   2.0pt;margin-left:0in;page-break-after:avoid"><b><span lang="BG"> </span></b></p> </td> <td style="width:143.45pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" width="191"> <p align="center" class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;   margin-bottom:2.0pt;margin-left:0in;text-align:center;page-break-after:avoid"><span lang="BG">144</span></p> </td> <td style="width:67.0pt;border-top:none;border-left:none;border-bottom:   solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt" width="89"> <p align="center" class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;   margin-bottom:2.0pt;margin-left:0in;text-align:center;page-break-after:avoid"><span lang="BG">72</span></p> </td> <td style="width:142.85pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" width="190"> <p align="center" class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;   margin-bottom:2.0pt;margin-left:0in;text-align:center;page-break-after:avoid"><span lang="BG">9,4 (10,8)</span></p> </td> </tr> <tr> <td style="width:99.85pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="133"> <p class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;margin-bottom:   2.0pt;margin-left:28.35pt;page-break-after:avoid"><b><span lang="BG">Плацебо</span></b></p> </td> <td style="width:143.45pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" width="191"> <p align="center" class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;   margin-bottom:2.0pt;margin-left:0in;text-align:center;page-break-after:avoid"><span lang="BG">0*</span></p> </td> <td style="width:67.0pt;border-top:none;border-left:none;border-bottom:   solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt" width="89"> <p align="center" class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;   margin-bottom:2.0pt;margin-left:0in;text-align:center;page-break-after:avoid"><span lang="BG">67</span></p> </td> <td style="width:142.85pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" width="190"> <p align="center" class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;   margin-bottom:2.0pt;margin-left:0in;text-align:center;page-break-after:avoid"><span lang="BG">-1,2 (7,8)<span style="color:#1F497D">†</span></span></p> </td> </tr> <tr> <td style="width:99.85pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="133"> <p class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;margin-bottom:   2.0pt;margin-left:0in;page-break-after:avoid"><b><span lang="BG"> </span></b></p> </td> <td style="width:143.45pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" width="191"> <p align="center" class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;   margin-bottom:2.0pt;margin-left:0in;text-align:center;page-break-after:avoid"><span lang="BG">96</span></p> </td> <td style="width:67.0pt;border-top:none;border-left:none;border-bottom:   solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt" width="89"> <p align="center" class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;   margin-bottom:2.0pt;margin-left:0in;text-align:center;page-break-after:avoid"><span lang="BG">55</span></p> </td> <td style="width:142.85pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" width="190"> <p align="center" class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;   margin-bottom:2.0pt;margin-left:0in;text-align:center;page-break-after:avoid"><span lang="BG">9,5 (11,2)</span></p> </td> </tr> <tr> <td colspan="4" style="width:453.15pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="604"> <p class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;margin-bottom:   2.0pt;margin-left:0in;page-break-after:avoid"><b><span lang="BG">Проучване 2</span></b></p> </td> </tr> <tr> <td style="width:99.85pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="133"> <p class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;margin-bottom:   2.0pt;margin-left:28.35pt;page-break-after:avoid"><b><span lang="BG">Ивакафтор</span></b></p> </td> <td style="width:143.45pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" width="191"> <p align="center" class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;   margin-bottom:2.0pt;margin-left:0in;text-align:center;page-break-after:avoid"><span lang="BG">48*</span></p> </td> <td style="width:67.0pt;border-top:none;border-left:none;border-bottom:   solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt" width="89"> <p align="center" class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;   margin-bottom:2.0pt;margin-left:0in;text-align:center;page-break-after:avoid"><span lang="BG">26</span></p> </td> <td style="width:142.85pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" width="190"> <p align="center" class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;   margin-bottom:2.0pt;margin-left:0in;text-align:center;page-break-after:avoid"><span lang="BG">10,2 (15,7)</span></p> </td> </tr> <tr> <td style="width:99.85pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="133"> <p class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;margin-bottom:   2.0pt;margin-left:0in;page-break-after:avoid"><b><span lang="BG"> </span></b></p> </td> <td style="width:143.45pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" width="191"> <p align="center" class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;   margin-bottom:2.0pt;margin-left:0in;text-align:center;page-break-after:avoid"><span lang="BG">144</span></p> </td> <td style="width:67.0pt;border-top:none;border-left:none;border-bottom:   solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt" width="89"> <p align="center" class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;   margin-bottom:2.0pt;margin-left:0in;text-align:center;page-break-after:avoid"><span lang="BG">25</span></p> </td> <td style="width:142.85pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" width="190"> <p align="center" class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;   margin-bottom:2.0pt;margin-left:0in;text-align:center;page-break-after:avoid"><span lang="BG">10,3 (12,4)</span></p> </td> </tr> <tr> <td style="width:99.85pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="133"> <p class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;margin-bottom:   2.0pt;margin-left:28.35pt;page-break-after:avoid"><b><span lang="BG">Плацебо</span></b></p> </td> <td style="width:143.45pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" width="191"> <p align="center" class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;   margin-bottom:2.0pt;margin-left:0in;text-align:center;page-break-after:avoid"><span lang="BG">0*</span></p> </td> <td style="width:67.0pt;border-top:none;border-left:none;border-bottom:   solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt" width="89"> <p align="center" class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;   margin-bottom:2.0pt;margin-left:0in;text-align:center;page-break-after:avoid"><span lang="BG">22</span></p> </td> <td style="width:142.85pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" width="190"> <p align="center" class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;   margin-bottom:2.0pt;margin-left:0in;text-align:center;page-break-after:avoid"><span lang="BG">-0,6 (10,1)<span style="color:#1F497D">†</span></span></p> </td> </tr> <tr> <td style="width:99.85pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="133"> <p class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;margin-bottom:   2.0pt;margin-left:0in;page-break-after:avoid"><b><span lang="BG"> </span></b></p> </td> <td style="width:143.45pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" width="191"> <p align="center" class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;   margin-bottom:2.0pt;margin-left:0in;text-align:center;page-break-after:avoid"><span lang="BG">96</span></p> </td> <td style="width:67.0pt;border-top:none;border-left:none;border-bottom:   solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt" width="89"> <p align="center" class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;   margin-bottom:2.0pt;margin-left:0in;text-align:center;page-break-after:avoid"><span lang="BG">21</span></p> </td> <td style="width:142.85pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" width="190"> <p align="center" class="MsoNormal" style="margin-top:2.0pt;margin-right:0in;   margin-bottom:2.0pt;margin-left:0in;text-align:center;page-break-after:avoid"><span lang="BG">10,5 (11,5)</span></p> </td> </tr> </table><p class="MsoNormal" style="margin-top:6.0pt;margin-right:0in;margin-bottom:0in; margin-left:14.2pt;margin-bottom:.0001pt;text-indent:-14.2pt;page-break-after: avoid"><span lang="BG" style="font-size:9.0pt;color:black">*    Лечението се извършва по време на заслепено, контролирано, 48-седмично проучване фаза</span><span lang="EN-GB" style="font-size:9.0pt; color:black"> </span><span lang="BG" style="font-size:9.0pt;color:black">3.</span></p><p class="MsoNormal" style="margin-left:14.2pt;text-indent:-14.2pt"><span lang="BG" style="font-size:9.0pt;color:black">†    Промяна от изходно ниво на предишното проучване след 48</span><span lang="EN-GB" style="font-size:9.0pt;color:black"> </span><span lang="BG" style="font-size:9.0pt;color:black">седмици лечение с плацебо.</span></p><p class="MsoNormal"><span lang="BG" style="color:black"> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif; color:black'>Когато средната (SD) абсолютна промяна в процента на прогнозирания ФЕО<sub>1</sub> бъде сравнена на изходно ниво при проучване</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="RU" style='font-family:"Times New Roman",serif'>4</span><span lang="RU" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="RU" style='font-family:"Times New Roman",serif'>за пациентите в групата на ивакафтор/ивакафтор (</span><span style='font-family:"Times New Roman",serif'>n</span><span lang="RU" style='font-family:"Times New Roman",serif'>=72), които са п</span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>рехвърлени от проучване</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>1, средната (SD) абсолютна промяна в процента на прогнозирания ФЕО<sub>1</sub> е 0,0% (9,05), докато за пациентите в групата на ивакафтор/ивакафтор (n=25), прехвърлени от проучване</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>2, тази цифра е 0,6% (9,1). Това показва, че пациентите в групата на ивакафтор/ивакафтор запазват подобрението, наблюдавано на седмица</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>48 от първоначалното проучване (ден</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>0 до седмица</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>48), в процента на прогнозирания ФЕО<sub>1</sub> до седмица</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>144. Няма допълнителни подобрения в проучване</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>4 (седмица</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>48 до седмица</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>144).</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif; color:black'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif; color:black'>За пациентите в групата на плацебо/ивакафтор от проучване</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>1 честотата на пулмоналните екзацербации на годишна база е по-висока в първоначалното проучване, когато пациентите са на плацебо (1,34 събития/година), отколкото при последващото проучване</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>4, когато пациентите са прехвърлени на ивакафтор (0,48</span><span lang="EN-GB" style='font-family:"Times New Roman",serif; color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif; color:black'>събития/година от ден</span><span lang="EN-GB" style='font-family: "Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>1 до седмица</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>48 и 0,67</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>събития/година от седмица 48 до 96). За пациентите в групата на ивакафтор/ивакафтор от проучване</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>1 честотата на пулмоналните екзацербации на годишна база е 0,57</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>събития/година от ден</span><span lang="EN-GB" style='font-family: "Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>1 до седмица</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>48, когато пациентите са на ивакафтор. Когато те са прехвърлени в проучване</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>4, честотата на пулмоналните екзацербации на годишна база е 0,91</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>събития/година от ден</span><span lang="EN-GB" style='font-family: "Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>1 до седмица</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>48 и 0,77</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>събития/година от седмица 48 до 96.</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif; color:black'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif; color:black'>За пациентите, прехвърлени от проучване</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>2, броят на събитията е като цяло малък.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><i><u><span lang="BG">Проучване</span></u></i><i><u><span lang="EN-GB"> </span></u></i><i><u><span lang="BG">6: проучване при пациенти с КФ с </span></u></i><i><u>R</u></i><i><u><span lang="BG">117</span></u></i><i><u>H</u></i><i><u> <span lang="BG">мутация на </span></u></i><i><u>CFTR</u></i><i><u> <span lang="BG">гена </span></u></i></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">В проучване 6 са оценени 69</span> <span lang="BG">пациенти на възраст 6</span> <span lang="BG">и повече години; 53 (76,8%) пациенти имат мутацията </span><i>F</i><i><span lang="BG">508</span></i><i>del</i> <span lang="BG">във втория алел. Потвърденият </span><i>R</i><i><span lang="BG">117</span></i><i>H</i><i> </i><span lang="BG">поли-</span>T<span lang="BG"> вариант е <i>5</i></span><i>T</i><i> </i><span lang="BG">при 38 пациенти </span><span lang="BG">и <i>7</i></span><i>T</i><span lang="BG"> при 16 пациенти</span><span lang="BG">. На изходното ниво средният прогнозиран ФЕО<sub>1</sub> е 73% (диапазон: 32,5% до 105,5%), а средната възраст е 31 години (диапазон: 6 до 68 години). Средната абсолютна промяна от изходно ниво до седмица 24 в процента на прогнозирания ФЕО<sub>1</sub> (първична крайна точка за ефикасност) е 2,57 процентни точки в групата на ивакафтор и 0,46 процентни точки в групата на плацебо. Изчислената разлика в лечението за ивакафтор спрямо плацебо е 2,1 процентни точки (95% ДИ</span><span lang="EN-GB"> </span><span lang="BG">‑1,1;</span><span lang="EN-GB"> </span><span lang="BG">5,4).</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Предварително планиран подгрупов анализ е проведен при пациенти на 18 и повече години (26</span><span lang="EN-GB"> </span><span lang="BG">пациенти на плацебо и 24 на ивакафтор). Лечението с ивакафтор води до средна абсолютна промяна в процента на прогнозирания ФЕО<sub>1</sub> до седмица</span> <span lang="BG">24 с 4,5</span> <span lang="BG">процентни точки в групата на ивакафтор спрямо ‑0,46</span> <span lang="BG">процентни точки в групата на плацебо. Изчислената разлика в лечението за ивакафтор спрямо плацебо е 5,0 процентни точки (95%</span><span lang="EN-GB"> </span><span lang="BG">ДИ</span><span lang="EN-GB"> </span><span lang="BG">1,1;</span><span lang="EN-GB"> </span><span lang="BG">8,8).</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">В подгрупов анализ при пациенти с потвърден </span><i>R</i><i><span lang="BG">117</span></i><i>H</i><i><span lang="BG">-5</span></i><i>T</i><i> </i><span lang="BG">генетичен вариант разликата в </span><span lang="BG">средната абсолютна промяна от изходно ниво до седмица </span><span lang="BG">24 в процента на прогнозирания ФЕО<sub>1</sub> между ивакафтор и плацебо е 5,3% (95% ДИ</span><span lang="EN-GB"> </span><span lang="BG">1,3;</span><span lang="EN-GB"> </span><span lang="BG">9,3). При пациентите с потвърден </span><i>R</i><i><span lang="BG">117</span></i><i>H</i><i><span lang="BG">-7</span></i><i>T</i><i> </i><span lang="BG">генетичен вариант </span><span lang="BG">разликата в лечението между ивакафтор и плацебо е </span><span lang="BG">0,2% (95% ДИ</span><span lang="EN-GB"> </span><span lang="BG">‑8,1;</span><span lang="EN-GB"> </span><span lang="BG">8,5).</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">При вторичните променливи за ефикасност не се наблюдават разлики между леченията с ивакафтор спрямо плацебо по отношение на абсолютната промяна от изходно ниво в </span><span lang="EN-GB">BMI</span><span lang="EN-GB"> </span><span lang="BG">на седмица 24 или времето до първата пулмонална екзацербация. Наблюдавани са разлики между леченията по отношение на абсолютната промяна в скора на респираторния домейн на<b> </b></span><span lang="EN-GB">CFQ</span><span lang="BG">‑</span><span lang="EN-GB">R</span><span lang="EN-GB"> </span><span lang="BG">до седмица 24 (разликата между лечението с ивакафтор спрямо плацебо</span><span lang="BG"> </span><span lang="BG">е 8,4 [95%</span><span lang="EN-GB"> </span><span lang="BG">ДИ 2,2; 14,6] точки) и на средната промяна от изходно ниво на хлорните йони в потта (вж. „Фармакодинамични ефекти“).</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG">Ивакафтор в комбинирана схема с тезакафтор/ивакафтор или ивакафтор/тезакафтор/елексакафтор</span></i></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG"> </span></i></p><p class="MsoNormal"><span lang="BG">Ефикасността и безопасността на ивакафтор в комбинирана схема с тезакафтор/ивакафтор при пациенти с КФ на възраст 12 и повече години са оценени в две клинични проучвания: едно 24-седмично, рандомизирано, двойносляпо, плацебо-контролирано проучване с 504</span><span lang="EN-GB"> </span><span lang="BG">пациенти на възраст 12</span><span lang="EN-GB"> </span><span lang="BG">и повече години, които са хомозиготни за мутацията </span><i><span lang="EN-GB">F</span></i><i><span lang="BG">508</span></i><i><span lang="EN-GB">del</span></i><span lang="BG">; и едно рандомизирано, двойносляпо, плацебо- и ивакафтор-контролирано, 8‑седмично кръстосано проучване с 2</span><span lang="EN-GB"> </span><span lang="BG">периода и 3</span><span lang="EN-GB"> </span><span lang="BG">лечения при 244</span><span lang="EN-GB"> </span><span lang="BG">пациенти на възраст 12</span><span lang="EN-GB"> </span><span lang="BG">и повече години, които са хетерозиготни за мутацията </span><i><span lang="EN-GB">F</span></i><i><span lang="BG">508</span></i><i><span lang="EN-GB">del</span></i><span lang="EN-GB"> </span><span lang="BG">и имат втора мутация, свързана с остатъчна активност на </span><i><span lang="EN-GB">CFTR</span></i><span lang="BG"> гена. </span><span lang="EN-GB">Дългосрочната безопасност и ефикасност на </span><span lang="BG">комбинираната схема е оценена и при двете популации пациенти в едно</span><span lang="BG"> </span><span lang="BG">96-седмично открито, </span><span lang="EN-GB">rollover</span><span lang="BG">, дългосрочно разширено проучване. Вижте </span><span lang="BG">к</span><span lang="BG">ратка характеристика на продукта, съдържащ тезакафтор/ивакафтор за допълнителна информация.</span></p><p class="MsoNormal"><span lang="BG" style="color:black"> </span></p><p class="MsoNormal"><span lang="BG">Ефикасността и безопасността на </span><span lang="BG">ивакафтор </span><span lang="BG">в комбинирана схема с ивакафтор/тезакафтор/елексакафтор при пациенти на възраст </span><span lang="EN-GB">12</span><span lang="EN-GB"> </span><span lang="EN-GB">и повече години </span><span lang="BG">са демонстрирани в две </span><span lang="EN-GB">проучван</span><span lang="BG">ия</span><span lang="BG"> </span><span lang="BG">фаза 3, рандомизирано, двойносляпо, плацебо-контролирано (пациенти, хетерозиготни за </span><i><span lang="EN-GB">F508del</span></i><span lang="BG">,</span><span lang="EN-GB"> n=</span><span lang="BG">403) и активно контролирано (пациенти, хомозиготни за мутацията </span><i><span lang="EN-GB">F508del</span></i><span lang="BG">,</span><span lang="EN-GB"> n=</span><span lang="BG">107) с продължителност съответно 24 и 4 седмици. Хетерозиготните за мутацията </span><i><span lang="EN-GB">F508del</span></i><span lang="EN-GB"> </span><span lang="BG">пациенти имат </span><span lang="EN-GB">мутация </span><span lang="BG">с минимална функция (МФ) на втория алел, дефинирана като </span><span lang="EN-GB">мутация</span><span lang="BG">, която води или до липса на синтез на</span><span lang="BG"> </span><span lang="BG">белтък </span><span lang="EN-GB">CFTR (</span><span lang="BG">т.е. клас </span><span lang="FR">I</span><span lang="BG">), или до синтез на белтък </span><span lang="EN-GB">CFTR</span><span lang="BG">, който не изпълнява функцията да транспортира хлориди и няма вероятност да има отговор към други </span><span lang="EN-GB">CFTR</span><span lang="BG"> модулатори (тезакафтор, ивакафтор или комбинацията от тях). Хомозиготните за мутацията </span><i><span lang="EN-GB">F508del</span></i><span lang="EN-GB"> </span><span lang="BG">пациенти получават схема с тезакафтор</span><span lang="EN-GB">/</span><span lang="BG">ивакафтор</span><span lang="BG"> </span><span lang="BG">и</span><span lang="BG"> </span><span lang="BG">ивакафтор</span><span lang="BG"> </span><span lang="BG">по време на </span><span lang="EN-GB">4-</span><span lang="BG">седмичен открит период на въвеждане, след което са рандомизирани да получават</span><span lang="BG"> </span><span lang="BG">ивакафтор в </span><span lang="BG">комбинация с ивакафтор/тезакафтор/елексакафтор по време на </span><span lang="EN-GB">4-</span><span lang="BG">седмичен период на двойносляпо лечение</span><span lang="EN-GB">. Пациенти </span><span lang="BG">и от двете проучвания са подходящи за влизане в едно открито, </span>rollover, <span lang="EN-GB">96-седмично</span><span lang="EN-GB"> </span><span lang="EN-GB">проучване. </span><span lang="BG">Вижте кратка характеристика на продукта, съдържащ ивакафтор/тезакафтор/елексакафтор за допълнителна информация</span><span lang="EN-GB">.</span></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB"><span style="text-decoration:none"> </span></span></u></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Педиатрична популация"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal"><i><span lang="BG">Ивакафтор в комбинирана схема с тезакафтор/ивакафтор</span></i></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Ефикасността и безопасността при пациенти на възраст от 6 до под 12 години (средна възраст 8,6 години) са оценени в едно 8-седмично, двойносляпо изпитване фаза 3 с 67 пациенти, рандомизирани 4:1 или на ивакафтор в комбинирана схема с </span><span lang="BG">тезакафтор/ивакафтор, или в заслепена група. Четиридесет и двама пациенти са хомозиготни за мутацията </span><i><span lang="EN-GB">F508del</span></i><i><span lang="EN-GB"> </span></i><span lang="BG">(</span><span lang="EN-GB">F/F</span><span lang="BG">)<i>, </i>а 12 са хетерозиготни за </span><span lang="BG">мутацията </span><i><span lang="EN-GB">F508del</span></i><span lang="BG"> и </span><span lang="BG">имат втора мутация, свързана с остатъчна активност на </span><i><span lang="EN-GB">CFTR</span></i><span lang="BG"> гена </span><span lang="FR">(F/RF). </span><span lang="BG">Вижте кратка характеристика на продукта, съдържащ тезакафтор</span>/<span lang="BG">ивакафор за допълнителна информация.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Европейската агенция по лекарствата отлага задължението за предоставяне на резултатите от проучванията с </span><span lang="EN-GB">Kalydeco</span><span lang="EN-GB"> </span><span lang="BG">в една или повече подгрупи на педиатричната популация с кистозна фиброза (вж. точка 4.2 за информация относно употреба в педиатрията).</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.2     Фармакокинетични свойства"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Фармакокинетиката на ивакафтор е сходна при здрави възрастни доброволци и пациенти с КФ.</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">След пероралното приложение на единична доза от 150 mg на здрави доброволци след хранене средните стойности (±SD) за AUC и C<sub>max</sub> са съответно 10</span><span lang="EN-GB"> </span><span lang="BG">600 (5260) ng*час/m</span><span lang="EN-GB">l</span><span lang="BG"> и 768 (233) ng/m</span><span lang="EN-GB">l</span><span lang="BG">. След приложение на всеки 12</span><span lang="EN-GB"> </span><span lang="BG">часа стационарните плазмени концентрации на ивакафтор се достигат между ден</span><span lang="EN-GB"> </span><span lang="BG">3 до ден</span><span lang="EN-GB"> </span><span lang="BG">5, със съотношение на кумулиране от 2,2 до 2,9.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Абсорбция"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="labeltextheading"><u><span lang="BG" style='font-family:"Times New Roman",serif; font-style:normal'><span style="text-decoration:none"> </span></span></u></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>След многократно перорално приложение на ивакафтор експозицията на ивакафтор обикновено нараства с дозата от 25 mg на всеки 12 часа до 450 mg на всеки 12 часа. Когато се дава с храна, съдържаща мазнини, експозицията на ивакафтор нараства приблизително 2,5 до 4</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>пъти. Когато се прилага едновременно с тезакафтор и елексакафтор, повишението на </span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>AUC</span><span lang="BG" style='font-family:"Times New Roman",serif'> е подобно (приблизително съответно 3</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>пъти и 2,5 до 4 пъти). Ето защо ивакафтор, прилаган като монотерапия или в комбинирана схема с тезакафтор/ивакафтор или ивакафтор/тезакафтор/елексакафтор, трябва да се прилага с храна, съдържаща мазнини. Медианата (диапазона) на t<sub>max</sub> е приблизително 4,0 (3,0; 6,0) часа след хранене.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Гранулите ивакафтор (2</span><span lang="EN-GB"> x </span><span lang="BG">75</span><span lang="EN-GB"> mg</span><span lang="BG"> сашета) имат подобна бионаличност, както и таблетката от 150</span><span lang="EN-GB"> mg</span><span lang="BG">, когато се дават със съдържаща мазнини храна на здрави възрастни. Средното геометрично съотношение по метода на най-малките квадрати (90%</span><span lang="EN-GB"> </span><span lang="BG">ДИ) за гранулите в сравнение с таблетките е 0,951</span><span lang="EN-GB"> </span><span lang="BG">(0,839; 1,08) за </span><span lang="EN-GB">AUC</span><sub><span lang="BG">0-</span></sub><sub><span lang="EN-GB" style="font-family:SimSun">∞</span></sub><span lang="BG"> и 0,918</span><span lang="EN-GB"> </span><span lang="BG">(0,750; 1,12) за </span><span lang="EN-GB">C<sub>max</sub></span><span lang="BG">. Ефектът на храната върху абсорбцията на ивакафтор е сходен за двете лекарствени форми, т.е. таблетки и гранули.</span></p><p class="MsoNormal"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Разпределение"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Ивакафтор се свързва приблизително 99% с плазмените белтъци, основно с алфа-1-кисел гликопротеин и албумин. Ивакафтор не се свързва с човешките еритроцити. След перорално приложение на ивакафтор 150 mg на всеки 12 часа в продължение на 7 дни при здрави доброволци след хранене средният (±SD) привиден обем на разпределение е 353 </span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>l</span><span lang="BG" style='font-family:"Times New Roman",serif'> (122).</span></p><p class="labeltext" style="page-break-after:avoid"><u><span lang="BG" style='font-family:"Times New Roman",serif'><span style="text-decoration:none"> </span></span></u></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Биотрансформация"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="labeltext" style="page-break-after:avoid"><i><u><span lang="BG" style='font-family:"Times New Roman",serif'><span style="text-decoration:none"> </span></span></u></i></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Ивакафтор се метаболизира в значителна степен при хора. <i>In</i></span><i><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span></i><i><span lang="BG" style='font-family:"Times New Roman",serif'>vitro</span></i><span lang="BG" style='font-family:"Times New Roman",serif'> и <i>in</i></span><i><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span></i><i><span lang="BG" style='font-family:"Times New Roman",serif'>vivo</span></i><span lang="BG" style='font-family:"Times New Roman",serif'> данните показват, че ивакафтор се метаболизира основно чрез CYP3A. M1 и M6 са двата основни метаболита на ивакафтор при хора. M1 притежава приблизително една шеста от мощта на ивакафтор и се счита за фармакологично активен. M6 притежава по-малко от една петдесета от мощта на ивакафтор и не се счита за фармакологично активен.</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Ефектът, който се получава върху експозицията на ивакафтор, тезакафтор и елексакафтор при </span><span lang="FR" style='font-family:"Times New Roman",serif'>CYP3A4*22 </span><span lang="BG" style='font-family:"Times New Roman",serif'>хетерозиготен генотип, е подобен на този, който се получава при едновременното приложение на слаб инхибитор на </span><span lang="FR" style='font-family:"Times New Roman",serif'>CYP3A4</span><span lang="BG" style='font-family:"Times New Roman",serif'>, което няма клинична значимост. Не се счита за необходимо да се коригира дозата на ивакафтор, тезакафтор или елексакафтор. Ефектът се очаква да бъде по-силно изразен при пациентите с </span><span lang="FR" style='font-family:"Times New Roman",serif'>CYP3A4*22 </span><span lang="BG" style='font-family:"Times New Roman",serif'>хомозиготен генотип. Липсват обаче данни за такива пациенти.</span></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Елиминиране"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>След перорално приложение при здрави доброволци основната част от ивакафтор (87,8%) се елиминира с фецеса след метаболитно преобразуване. На основните метаболити M1 и M6 се пада приблизително 65% от общата елиминирана доза: 22% като M1 и 43% като M6. Има незначителна екскреция с урината на ивакафтор като непроменено изходно вещество. Привидният терминален полуживот е приблизително 12 часа след приложение на единична доза след хранене. Привидният клирънс (CL/F) на ивакафтор е сходен при здрави лица и пациенти с КФ. Средната стойност (±SD) на CL/F за единична доза 150 mg е 17,3 (8,4) </span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>l</span><span lang="BG" style='font-family:"Times New Roman",serif'>/час при здрави лица.</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Линейност/нелинейност"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="labeltext" style="page-break-after:avoid"><u><span lang="BG" style='font-family:"Times New Roman",serif'><span style="text-decoration:none"> </span></span></u></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Фармакокинетиката на ивакафтор обикновено е линейна по отношение на времето или дозата, варираща от 25 mg до 250 mg.</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext" style="page-break-after:avoid"><u><span lang="BG" style='font-family:"Times New Roman",serif'>Специални популации</span></u></p><p class="labeltext" style="page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="BG" style='font-family:"Times New Roman",serif'>Чернодробно увреждане</span></i></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="BG" style='font-family:"Times New Roman",serif'> </span></i></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>След единична доза от 150 mg ивакафтор възрастните пациенти с умерено нарушена чернодробна функция (клас B по Child-Pugh, скор 7 до 9) имат сходна стойност на C<sub>max</sub> на ивакафтор, (средна стойност [±SD] от 735 [331] ng/m</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>l</span><span lang="BG" style='font-family:"Times New Roman",serif'>), но приблизително двукратно увеличение на AUC<sub>0-</sub></span><sub><span style="font-family:SimSun">∞</span></sub><span style='font-family:"Times New Roman",serif'> <span lang="BG">на ивакафтор (средна стойност [±SD] от 16 800 [6140] ng*час/m</span></span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>l</span><span lang="BG" style='font-family:"Times New Roman",serif'>), в сравнение със здрави лица, съответстващи демографски. Симулации за прогнозиране на експозицията в стационарно състояние на ивакафтор показват, че чрез намаляване на дозата от 150 mg на всеки 12 часа на 150 mg веднъж дневно възрастните с умерено чернодробно увреждане биха имали сравними стойности на C<sub>min</sub> в стационарно състояние с тези, получени с доза от 150 mg на всеки 12 часа при възрастни без чернодробно увреждане. </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="MsoNormal"><span lang="BG">При участниците с умерено увредена чернодробна функция (клас В по </span>Child<span lang="BG">‑</span>Pugh<span lang="BG">, скор</span> <span lang="BG">7 до 9) </span>AUC<span lang="BG"> на ивакафтор се повишава с приблизително 50% след многократно приложение в продължение на 10 дни на или тезакафтор и ивакафтор, или на ивакафтор, тезакафтор и елексакафтор. </span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Въздействието на тежко чернодробно увреждане (клас C по Child-Pugh, скор 10 до 15) върху фармакокинетиката на ивакафтор като монотерапия или в комбинирана схема с тезакафтор/ивакафтор или ивакафтор/тезакафтор/елексакафтор не е проучено. Величината на повишението на експозицията при тези пациенти е неизвестна, но се очаква да е по-висока, отколкото се наблюдава при пациенти с умерено чернодробно увреждане. </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>За насоки относно подходящата употреба и промяната на дозата вижте Таблица 3 в точка 4.2.</span></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="BG" style='font-family:"Times New Roman",serif'> </span></i></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="BG" style='font-family:"Times New Roman",serif'>Бъбречно увреждане</span></i></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="BG" style='font-family:"Times New Roman",serif'> </span></i></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Не са провеждани фармакокинетични проучвания с ивакафтор при пациенти с бъбречно увреждане или като монотерапия, или в комбинирана схема с тезакафтор/ивакафтор или с ивакафтор/тезакафтор/елексакафтор. При едно фармакокинетично проучване с монотерапия с ивакафтор при хора има минимално елиминиране на ивакафтор и неговите метаболити в урината (само 6,6% от общата радиоактивност се открива в урината). Има незначителна екскреция с урината на ивакафтор като непроменено изходно вещество (по-малко от 0,01% след единична перорална доза от 500 mg). </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Не се препоръчва корекция на дозата при леко и умерено бъбречно увреждане. Препоръчва се повишено внимание при приложение на ивакафтор или като монотерапия, или в комбинация с тезакафтор/ивакафтор или с ивакафтор/тезакафтор/елексакафтор на пациенти с тежко бъбречно увреждане (креатининов клирънс по-нисък или равен на 30 m</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>l</span><span lang="BG" style='font-family:"Times New Roman",serif'>/min) или терминална бъбречна недостатъчност (вж. точка 4.2 и</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>4.4). </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="BG" style='font-family:"Times New Roman",serif'>Расова принадлежност</span></i></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="BG" style='font-family:"Times New Roman",serif'> </span></i></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Расовата принадлежност няма клинично значим ефект върху ФК на ивакафтор при пациенти от бялата (</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>n</span><span lang="BG" style='font-family:"Times New Roman",serif'>=379) и останалите раси (</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>n</span><span lang="BG" style='font-family:"Times New Roman",serif'>=29) въз основа на популационен ФК анализ.</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="BG" style='font-family:"Times New Roman",serif'>Пол</span></i></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="BG" style='font-family:"Times New Roman",serif'> </span></i></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Фармакокинетичните параметри на ивакафтор или като монотерапия, или в комбинация с тезакафтор/ивакафтор </span><span lang="BG" style='font-family:"Times New Roman",serif'>или ивакафтор/тезакафтор/елексакафтор са подобни при мъжете и при жените.</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="BG" style='font-family:"Times New Roman",serif'>Старческа възраст</span></i></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="BG" style='font-family:"Times New Roman",serif'> </span></i></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Клиничните проучвания на ивакафтор като монотерапия не включват достатъчен брой пациенти на възраст 65</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>и повече години, за да се определи дали фармакокинетичните параметри са подобни на тези при по-младите възрастни. </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Фармакокинетичните параметри на ивакафтор в комбинация с тезакафтор при пациентите в старческа възраст (65‑72</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>години) са сравними с тези при по-младите възрастни. В клиничните проучвания на ивакафтор/тезакафтор/елексакафтор не са включени пациенти на възраст 65 и повече години, затова не може да се определи дали фармакокинетичните параметри са подобни на тези при по-младите възрастни. </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltextheading"><u><span lang="BG" style='font-family:"Times New Roman",serif; font-style:normal'>Педиатрична популация</span></u></p><p class="labeltextheading"><u><span lang="BG" style='font-family:"Times New Roman",serif; font-style:normal'><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal"><span lang="BG">Прогнозираната експозиция на ивакафтор, основаваща се на наблюдаваните концентрации на ивакафтор при проучвания фаза</span><span lang="EN-GB"> </span><span lang="BG">2 и фаза</span><span lang="EN-GB"> </span><span lang="BG">3, определена с използване на популационен ФК анализ, е представена по възрастови групи в Таблица</span> <span lang="BG">9.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-bottom:6.0pt;page-break-after:avoid"><b><span lang="BG">Таблица</span></b><b> </b><b><span lang="BG">9: Средна (</span></b><b>SD</b><b><span lang="BG">) експозиция на ивакафтор по възрастови групи</span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="border-collapse:collapse;border:none"> <thead> <tr style="page-break-inside:avoid;height:23.9pt"> <td style="width:133.0pt;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="177"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><b><span lang="BG">Възрастова    група</span></b></p> </td> <td style="width:127.55pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="170"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><b><span lang="BG">Доза</span></b></p> </td> <td style="width:79.4pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="106"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><b>C<sub>min, ss</sub> </b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><b>(ng/ml)</b></p> </td> <td style="width:99.25pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="132"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><b>AUC</b><b><sub><span lang="EN-GB">τ, ss</span></sub></b><b> (</b><b><span lang="BG">ng*час</span></b><b>/ml)</b></p> </td> </tr> </thead> <tr style="page-break-inside:avoid;height:23.9pt"> <td style="width:133.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="177"> <p class="labeltext" style="page-break-after:avoid"><span lang="RU" style='font-family:"Times New Roman",serif'>6- до   под 12-месечни</span></p> <p class="labeltext" style="page-break-after:avoid"><span lang="RU" style='font-family:"Times New Roman",serif'>(5</span><span style='font-family:   "Times New Roman",serif'> kg</span><span style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>до</span><span lang="RU" style='font-family:"Times New Roman",serif'> &lt;7</span><span style='font-family:"Times New Roman",serif'> kg</span><span lang="RU" style='font-family:"Times New Roman",serif'>)</span><sup><span style='font-family:"Times New Roman",serif'>*</span></sup></p> </td> <td style="width:127.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="170"> <p class="MsoNormal"><span lang="BG">2</span><span lang="EN-GB">5 mg </span><span lang="BG">на всеки   12 часа</span></p> </td> <td style="width:79.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="106"> <p class="MsoNormal"><span lang="BG">3</span><span lang="EN-GB">36</span></p> </td> <td style="width:99.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="132"> <p class="MsoNormal"><span lang="BG">5</span><span lang="EN-GB">41</span><span lang="BG">0</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:23.9pt"> <td style="width:133.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="177"> <p class="labeltext" style="page-break-after:avoid"><span lang="RU" style='font-family:"Times New Roman",serif'>6- до   под 12-месечни</span></p> <p class="labeltext" style="page-break-after:avoid"><span lang="RU" style='font-family:"Times New Roman",serif'>(7</span><span style='font-family:   "Times New Roman",serif'> kg</span><span style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>до</span><span lang="RU" style='font-family:"Times New Roman",serif'> &lt;14</span><span style='font-family:"Times New Roman",serif'> kg</span><span lang="RU" style='font-family:"Times New Roman",serif'>)</span></p> </td> <td style="width:127.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="170"> <p class="MsoNormal"><span lang="EN-GB">50 mg </span><span lang="BG">на   всеки 12 часа</span></p> </td> <td style="width:79.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="106"> <p class="MsoNormal"><span lang="BG">5</span><span lang="EN-GB">08</span><span lang="BG"> (2</span><span lang="EN-GB">52</span><span lang="BG">)</span></p> </td> <td style="width:99.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="132"> <p class="MsoNormal"><span lang="BG">9</span><span lang="EN-GB">140</span><span lang="BG"> (</span><span lang="EN-GB">420</span><span lang="BG">0)</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:23.9pt"> <td style="width:133.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="177"> <p class="labeltext" style="page-break-after:avoid"><span lang="RU" style='font-family:"Times New Roman",serif'>12</span><span lang="BG" style='font-family:"Times New Roman",serif'>‑ до   под 24‑месечни</span></p> <p class="MsoNormal"><span lang="RU">(7</span><span lang="EN-GB"> kg</span><span lang="EN-GB"> </span><span lang="BG">до</span><span lang="RU"> &lt;14</span><span lang="EN-GB"> kg</span><span lang="RU">)</span></p> </td> <td style="width:127.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="170"> <p class="MsoNormal"><span lang="EN-GB">50 mg </span><span lang="BG">на   всеки 12 часа</span></p> </td> <td style="width:79.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="106"> <p class="MsoNormal"><span lang="EN-GB">440 (212)</span></p> </td> <td style="width:99.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="132"> <p class="MsoNormal"><span lang="EN-GB">9050 (3050)</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:23.9pt"> <td style="width:133.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="177"> <p class="labeltext" style="page-break-after:avoid"><span lang="RU" style='font-family:"Times New Roman",serif'>12</span><span lang="BG" style='font-family:"Times New Roman",serif'>‑ до   под 24</span><span lang="RU" style='font-family:"Times New Roman",serif'>‑</span><span lang="BG" style='font-family:"Times New Roman",serif'>месечни</span></p> <p class="MsoNormal"><span lang="RU">(</span>≥<span lang="RU">14</span><span lang="EN-GB"> kg</span><span lang="EN-GB"> </span><span lang="BG">до</span><span lang="RU"> &lt;25</span><span lang="EN-GB"> kg</span><span lang="RU">)</span></p> </td> <td style="width:127.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="170"> <p class="MsoNormal"><span lang="EN-GB">75 mg </span><span lang="BG">на   всеки 12 часа</span></p> </td> <td style="width:79.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="106"> <p class="MsoNormal"><span lang="EN-GB">451 (125)</span></p> </td> <td style="width:99.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="132"> <p class="MsoNormal"><span lang="EN-GB">9600 (1800)</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:23.9pt"> <td style="width:133.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="177"> <p class="MsoNormal">2<span lang="BG">- до</span>   5-годишни</p> <p class="MsoNormal">(&lt;14 kg)</p> </td> <td style="width:127.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="170"> <p class="MsoNormal">50 mg <span lang="BG">на   всеки 12 часа</span></p> </td> <td style="width:79.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="106"> <p class="MsoNormal">577 (317)</p> </td> <td style="width:99.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="132"> <p class="MsoNormal">10500 (4260)</p> </td> </tr> <tr style="page-break-inside:avoid;height:23.9pt"> <td style="width:133.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="177"> <p class="MsoNormal"><span lang="RU">2- </span><span lang="BG">до</span><span lang="RU"> 5-годишни</span></p> <p class="MsoNormal"><span lang="RU">(≥14</span> kg <span lang="BG">до</span><span lang="RU"> &lt;25</span> kg<span lang="RU">)</span></p> </td> <td style="width:127.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="170"> <p class="MsoNormal">75 mg <span lang="BG">на   всеки 12 часа</span></p> </td> <td style="width:79.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="106"> <p class="MsoNormal">629 (296)</p> </td> <td style="width:99.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="132"> <p class="MsoNormal">11300 (3820)</p> </td> </tr> <tr style="page-break-inside:avoid;height:23.9pt"> <td style="width:133.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="177"> <p class="MsoNormal"><span lang="RU">6- </span><span lang="BG">до</span><span lang="RU"> 11-годишни</span><span lang="EN-GB"> <sup>†</sup></span></p> <p class="MsoNormal"><span lang="RU">(</span>≥<span lang="RU">14</span> kg<span lang="RU"> до &lt;25</span> kg<span lang="RU">)</span></p> </td> <td style="width:127.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="170"> <p class="MsoNormal">75 mg <span lang="BG">на   всеки 12 часа</span></p> </td> <td style="width:79.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="106"> <p class="MsoNormal">641 (329)</p> </td> <td style="width:99.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="132"> <p class="MsoNormal">10760 (4470)</p> </td> </tr> <tr style="page-break-inside:avoid;height:23.15pt"> <td style="width:133.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.15pt" valign="top" width="177"> <p class="MsoNormal">6- <span lang="BG">до</span>   11-годишни<span lang="EN-GB"> <sup>†</sup></span></p> <p class="MsoNormal">(≥25 kg)</p> </td> <td style="width:127.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.15pt" valign="top" width="170"> <p class="MsoNormal">150 mg <span lang="BG">на   всеки 12 часа</span></p> </td> <td style="width:79.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.15pt" valign="top" width="106"> <p class="MsoNormal">958 (546)</p> </td> <td style="width:99.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.15pt" valign="top" width="132"> <p class="MsoNormal">15300 (7340)</p> </td> </tr> <tr style="page-break-inside:avoid;height:24.75pt"> <td style="width:133.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:24.75pt" valign="top" width="177"> <p class="MsoNormal">12- <span lang="BG">до</span>   17-годишни</p> </td> <td style="width:127.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:24.75pt" valign="top" width="170"> <p class="MsoNormal">150 mg <span lang="BG">на   всеки 12 часа</span></p> </td> <td style="width:79.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:24.75pt" valign="top" width="106"> <p class="MsoNormal">564 (242)</p> </td> <td style="width:99.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:24.75pt" valign="top" width="132"> <p class="MsoNormal">9240 (3420)</p> </td> </tr> <tr style="page-break-inside:avoid;height:23.15pt"> <td style="width:133.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.15pt" valign="top" width="177"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Възрастни</span>   (≥18<span lang="BG">-годишни</span>)</p> </td> <td style="width:127.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.15pt" valign="top" width="170"> <p class="MsoNormal" style="page-break-after:avoid">150 mg<span lang="BG">   на всеки   12 часа</span></p> </td> <td style="width:79.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.15pt" valign="top" width="106"> <p class="MsoNormal" style="page-break-after:avoid">701 (317)</p> </td> <td style="width:99.25pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.15pt" valign="top" width="132"> <p class="MsoNormal" style="page-break-after:avoid">10700 (4100)</p> </td> </tr> </table><p class="MsoNormal" style="margin-top:6.0pt;margin-right:0in;margin-bottom:0in; margin-left:14.2pt;margin-bottom:.0001pt;text-indent:-14.2pt;page-break-after: avoid"><sup><span lang="BG" style="font-size:9.0pt">*</span></sup><span lang="BG" style="font-size:9.0pt">     Стойности въз основа на данни от един единствен пациент; стандартни отклонения не се съобщават.</span></p><p class="MsoNormal" style="margin-left:14.2pt;text-indent:-14.2pt"><sup><span lang="BG" style="font-size:9.0pt">†*</span></sup><span lang="BG" style="font-size: 9.0pt">    Експозициите при 6‑ до 11‑годишните са прогнози въз основа на симулации от популационния ФК модел с използване на данни, получени за тази възрастова група.</span></p><p class="MsoNormal"><span lang="RU"> </span></p><p class="MsoNormal"><span lang="BG">Експозицията </span><span lang="RU">на ивакафтор в комбинация с тезакафтор и с тезакафтор/елексакафтор </span><span lang="BG">е дадена в</span><span lang="BG"> </span><span lang="EN-GB">Таблица </span><span lang="BG">10</span><span lang="EN-GB">. </span></p><p class="MsoNormal"> </p><p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:6.0pt; margin-left:56.7pt;text-indent:-56.7pt;page-break-after:avoid"><b><span lang="RU">Таблица</span></b><b> </b><b><span lang="BG">10:</span></b><b><span lang="BG"> </span></b><b><span lang="BG">Средна стойност</span></b><b><span lang="RU"> (</span></b><b>SD</b><b><span lang="RU">) </span></b><b><span lang="BG">на експозицията на </span></b><b><span lang="RU">ивакафтор, прилаган в комбинация, </span></b><b><span lang="BG">по възрастови групи</span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:453.35pt;border-collapse:collapse;border:none" width="604"> <thead> <tr style="page-break-inside:avoid;height:26.55pt"> <td style="width:169.85pt;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:26.55pt" valign="top" width="226"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><b><span lang="BG">Възрастова    група</span></b></p> </td> <td style="width:141.75pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 0in 0in 0in;height:26.55pt" valign="top" width="189"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><b><span lang="BG">Доза</span></b></p> </td> <td style="width:141.75pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 0in 0in 0in;height:26.55pt" valign="top" width="189"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><b><span lang="BG">Средна    стойност </span></b><b><span lang="RU">(</span></b><b><span lang="EN-GB">SD</span></b><b><span lang="RU">) </span></b><b><span lang="BG">за и</span></b><b><span lang="RU">вакафтор</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><b><span lang="EN-GB">AUC</span></b><b><sub><span lang="EN-GB">0-12h</span></sub></b><b><span lang="RU">,</span></b><b><span lang="EN-GB">ss</span></b><b><span lang="RU"> (</span></b><b><span lang="EN-GB">ng</span></b><b><span lang="BG">*час</span></b><b><span lang="RU">/</span></b><b>ml</b><b><span lang="RU">)</span></b></p> </td> </tr> </thead> <tr style="page-break-inside:avoid;height:.35in"> <td style="width:169.85pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.35in" valign="top" width="226"> <p class="MsoNormal"><span lang="BG">Деца (6   до под 12</span><span lang="BG"> </span><span lang="BG">години), &lt;30 </span><span lang="EN-GB">kg<br/>   n = 71</span></p> </td> <td style="width:141.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 0in 0in 0in;height:.35in" valign="top" width="189"> <p class="MsoNormal" style="margin-left:7.1pt"><span lang="BG">тезакафтор   </span><span lang="EN-GB">50 mg</span><span lang="BG">   веднъж   дневно/ивакафтор   7</span><span lang="EN-GB">5 mg</span><span lang="BG"> <br/>   на всеки   12 часа</span></p> </td> <td style="width:141.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 0in 0in 0in;height:.35in" valign="top" width="189"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="BG">7100 (1950)</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.35in"> <td style="width:169.85pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.35in" valign="top" width="226"> <p class="MsoNormal"><span lang="BG">Деца (6   до под 12</span><span lang="BG"> </span><span lang="BG">години), ≥30 </span><span lang="EN-GB">kg*<br/>   n = 51</span></p> </td> <td style="width:141.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 0in 0in 0in;height:.35in" valign="top" width="189"> <p class="MsoNormal" style="margin-left:7.1pt"><span lang="BG">тезакафтор   </span><span lang="EN-GB">100 mg</span><span lang="BG">   веднъж   дневно/ивакафтор   1</span><span lang="EN-GB">5</span><span lang="BG">0</span><span lang="EN-GB"> mg</span><span lang="BG"> <br/>   на всеки   12 часа</span></p> </td> <td style="width:141.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 0in 0in 0in;height:.35in" valign="top" width="189"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="BG">11800   (3890)</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.35in"> <td style="width:169.85pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.35in" valign="top" width="226"> <p class="MsoNormal"><span lang="BG">Пациенти   юноши (</span><span lang="EN-GB">12</span><span lang="EN-GB"> </span><span lang="BG">до</span><span lang="BG"> </span><span lang="BG">под </span><span lang="EN-GB">1</span><span lang="BG">8   години)</span></p> <p class="MsoNormal">n=97</p> </td> <td rowspan="2" style="width:141.75pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 0in 0in 0in;height:.35in" valign="top" width="189"> <p class="MsoNormal" style="margin-left:7.1pt"><span lang="RU">тезакафтор   100</span><span lang="ES"> mg</span><span lang="ES"> </span><span lang="BG">веднъж   дневно</span><span lang="RU">/<br/>   ивакафтор 150</span><span lang="ES"> mg</span><span lang="ES"> </span><span lang="BG">на   всеки 12 часа</span></p> </td> <td style="width:141.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 0in 0in 0in;height:.35in" valign="top" width="189"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB"> </span></p> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">11400   (5500)</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:.35in"> <td style="width:169.85pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.35in" valign="top" width="226"> <p class="MsoNormal"><span lang="BG">Възрастни   пациенти (</span><span lang="EN-GB">1</span><span lang="BG">8 и   повече години)</span></p> <p class="MsoNormal">n=<span lang="BG">389</span></p> <p class="MsoNormal"><span lang="EN-GB"> </span></p> </td> <td style="width:141.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 0in 0in 0in;height:.35in" valign="top" width="189"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="BG"> </span></p> <p align="center" class="MsoNormal" style="text-align:center"><span lang="BG">11400   (4140)</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:37.8pt"> <td style="width:169.85pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:37.8pt" valign="top" width="226"> <p class="MsoNormal"><span lang="BG">Пациенти   юноши </span>(<span lang="EN-GB">12</span><span lang="EN-GB"> </span><span lang="BG">до</span><span lang="BG"> </span><span lang="BG">под </span><span lang="EN-GB">1</span><span lang="BG">8   години</span>)</p> <p class="MsoNormal">n=<span lang="BG">69</span></p> </td> <td rowspan="2" style="width:141.75pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 0in 0in 0in;height:37.8pt" valign="top" width="189"> <p class="MsoNormal" style="margin-left:7.1pt"><span lang="RU">елексакафтор   200</span><span lang="BG"> </span><span lang="ES">mg</span><span lang="ES"> </span><span lang="BG">веднъж   дневно</span><span lang="RU">/<br/>   тезакафтор 100</span><span lang="ES"> mg</span><span lang="ES"> </span><span lang="BG">веднъж   дневно</span><span lang="RU">/<br/>   ивакафтор 150</span><span lang="ES"> mg</span><span lang="ES"> </span><span lang="BG">на   всеки 12 часа</span></p> </td> <td style="width:141.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 0in 0in 0in;height:37.8pt" valign="top" width="189"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB"> </span></p> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">1</span><span lang="BG">06</span><span lang="EN-GB">00 (</span><span lang="BG">3350</span><span lang="EN-GB">)</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:37.8pt"> <td style="width:169.85pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:37.8pt" valign="top" width="226"> <p class="MsoNormal"><span lang="BG">Възрастни   пациенти (</span><span lang="EN-GB">1</span><span lang="BG">8 и   повече години)</span></p> <p class="MsoNormal">n=<span lang="BG">186</span></p> <p class="MsoNormal"><span lang="BG"> </span></p> </td> <td style="width:141.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 0in 0in 0in;height:37.8pt" valign="top" width="189"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="BG"> </span></p> <p align="center" class="MsoNormal" style="text-align:center"><span lang="BG">12100   (4170)</span></p> </td> </tr> </table><p class="labeltextheading" style="page-break-after:auto"><u><span lang="EN-GB" style='font-size:10.0pt;font-family:"Times New Roman",serif;font-style:normal'>*</span></u><u><span lang="BG" style='font-size:10.0pt;font-family:"Times New Roman",serif;font-style: normal'>Експозициите в границите на теглото от ≥30 </span></u><u><span lang="EN-GB" style='font-size:10.0pt; font-family:"Times New Roman",serif;font-style:normal'>kg </span></u><u><span lang="BG" style='font-size:10.0pt;font-family:"Times New Roman",serif;font-style: normal'>до &lt;40 </span></u><u><span lang="EN-GB" style='font-size:10.0pt;font-family:"Times New Roman",serif;font-style:normal'>kg</span></u><u><span lang="BG" style='font-size:10.0pt;font-family:"Times New Roman",serif;font-style: normal'> са прогнози, получени от популационния ФК модел.</span></u></p><p class="labeltextheading" style="page-break-after:auto"><u><span lang="BG" style='font-family:"Times New Roman",serif;font-style:normal'><span style="text-decoration:none"> </span></span></u></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.3     Предклинични данни за безопасност"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Неклиничните данни</span><span lang="BG"> </span><span lang="BG">не показват особен риск за хора на базата на конвенционалните фармакологични проучвания за безопасност</span><span lang="BG">, проучвания за токсичност при многократно прилагане, генотоксичност и канцерогенен потенциал.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG">Бременност и фертилитет</span></u></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Ивакафтор се свързва с леки понижения на теглото на семенните мехурчета, понижение на индекса на общия фертилитет и броя на бременностите при женските, чифтосани с третирани мъжки, и със значими намаления на броя на жълтите тела и на имплантационните места с последващо намаление на средния брой на малките в поколението и средния брой жизнеспособни ембриони за поколение при третираните женски. Нивото без наблюдавани нежелани ефекти (</span><span lang="EN-GB" style="color:black;background:white">No</span><span lang="EN-GB" style="color:black;background:white"> </span><span lang="EN-GB" style="color:black;background:white">Observed</span><span lang="EN-GB" style="color:black;background:white"> </span><span lang="EN-GB" style="color: black;background:white">Adverse</span><span lang="EN-GB" style="color:black; background:white"> </span><span lang="EN-GB" style="color:black;background:white">Effect</span><span lang="EN-GB" style="color:black;background:white"> </span><span lang="EN-GB" style="color:black;background:white">Level</span><span lang="BG">, </span><span lang="EN-GB">NOAEL</span><span lang="BG">) при находките за фертилитета дава ниво на експозиция приблизително 4</span><span lang="EN-GB"> </span><span lang="BG">пъти системната експозиция на ивакафтор и неговите метаболити, когато се прилага като монотерапия с ивакафтор на възрастни хора при максималната препоръчителна доза за хора (</span><span lang="BG" style="color:black">МПДХ</span><span lang="BG">). </span><span lang="BG">Преминаване на</span><span lang="BG"> </span><span lang="BG">ивакафтор</span><span lang="BG"> </span><span lang="BG">през плацентата е наблюдавано при бременни плъхове и зайци</span><span lang="BG">.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG">Пери- и постнатално развитие</span></u></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Ивакафтор понижава </span><span lang="BG">индексите за преживяемост и лактация и причинява намаление на телесното тегло на малките. </span><span lang="EN-GB">NOAEL</span><span lang="EN-GB"> </span><span lang="BG">за жизнеспособността и растежа при потомството</span><span lang="BG"> дава ниво на експозиция приблизително 3</span><span lang="EN-GB"> </span><span lang="BG">пъти системната експозиция на ивакафтор и неговите метаболити, когато се прилага като монотерапия с ивакафтор на възрастни хора при МПДХ. </span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG">Проучвания при ювенилни животни</span></u></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Находки на катаракта се наблюдават при ювенилни плъхове, третирани след раждането от ден</span><span lang="EN-GB"> </span><span lang="BG">7‑ми до 35‑ти при нива на експозиция на ивакафтор 0,22</span><span lang="EN-GB"> </span><span lang="BG">пъти </span><span lang="BG" style="color:black">МПДХ</span><span lang="BG"> на базата на системната експозиция на ивакафтор и неговите метаболити, когато се прилага като монотерапия с ивакафтор. Тази находка не е наблюдавана при фетуси, получени от плъхове майки, третирани с ивакафтор, в гестационни дни от 7‑ми до 17‑ти, при малки с експозиция на ивакафтор чрез погълнатото мляко до ден 20‑ти след раждането, при 7‑седмични плъхове или при 3,5‑ до 5‑месечни кучета, третирани с ивакафтор. Потенциалната значимост на тези находки при хората е неизвестна.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="6.       ФАРМАЦЕВТИЧНИ ДАННИ"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="6.1     Списък на помощните вещества"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG"> </span></i></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG">Ядро на таблетката</span></u></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal"><span lang="BG">Микрокристална целулоза</span></p><p class="MsoNormal"><span lang="BG">Лактоза монохидрат</span></p><p class="MsoNormal"><span lang="BG">Хипромелозен ацетат сукцинат</span></p><p class="MsoNormal"><span lang="BG">Кроскармелоза натрий</span></p><p class="MsoNormal"><span lang="BG">Натриев лаурилсулфат</span></p><p class="MsoNormal"><span lang="BG">Силициев диоксид, колоиден безводен</span></p><p class="MsoNormal"><span lang="BG">Магнезиев стеарат</span></p><p class="MsoNormal"><i><span lang="BG"> </span></i></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG">Филмово покритие на таблетката</span></u></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Поливинилов алкохол</span></p><p class="MsoNormal"><span lang="BG">Титанов диоксид</span><span lang="BG"> </span><span lang="BG">(E171)</span></p><p class="MsoNormal"><span lang="BG">Макрогол</span><span lang="BG"> (</span><span lang="IT">PEG</span><span lang="BG"> 3350)</span></p><p class="MsoNormal"><span lang="BG">Талк</span></p><p class="MsoNormal"><span lang="BG">Индигокармин алуминиев лак (E132)</span></p><p class="MsoNormal"><span lang="BG">Карнаубски восък</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG">Печатно мастило</span></u></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Шеллак</span></p><p class="MsoNormal"><span lang="BG">Черен железен диоксид (E172)</span></p><p class="MsoNormal"><span lang="BG">Пропиленгликол (Е1520)</span></p><p class="MsoNormal"><span lang="BG">Разтвор на амоняк, концентриран</span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.2     Несъвместимости"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Неприложимо</span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.3     Срок на годност"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">4 години</span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.4     Специални условия на съхранение"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;page-break-after: avoid"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Този лекарствен продукт не изисква специални условия на съхранение.</span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.5     Вид и съдържание на опаковката"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Филмираните таблетки са опаковани в термоформован блистер (полихлоротрифлуороетилен [PCTFE]/фолио) или бутилка от полиетилен с висока плътност (HDPE) с полипропиленова защитена от деца запушалка с индукционно запечатано фолио и сушител молекулно сито</span><span lang="BG" style="color:black">.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Kalydeco </span><span lang="EN-GB">7</span><span lang="BG">5 mg филмирани таблетки</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Предлагат се следните опаковки:</span></p><p class="MsoNormal" style="margin-left:13.5pt;text-indent:.7pt"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">-<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">Опаковка с блистер-карти, съдържаща 28 филмирани таблетки </span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Kalydeco 150 mg филмирани таблетки</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Предлагат се следните опаковки:</span></p><p class="MsoNormal" style="margin-left:13.5pt;text-indent:-13.5pt"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">-<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">Опаковка с блистер-карти, съдържаща 28 филмирани таблетки </span></p><p class="MsoNormal" style="margin-left:13.5pt;text-indent:-13.5pt"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">-<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">Опаковка с блистери, съдържаща 56 филмирани таблетки</span></p><p class="MsoNormal" style="margin-left:13.5pt;text-indent:-13.5pt"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">-<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">Бутилка, съдържаща 56 филмирани таблетки</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><a name="OLE_LINK1"><span lang="BG"> </span></a></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="BG">Не всички видове опаковки могат да бъдат пуснати на пазара.</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.6     Специални предпазни мерки при изхвърляне и работа"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG"> </span></i></p><p class="MsoNormal"><span lang="BG">Неизползваният лекарствен продукт или отпадъчните материали от него трябва да се изхвърлят в съответствие с местните изисквания</span><span lang="BG">.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="7.       ПРИТЕЖАТЕЛ НА РАЗРЕШЕНИЕТО ЗА УПОТРЕБА"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="EN-GB">Vertex</span><span lang="EN-GB"> </span><span lang="EN-GB">Pharmaceuticals</span><span lang="BG"> (</span><span lang="EN-GB">Ireland</span><span lang="BG">) </span><span lang="EN-GB">Limited</span></p><p class="MsoNormal"><span lang="EN-GB">28-32 Pembroke Street Upper</span></p><p class="MsoNormal"><span lang="EN-GB">Dublin 2, D02 EK84</span></p><p class="MsoNormal"><span lang="EN-GB">Ирландия</span><span lang="EN-GB"> </span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="8.       НОМЕР(А) НА РАЗРЕШЕНИЕТО ЗА УПОТРЕБА "/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG"> </span></i></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">EU/1/12/782/001</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">EU</span><span lang="BG">/1/12/782/002</span></p><p class="MsoNormal"><span lang="EN-GB">EU</span><span lang="BG">/1/12/782/005</span></p><p class="MsoNormal"><span lang="EN-GB">EU/1/12/782/007</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="9.       ДАТА НА ПЪРВО РАЗРЕШАВАНЕ/ПОДНОВЯВАНЕ НА РАЗРЕШЕНИЕТО ЗА УПОТРЕБА"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Дата на първо разрешаване: 23 </span><span lang="BG">юли 2012 г.</span></p><p class="MsoNormal"><span lang="BG">Дата на последно подновяване: 28 април </span><span lang="BG">2017 </span><span lang="BG">г.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="10.     ДАТА НА АКТУАЛИЗИРАНЕ НА ТЕКСТА"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Подробна информация за този лекарствен продукт е предоставена на уебсайта на Европейската агенция по лекарствата</span><span lang="BG"> </span><span lang="EN-GB"><a href="http://www.emea.europa.eu"><span lang="BG">http://www.ema.europa.eu</span></a></span><span lang="BG" style="color:blue">.</span></p><b><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'><br clear="all" style="page-break-before:always"/> </span></b><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'><br clear="all" style="page-break-before:always"/> </span><br clear="all" style="page-break-before:always"/>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
	
		
		
    	    
				
			    
						
		               
<section>
			<title value="1.       ИМЕ НА ЛЕКАРСТВЕНИЯ ПРОДУКТ"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Kalydeco 25 mg гранули в саше</span></p><p class="MsoNormal"><span lang="BG">Kalydeco 50 mg гранули в саше</span></p><p class="MsoNormal" style="line-height:13.0pt"><span lang="EN-GB">Kalydeco</span><span lang="BG"> 75</span><span lang="EN-GB"> mg</span><span lang="BG"> гранули в саше</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="2.       КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG">Kalydeco 25 mg гранули в саше</span></u><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Всяко саше съдържа 25 mg ивакафтор (ivacaftor). </span></p><p class="MsoNormal"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG">Помощно вещество с известно действие</span></i></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG"> </span></i></p><p class="MsoNormal"><span lang="BG">Всяко саше съдържа 36,6 mg лактоза монохидрат.</span></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG">Kalydeco 50 mg гранули в саше</span></u><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Всяко саше съдържа 50 mg ивакафтор (ivacaftor). </span></p><p class="MsoNormal"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG">Помощно вещество с известно действие</span></i></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG"> </span></i></p><p class="MsoNormal"><span lang="BG">Всяко саше съдържа 73,2 mg лактоза монохидрат.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG">Kalydeco 75 mg гранули в саше</span></u></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal" style="line-height:13.0pt"><span lang="BG">Всяко саше съдържа 75 mg ивакафтор (ivacaftor). </span></p><p class="MsoNormal"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal" style="line-height:13.0pt;page-break-after:avoid"><i><span lang="BG">Помощно вещество с известно действие</span></i></p><p class="MsoNormal" style="line-height:13.0pt;page-break-after:avoid"><i><span lang="BG"> </span></i></p><p class="MsoNormal" style="line-height:13.0pt"><span lang="BG">Всяко саше съдържа 109,8 mg лактоза монохидрат</span><span lang="BG">.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">За пълния списък на помощните вещества вижте точка 6.1.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="3.       ЛЕКАРСТВЕНА ФОРМА"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><span lang="BG"> </span></p><p class="MsoNormal" style="text-autospace:none"><span lang="BG">Гранули в саше</span></p><p class="MsoNormal" style="text-autospace:none"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Бели до почти бели гранули с диаметър приблизително </span><span lang="BG">2</span><span lang="EN-GB"> mm</span><span lang="BG">.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="4.       КЛИНИЧНИ ДАННИ"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="4.1     Терапевтични показания"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Гранулите Kalydeco са показани за лечение на кърмачета на възраст най-малко 4 месеца, малки деца и </span><span lang="BG" style='font-family:"Times New Roman",serif'>деца с тегло от 5</span><span style='font-family:"Times New Roman",serif'> kg</span><span lang="BG" style='font-family:"Times New Roman",serif'> до под 25</span><span style='font-family:"Times New Roman",serif'> kg</span><span style='font-family:"Times New Roman",serif'> <span lang="BG">с кистозна фиброза (КФ), които имат </span></span><i><span lang="EN-GB" style='font-family:"Times New Roman",serif'>R117H CFTR</span></i><span lang="BG" style='font-family:"Times New Roman",serif'> мутация или една от следните водещи до каналопатии мутации (клас III) на <i>CFTR</i> гена: <i>G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N </i>или<i> S549R</i> (вж. точка</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>4.4 и</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>5.1).</span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.2     Дозировка и начин на приложение"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Kalydeco трябва да се предписва само от лекари с опит в лечението на кистозна фиброза. Ако генотипът на пациента не е известен, преди започване на лечението трябва да се приложи точен и валидиран метод за генотипизиране, за да се потвърди наличието на показана мутация в най-малко един алел на <i>CFTR</i> гена (вж. точка 4.1). Фазата на поли‑</span><span lang="EN-GB">T</span><span lang="BG"> варианта, идентифициран с </span><i><span lang="EN-GB">R</span></i><i><span lang="BG">117H</span></i><span lang="BG"> мутацията, трябва да се определи в съответствие с местните клинични препоръки.</span></p><p class="MsoNormal"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Дозировка"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG"> </span></i></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Дозата за кърмачета </span><span lang="BG">на възраст най-малко 4 месеца, малки </span><span lang="BG">деца, деца, </span><span lang="BG">юноши и възрастни трябва да се определя според Таблица 1.</span></p><p class="MsoNormal" style="page-break-after:avoid"><b><i><span lang="BG"> </span></i></b></p><p class="MsoNormal" style="margin-bottom:6.0pt;page-break-after:avoid"><b><span lang="BG">Таблица 1: Препоръки за дозиране за пациенти на възраст</span></b><b> </b><b><span lang="BG">4 месеца и по-големи</span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:99.0%;border-collapse:collapse;border:none" width="99%"> <tr style="height:10.85pt"> <td style="width:21.68%;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="21%"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Възраст</span></b></p> </td> <td style="width:21.68%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="21%"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Тегло</span></b></p> </td> <td style="width:36.18%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="36%"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Доза</span></b></p> </td> <td style="width:20.46%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="20%"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Обща   дневна доза</span></b></p> </td> </tr> <tr style="height:10.85pt"> <td style="width:21.68%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="21%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">от   4 месеца до   под 6 месеца</span></p> </td> <td style="width:21.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="21%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">≥5 kg</span></p> </td> <td style="width:36.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="36%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">25</span><span lang="BG"> </span><span lang="EN-GB">mg </span><span lang="BG">гранули,   приемани   пeрорално на   всеки 12 часа с   храна,   съдържаща   мазнини</span></p> </td> <td style="width:20.46%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="20%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">50 mg</span></p> </td> </tr> <tr style="height:10.85pt"> <td rowspan="4" style="width:21.68%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.85pt" width="21%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">6</span><span lang="BG"> и повече   месеца</span></p> </td> <td style="width:21.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="21%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">≥</span><span lang="BG">5</span><span lang="EN-GB"> kg </span><span lang="BG">до</span><span lang="BG"> </span><span lang="EN-GB">&lt;</span><span lang="BG">7</span><span lang="EN-GB"> kg</span></p> </td> <td style="width:36.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="36%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">25 mg   гранули,   приемани   пeрорално на   всеки 12 часа   с храна,   съдържаща   мазнини </span></p> </td> <td style="width:20.46%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="20%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">50 mg</span></p> </td> </tr> <tr style="height:10.85pt"> <td style="width:21.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="21%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">≥7 kg   </span><span lang="BG">до</span><span lang="BG"> </span><span lang="EN-GB">&lt;14 kg</span></p> </td> <td style="width:36.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="36%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">50 mg   гранули,   приемани   пeрорално на   всеки 12 часа   с храна,   съдържаща   мазнини </span></p> </td> <td style="width:20.46%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="20%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">100 mg</span></p> </td> </tr> <tr style="height:10.85pt"> <td style="width:21.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="21%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">≥14 kg   </span><span lang="BG">до</span><span lang="EN-GB"> &lt;25 kg</span></p> </td> <td style="width:36.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="36%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">75 mg   гранули,   приемани   пeрорално на   всеки 12 часа   с храна,   съдържаща   мазнини</span></p> </td> <td style="width:20.46%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="20%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">150 mg</span></p> </td> </tr> <tr style="height:15.7pt"> <td style="width:21.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.7pt" valign="top" width="21%"> <p class="MsoNormal"><span lang="EN-GB">≥25 kg</span></p> </td> <td colspan="2" style="width:56.64%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.7pt" valign="top" width="56%"> <p class="MsoNormal"><span lang="BG">Вижте   КХП на Kalydeco таблетки   за допълнителна   информация.</span></p> </td> </tr> </table><p class="MsoNormal" style="text-autospace:none"><span lang="RU"> </span></p><p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><i><span lang="BG">Пропусната доза</span></i></p><p class="MsoNormal" style="text-autospace:none"><span lang="BG"> </span></p><p class="MsoNormal" style="text-autospace:none"><span lang="BG">Ако са изминали 6</span> <span lang="BG">или по-малко часа от пропуснатата сутрешна или вечерна доза, пациентът трябва да бъде посъветван да я приеме веднага, щом е възможно, и след това да приеме следващата доза в обичайното време. Ако са изминали повече от 6</span> <span lang="BG">часа от обичайното време, в което се приема дозата, пациентът трябва да бъде посъветван да изчака до следващата доза по схемата.</span></p><p class="labeltext"><i><span lang="BG" style='font-family:"Times New Roman",serif'> </span></i></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="BG" style='font-family:"Times New Roman",serif'>Съпътстващо приложение на инхибитори на CYP3A</span></i></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="BG" style='font-family:"Times New Roman",serif'> </span></i></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Когато се прилага едновременно със силни инхибитори на CYP3A при пациенти на възраст 6 и повече месеца, дозата ивакафтор трябва да се намали до едно саше (ивакафтор 25 </span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>mg</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>за пациенти от </span><span lang="BG" style='font-family:"Times New Roman",serif'>5</span><span style='font-family:"Times New Roman",serif'> kg </span><span lang="BG" style='font-family:"Times New Roman",serif'>до</span><span lang="BG" style='font-family:"Times New Roman",serif'> </span><span style='font-family: "Times New Roman",serif'>&lt;</span><span lang="BG" style='font-family:"Times New Roman",serif'>7</span><span style='font-family:"Times New Roman",serif'> kg</span><span lang="BG" style='font-family:"Times New Roman",serif'>, ивакафтор 50</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> mg</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>за пациенти </span><span lang="BG" style='font-family:"Times New Roman",serif'>от </span><span style='font-family:"Times New Roman",serif'>7 kg </span><span lang="BG" style='font-family:"Times New Roman",serif'>до</span><span lang="BG" style='font-family:"Times New Roman",serif'> </span><span style='font-family: "Times New Roman",serif'>&lt;14 kg</span><span lang="BG" style='font-family: "Times New Roman",serif'>, ивакафтор 75</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> mg</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>за пациенти </span><span lang="BG" style='font-family:"Times New Roman",serif'>от 14</span><span style='font-family:"Times New Roman",serif'> kg </span><span lang="BG" style='font-family:"Times New Roman",serif'>до</span><span lang="BG" style='font-family:"Times New Roman",serif'> </span><span style='font-family: "Times New Roman",serif'>&lt;</span><span lang="BG" style='font-family:"Times New Roman",serif'>25</span><span style='font-family:"Times New Roman",serif'> kg</span><span lang="BG" style='font-family:"Times New Roman",serif'>) два пъти седмично (вж. точка 4.4 и 4.5).</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Когато се прилага едновременно с умерени инхибитори на CYP3A при пациенти на възраст 6 и повече месеца, дозата ивакафтор е както се препоръчва по-горе, но се прилага веднъж дневно (вж. точка 4.4 и 4.5).</span></p><p class="labeltext" style="page-break-after:avoid"><i> </i></p><p class="MsoNormal"><span lang="BG">Поради различия в степента на матурация на цитохром</span><span lang="EN-GB"> (CYP) </span><span lang="BG">ензимите, участващи в метаболизма на ивакафтор, лечението с ивакафтор не се препоръчва, когато ще се прилага едновременно с умерени или силни инхибитори на</span><span lang="EN-GB"> CYP3A </span><span lang="BG">при пациенти на възраст от </span><span lang="EN-GB">4 </span><span lang="BG">до под </span><span lang="EN-GB">6 </span><span lang="BG">месеца, освен ако ползите не превишават рисковете. В такива случаи препоръчителната доза е едно саше с гранули от </span><span lang="EN-GB">25 mg </span><span lang="BG">два пъти седмично или по-рядко </span><span lang="EN-GB">(</span><span lang="BG">вж. точка </span><span lang="EN-GB">4.4 </span><span lang="BG">и </span><span lang="EN-GB">4.5). </span><span lang="BG">Интервалите на прилагане </span><span lang="BG">трябва да се променят според клиничния отговор и поносимостта</span><span lang="BG"> </span><span lang="EN-GB">(</span><span lang="BG">вж. точка </span><span lang="EN-GB">4.4 </span><span lang="BG">и </span><span lang="EN-GB">5.2)</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG">Специални популации</span></u></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="BG" style='font-family:"Times New Roman",serif'> </span></i></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG">Бъбречно увреждане</span></i></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG"> </span></i></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Не се налага корекция на дозата при пациенти с леко до умерено бъбречно увреждане. Препоръчва се повишено внимание при пациенти с тежко бъбречно увреждане (креатининов клирънс по-нисък или равен на 30 ml/min) или терминална бъбречна недостатъчност (вж. точка 4.4 и 5.2.)</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltextheading"><span lang="BG" style='font-family:"Times New Roman",serif'>Чернодробно увреждане</span></p><p class="labeltextheading"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Не се налага корекция на дозата при пациенти на възраст 6 и повече месеца с леко чернодробно увреждане (клас А по Child-Pugh). При пациенти на възраст 6 и повече месеца с умерено чернодробно увреждане (клас В по </span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>Child</span><span lang="BG" style='font-family:"Times New Roman",serif'>-</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>Pugh</span><span lang="BG" style='font-family:"Times New Roman",serif'>) се п</span><span lang="BG" style='font-family:"Times New Roman",serif'>репоръчва намалена доза от едно саше (ивакафтор 25 </span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>mg</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>за пациенти от </span><span lang="BG" style='font-family:"Times New Roman",serif'>5</span><span style='font-family:"Times New Roman",serif'> kg </span><span lang="BG" style='font-family:"Times New Roman",serif'>до</span><span lang="BG" style='font-family:"Times New Roman",serif'> </span><span style='font-family: "Times New Roman",serif'>&lt;</span><span lang="BG" style='font-family:"Times New Roman",serif'>7</span><span style='font-family:"Times New Roman",serif'> kg</span><span lang="BG" style='font-family:"Times New Roman",serif'>, ивакафтор 50</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> mg</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>за пациенти </span><span lang="BG" style='font-family:"Times New Roman",serif'>от </span><span style='font-family:"Times New Roman",serif'>7 kg </span><span lang="BG" style='font-family:"Times New Roman",serif'>до</span><span lang="BG" style='font-family:"Times New Roman",serif'> </span><span style='font-family: "Times New Roman",serif'>&lt;14 kg</span><span lang="BG" style='font-family: "Times New Roman",serif'>, ивакафтор 75</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> mg</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>за пациенти </span><span lang="BG" style='font-family:"Times New Roman",serif'>от 14</span><span style='font-family:"Times New Roman",serif'> kg </span><span lang="BG" style='font-family:"Times New Roman",serif'>до</span><span lang="BG" style='font-family:"Times New Roman",serif'> </span><span style='font-family: "Times New Roman",serif'>&lt;</span><span lang="BG" style='font-family:"Times New Roman",serif'>25</span><span style='font-family:"Times New Roman",serif'> kg</span><span lang="BG" style='font-family:"Times New Roman",serif'>) веднъж дневно. Липсва опит от употребата на ивакафтор при пациенти на възраст 6 и повече месеца с тежко чернодробно увреждане (клас С по Child-Pugh).</span><span lang="BG" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>Затова употребата му не се препоръчва, освен ако ползите не превишават рисковете. В такива случаи началната доза трябва да бъде както се препоръчва по-горе, като се прилага през ден. Интервалите на прилагане трябва да бъдат променени в съответствие с клиничния отговор и поносимостта (вж. точка4.4 и 5.2).</span></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="BG" style='font-family:"Times New Roman",serif'> </span></i></p><p class="labeltext" style="page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>Поради различия в степента на матурация на цитохром</span><span lang="FR" style='font-family:"Times New Roman",serif'> (CYP) </span><span lang="BG" style='font-family:"Times New Roman",serif'>ензимите, участващи в метаболизма на ивакафтор, лечението с ивакафтор не се препоръчва при пациенти на възраст от 4 до под 6 месеца с чернодробно увреждане, освен ако ползите не превишават рисковете. В такива случаи препоръчителната доза е едно саше (ивакафтор 25</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> mg</span><span lang="BG" style='font-family:"Times New Roman",serif'>) веднъж дневно или по-рядко. Интервалите на прилагане трябва да бъдат променени в съответствие с клиничния отговор и поносимостта (вж. точка 4.4 и 5.2).</span></p><p class="labeltext"><i><span lang="BG" style='font-family:"Times New Roman",serif'> </span></i></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Педиатрична популация"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG"> </span></i></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Безопасността и ефикасността на ивакафтор при пациенти под 4‑месечна възраст не са установени.</span><span lang="BG" style='font-family:"Times New Roman",serif'> Липсват данни.</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Наличните данни са ограничени при пациенти под 6-годишна възраст с </span><i><span lang="EN-GB" style='font-family:"Times New Roman",serif'>R</span></i><i><span lang="BG" style='font-family:"Times New Roman",serif'>117</span></i><i><span lang="EN-GB" style='font-family:"Times New Roman",serif'>H</span></i><i><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span></i><span lang="BG" style='font-family:"Times New Roman",serif'>мутация на </span><i><span lang="EN-GB" style='font-family:"Times New Roman",serif'>CFTR</span></i><i><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span></i><span lang="BG" style='font-family:"Times New Roman",serif'>гена</span><span lang="BG" style='font-family:"Times New Roman",serif'>. Наличните данни при пациенти на възраст 6 и повече години са описани в точка</span><span lang="EN-GB" style='font-family: "Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>4.8,</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>5.1 и</span><span style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>5.2.</span></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Начин на приложение"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><span lang="BG">За перорално приложение.</span></p><p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><span lang="BG" style="color:black"> </span></p><p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><span lang="BG">Всяко саше е само за еднократно приложение.</span></p><p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><span lang="BG"> </span></p><p class="MsoNormal" style="text-autospace:none"><span lang="BG">Всяко саше с гранули трябва да се смеси с 5</span><span lang="EN-GB"> ml</span><span lang="BG"> подходяща за възрастта мека храна или течност и да се приеме веднага и изцяло. Храната или течността трябва да са със стайна или по-ниска температура. Доказано е, че ако не се приеме веднага, сместа е стабилна в продължение на един час и следователно трябва да се погълне през този период. Непосредствено преди или непосредствено след приложението трябва да се приеме основно хранене или закуска, богати на мазнини.</span></p><p class="MsoNormal" style="text-autospace:none"><span lang="BG"> </span></p><p class="MsoNormal" style="text-autospace:none"><span lang="BG">По време на лечението трябва да се избягват храни или напитки, съдържащи грейпфрут (вж. точка 4.5).</span></p><p class="MsoNormal" style="text-autospace:none"><span lang="BG" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.3     Противопоказания"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormalIndent" style="margin:0in"><span lang="BG">Свръхчувствителност към активното вещество или към някое от помощните вещества, изброени в точка 6.1.</span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.4     Специални предупреждения и предпазни мерки при употреба"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;page-break-after: avoid"><i><span lang="BG"> </span></i></p><p class="MsoNormal"><span lang="BG">Само пациентите с КФ, които имат <i>G551D</i></span><i><span lang="BG">, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N</span></i><span lang="BG"> или <i>S549R</i> </span><span lang="BG">водеща до каналопатия мутация (клас III)</span><span lang="BG"> </span><span lang="BG">или<i> G970R</i> в най-малко един алел на <i>CFTR</i> гена, са включени в проучвания 1, 2, 5 и 7 (вж. точка 5.1).</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="BG"> </span></p><p class="labeltextheading" style="page-break-after:auto"><span lang="BG" style='font-family:"Times New Roman",serif;font-style:normal'>По-малко данни за положителен ефект на ивакафтор са налични за пациенти с </span><span lang="BG" style='font-family:"Times New Roman",serif'>R117H-7T</span><span lang="BG" style='font-family:"Times New Roman",serif;font-style:normal'> мутация, свързана с не толкова тежко заболяване в проучване 6 (вж. точка 5.1). </span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">В проучване 5 са включени четирима пациенти с мутацията <i>G970R</i>. При трима от четиримата пациенти промяната в теста за хлорни йони в потта е &lt;5 mmol/</span>l<span lang="BG"> и тази група н</span><span lang="EN-GB">e</span><span lang="BG"> показва клинично значимо подобрение на ФЕО<sub>1</sub> след 8 седмици лечение. Невъзможно e да се установи клиничната ефикасност при пациенти с мутацията <i>G970R </i>на <i>CFTR</i> гена (вж. точка 5.1).</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal"><span lang="BG">Резултатите за ефикасност от проучване фаза 2 при пациенти с КФ, които са хомозиготни за <i>F508del </i>мутацията на <i>CFTR</i> гена, не показват статистически значима разлика във ФЕО<sub>1</sub> след 16 седмици лечение с ивакафтор в сравнение с плацебо (вж. точка 5.1). Затова не се препоръчва употребата на ивакафтор като монотерапия при тези пациенти.</span></p><p class="labeltextheading" style="page-break-after:auto"><u><span lang="BG" style='font-family:"Times New Roman",serif;font-style:normal'><span style="text-decoration:none"> </span></span></u></p><p class="labeltextheading"><u><span lang="BG" style='font-family:"Times New Roman",serif; font-style:normal'>Ефект върху чернодробните функционални показатели</span></u></p><p class="labeltextheading"><u><span lang="BG" style='font-family:"Times New Roman",serif; font-style:normal'><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormalIndent" style="margin:0in"><span lang="BG">Умерено повишение на </span><span lang="BG">трансаминазите </span><span lang="BG">(аланин трансаминазата [</span>alanine transaminase<span lang="BG"> - ALT] или аспартат трансаминазата [</span>aspartate transaminase<span lang="BG"> - AST]) е често срещано при лица с КФ. </span><span lang="BG">При някои пациенти, лекувани с ивакафтор като монотерапия, се наблюдават повишения на трансаминазите. Затова </span><span lang="BG">за всички пациенти се препоръчва измерване на ч</span><span lang="BG">ернодробните функционални показатели преди започване на ивакафтор, на всеки 3 месеца през първата година на лечение и ежегодно след това. За всички пациенти с анамнеза за повишения на<i> </i>трансаминазите трябва да се помисли за по-често проследяване на чернодробните функционални показатели</span><span lang="BG">. В случай на значителни повишения на трансаминазите (напр. пациенти с </span><span lang="EN-GB">ALT</span><span lang="BG"> или </span><span lang="EN-GB">AST</span><span lang="BG"> &gt;5</span><span lang="EN-GB"> x </span><span lang="BG">горната граница на нормата (</span><i><span lang="EN-GB">upper</span></i><i><span lang="EN-GB"> </span></i><i><span lang="EN-GB">limit</span></i><i><span lang="EN-GB"> </span></i><i><span lang="EN-GB">of</span></i><i><span lang="EN-GB"> </span></i><i><span lang="EN-GB">normal</span></i><span lang="BG"> – </span><span lang="EN-GB">ULN</span><span lang="BG">), или </span><span lang="EN-GB">ALT</span><span lang="BG"> или </span><span lang="EN-GB">AST</span><span lang="BG"> &gt;3</span><span lang="EN-GB"> x ULN</span><span lang="BG"> с билирубин &gt;2</span><span lang="EN-GB"> x ULN</span><span lang="BG">) приложението трябва да бъде прекъснато и внимателно да се проследят лабораторните изследвания, докато отклоненията се нормализират. След изчезване на повишенията на трансаминазите трябва да се обмислят ползите и рисковете от възобновяване на лечението (вж. точка 4.8).</span></p><p class="MsoNormalIndent" style="margin:0in"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG">Чернодробно увреждане</span></u></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal"><span lang="BG">Не се препоръчва употреба на ивакафтор при пациенти с тежко чернодробно увреждане, освен ако не се очаква ползите да надвишават рисковете (вж. точка 4.2 и</span><span lang="EN-GB"> </span><span lang="BG">5.2).</span><span lang="BG"> Липсват данни за безопасността при кърмачета на възраст от 4 до под </span><span lang="EN-GB">12 </span><span lang="BG">месеца с умерено или тежко чернодробно увреждане, лекувани с ивакафтор</span><span lang="EN-GB">.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG">Бъбречно увреждане</span></u></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Повишено внимание се препоръчва при употребата на ивакафтор при пациенти с тежко бъбречно увреждане или терминална бъбречна недостатъчност (вж. точка 4.2 и</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>5.2). </span></p><p class="MsoNormal"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG">Пациенти след органна трансплантация</span></u></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal"><span lang="BG">Ивакафтор не е проучван при пациенти с КФ, които са претърпели органна трансплантация. Затова не се препоръчва употреба при трансплантирани пациенти. Вижте точка 4.5 за взаимодействия с циклоспорин или такролимус. </span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG">Взаимодействия с лекарствени продукти</span></u></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG">Индуктори на CYP3A</span></i></p><p class="MsoNormal" style="page-break-after:avoid"><i><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></i></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Експозицията на ивакафтор се намалява значително при съпътстващо приложение с индуктори на CYP3A, което потенциално води до загуба на ефикасност на ивакафтор. Затова не се препоръчва едновременно приложение на ивакафтор със силни индуктори на CYP3A (вж. точка 4.5). </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="BG" style='font-family:"Times New Roman",serif'>Инхибитори на CYP3A</span></i></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="BG" style='font-family:"Times New Roman",serif'> </span></i></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Експозицията на ивакафтор се повишава, когато се прилага едновременно със силни или умерени инхибитори на CYP3A. Дозата ивакафтор трябва да се коригира, когато се прилага съпътстващо със силни или умерени инхибитори на CYP3A (вж. точка 4.2 и 4.5). Липсват данни за безопасността при кърмачета на възраст от 4 до под 12 месеца, които са лекувани с ивакафтор и умерени или</span><span lang="BG" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>силни инхибитори на CYP3A4 (вж. точка 4.2 и 4.5).</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Педиатрична популация"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="labeltext"><u><span lang="BG" style='font-family:"Times New Roman",serif'><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal"><span lang="BG">Случаи на невродено помътняване на лещата/катаракта без въздействие върху зрението се съобщават при педиатрични пациенти, лекувани с ивакафтор. Въпреки че в някои случаи са налични други рискови фактори (като употреба на кортикостероиди и излагане на радиация), не може да се изключи възможен риск, приписван на лечението с ивакафтор. При педиатрични пациенти, започващи лечение с ивакафтор, се препоръчват офталмологични прегледи на изходно ниво и за проследяване.</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG">Съдържание на лактоза</span></u></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal"><span lang="EN-GB">Kalydeco</span><span lang="EN-GB"> </span><span lang="BG">съдържа лактоза. Пациенти с редки наследствени проблеми като непоносимост към галактоза, пълен лактазен дефицит или глюкозо-галактозна малабсорбция не трябва да приемат това лекарство.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG">Съдържание на натрий</span></u></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal"><span lang="BG">Това лекарство съдържа по-малко от 1 </span><span lang="EN-GB">mmol</span><span lang="EN-GB"> </span><span lang="BG">натрий (23</span><span lang="EN-GB"> mg</span><span lang="BG">) на доза, т.е. практически не съдържа натрий.</span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.5     Взаимодействие с други лекарствени продукти и други форми на взаимодействие"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoCommentText"><span lang="BG" style="font-size:11.0pt"> </span></p><p class="MsoCommentText"><span lang="BG" style="font-size:11.0pt">Ивакафтор е субстрат на CYP3A4 и CYP3A5. Той е слаб инхибитор на CYP3A и P‑gp и потенциален инхибитор на CYP2C9. </span><i><span lang="EN-GB" style="font-size:11.0pt">In vitro</span></i><span lang="BG" style="font-size:11.0pt"> проучванията показват, че ивакафтор не е субстрат на </span><span lang="EN-GB" style="font-size:11.0pt">P</span><span lang="BG" style="font-size:11.0pt">‑</span><span lang="EN-GB" style="font-size:11.0pt">gp</span><span lang="BG" style="font-size:11.0pt">. </span></p><p class="MsoCommentText"><span lang="BG" style="font-size:11.0pt;color:black"> </span></p><p class="labeltext" style="page-break-after:avoid"><u><span lang="BG" style='font-family:"Times New Roman",serif'>Лекарствени продукти, повлияващи фармакокинетиката на ивакафтор</span></u></p><p class="labeltext" style="page-break-after:avoid"><u><span lang="BG" style='font-family:"Times New Roman",serif'><span style="text-decoration:none"> </span></span></u></p><p class="MsoCommentText" style="page-break-after:avoid"><i><span lang="BG" style="font-size:11.0pt">Индуктори на </span></i><i><span lang="EN-GB" style="font-size:11.0pt">CYP</span></i><i><span lang="BG" style="font-size:11.0pt">3</span></i><i><span lang="EN-GB" style="font-size:11.0pt">A</span></i></p><p class="MsoCommentText" style="page-break-after:avoid"><i><span lang="BG" style="font-size:11.0pt"> </span></i></p><p class="MsoCommentText"><span lang="BG" style="font-size:11.0pt">Едновременното приложение на ивакафтор с рифампицин, силен индуктор на </span><span lang="EN-GB" style="font-size:11.0pt">CYP</span><span lang="BG" style="font-size: 11.0pt">3</span><span lang="EN-GB" style="font-size:11.0pt">A</span><span lang="BG" style="font-size:11.0pt">, понижава експозицията на ивакафтор (</span><span lang="EN-GB" style="font-size:11.0pt">AUC</span><span lang="BG" style="font-size:11.0pt">) с 89% и понижава хидроксиметил ивакафтор (</span><span lang="EN-GB" style="font-size:11.0pt">M</span><span lang="BG" style="font-size: 11.0pt">1) в по-малка степен, отколкото ивакафтор. Не се препоръчва едновременно приложение на ивакафтор</span><span lang="BG" style="font-size:11.0pt"> </span><span lang="BG" style="font-size:11.0pt">със силни индуктори на </span><span lang="EN-GB" style="font-size:11.0pt">CYP</span><span lang="BG" style="font-size:11.0pt">3</span><span lang="EN-GB" style="font-size: 11.0pt">A</span><span lang="BG" style="font-size:11.0pt"> като рифампицин, рифабутин, фенобарбитал, карбамазепин, фенитоин и жълт кантарион (</span><i><span lang="EN-GB" style="font-size:11.0pt">Hypericum</span></i><i><span lang="EN-GB" style="font-size:11.0pt"> </span></i><i><span lang="EN-GB" style="font-size:11.0pt">perforatum</span></i><span lang="BG" style="font-size:11.0pt">) (вж. точка</span><span lang="EN-GB" style="font-size: 11.0pt"> </span><span lang="BG" style="font-size:11.0pt">4.4).</span></p><p class="MsoCommentText"><span lang="BG" style="font-size:11.0pt"> </span></p><p class="MsoCommentText"><span lang="BG" style="font-size:11.0pt">Не се препоръчва корекция на дозата, когато ивакафтор</span><span lang="BG" style="font-size:11.0pt"> </span><span lang="BG" style="font-size:11.0pt">се прилага с умерени или слаби индуктори на CYP3A.</span></p><p class="labeltext"><u><span lang="BG" style='font-family:"Times New Roman",serif'><span style="text-decoration:none"> </span></span></u></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="BG" style='font-family:"Times New Roman",serif'>Инхибитори на CYP3A</span></i></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="BG" style='font-family:"Times New Roman",serif'> </span></i></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Ивакафтор е чувствителен субстрат на CYP3A. Едновременното приложение с кетоконазол, силен инхибитор на CYP3A, повишава 8,5 пъти експозицията на ивакафтор (измерена като площ под кривата [AUC]) и повишава M1 в по-малка степен, отколкото ивакафтор. Препоръчва се намаляване на дозата ивакафтор при едновременно приложение със силни инхибитори на CYP3A като кетоконазол, итраконазол, позаконазол, вориконазол, телитромицин и кларитромицин (вж. точка 4.2 и 4.4).</span></p><p class="MsoNormal"><b><span lang="BG"> </span></b></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Едновременното приложение с</span><span lang="BG" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>флуконазол, умерено силен инхибитор на CYP3A, повишава експозицията на ивакафтор 3 пъти и повишава M1 в по-малка степен, отколкото ивакафтор. Препоръчва се намаляване на дозата ивакафтор при пациенти, приемащи едновременно умерено силни инхибитори на CYP3A като флуконазол</span><span style='font-family:"Times New Roman",serif'>,</span><span lang="BG" style='font-family:"Times New Roman",serif'> еритромицин и верапамил (вж. точка 4.2 и 4.4). </span></p><p class="labeltext"><u><span lang="BG" style='font-family:"Times New Roman",serif'><span style="text-decoration:none"> </span></span></u></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Едновременното приложение на ивакафтор със сок от грейпфрут, който съдържа една или повече съставки, които умерено инхибират CYP3A, може да повиши експозицията на ивакафтор. По време на лечението с ивакафтор трябва да се избягват храните или напитките, съдържащи грейпфрут (вж. точка 4.2).</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="MsoNormal"><i><span lang="BG">Потенциал на ивакафтор да взаимодейства с транспортери</span></i></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><i><span lang="BG">In vitro</span></i><span lang="BG"> проучванията показват, че ивакафтор не е субстрат за OATP1B1 или OATP1B3. Ивакафтор и неговите метаболити са субстрати на BCRP in vitro. Поради неговия висок присъщ пермеабилитет и малката вероятност да бъде екскретиран непроменен, не се очаква едновременното приложение на инхибитори на BCRP да промени експозицията на ивакафтор и M1-IVA, а евентуалните промени в експозицията на M6-IVA не се очаква да бъдат клинично значими.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><i><span lang="BG">Ципрофлоксацин</span></i></p><p class="MsoNormal"><i><span lang="BG"> </span></i></p><p class="MsoNormal"><span lang="BG">Едновременното приложение на ципрофлоксацин с ивакафтор не повлиява експозицията на ивакафтор. Не се налага коригиране на дозата, когато ивакафтор се прилага едновременно с ципрофлоксацин.</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext" style="page-break-after:avoid"><u><span lang="BG" style='font-family:"Times New Roman",serif'>Лекарствени продукти, които се повлияват от ивакафтор</span></u></p><p class="MsoCommentText" style="page-break-after:avoid"><span lang="BG" style="font-size:11.0pt"> </span></p><p class="MsoCommentText"><span lang="BG" style="font-size:11.0pt">Приложението на ивакафтор може да повиши системната експозиция на лекарствени продукти, чувствителни субстрати на </span><span lang="EN-GB" style="font-size:11.0pt">CYP</span><span lang="BG" style="font-size: 11.0pt">2</span><span lang="EN-GB" style="font-size:11.0pt">C</span><span lang="BG" style="font-size:11.0pt">9 и/или </span><span lang="EN-GB" style="font-size:11.0pt">P</span><span lang="BG" style="font-size: 11.0pt">‑</span><span lang="EN-GB" style="font-size:11.0pt">gp</span><span lang="BG" style="font-size:11.0pt">, и/или </span><span lang="EN-GB" style="font-size:11.0pt">CYP</span><span lang="BG" style="font-size: 11.0pt">3</span><span lang="EN-GB" style="font-size:11.0pt">A</span><span lang="BG" style="font-size:11.0pt">, което може да повиши или удължи техния терапевтичен ефект и нежелани реакции.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG">Субстрати на CYP2C9</span></i></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG"> </span></i></p><p class="MsoCommentText"><span lang="BG" style="font-size:11.0pt">Ивакафтор може да инхибира </span><span lang="EN-GB" style="font-size:11.0pt">CYP</span><span lang="BG" style="font-size: 11.0pt">2</span><span lang="EN-GB" style="font-size:11.0pt">C</span><span lang="BG" style="font-size:11.0pt">9. Затова се препоръчва наблюдение на международното нормализирано съотношение (</span><i><span lang="EN-GB" style="font-size:11.0pt">international</span></i><i><span lang="EN-GB" style="font-size:11.0pt"> </span></i><i><span lang="EN-GB" style="font-size:11.0pt">normalised</span></i><i><span lang="EN-GB" style="font-size:11.0pt"> </span></i><i><span lang="EN-GB" style="font-size:11.0pt">ratio</span></i><span lang="BG" style="font-size:11.0pt"> – </span><span lang="EN-GB" style="font-size: 11.0pt">INR</span><span lang="BG" style="font-size:11.0pt">) по време на едновременното приложение на варфарин с ивакафтор. Другите лекарствени продукти, чиято експозиция може да се повиши, включват глимепирид и глипизид. Тези лекарствени продукти трябва да се прилагат с повишено внимание.</span></p><p class="MsoCommentText"><u><span lang="BG" style="font-size:11.0pt"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG">Дигоксин и други субстрати на </span></i><i><span lang="EN-GB">P</span></i><i><span lang="BG">-</span></i><i><span lang="EN-GB">gp</span></i></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG"> </span></i></p><p class="MsoCommentText"><span lang="BG" style="font-size:11.0pt">Едновременното приложение с </span><span lang="BG" style="font-size:11.0pt">дигоксин, чувствителен субстрат на </span><span lang="EN-GB" style="font-size:11.0pt">P</span><span lang="BG" style="font-size: 11.0pt">-</span><span lang="EN-GB" style="font-size:11.0pt">gp</span><span lang="BG" style="font-size:11.0pt">, повишава експозицията на дигоксин 1,3 пъти, което съответства на слабо инхибиране на </span><span lang="EN-GB" style="font-size:11.0pt">P</span><span lang="BG" style="font-size:11.0pt">‑</span><span lang="EN-GB" style="font-size:11.0pt">gp</span><span lang="BG" style="font-size:11.0pt"> от ивакафтор. Приложението на ивакафтор</span><span lang="BG" style="font-size:11.0pt"> </span><span lang="BG" style="font-size:11.0pt">може да повиши системната експозиция на лекарствени продукти, чувствителни субстрати на </span><span lang="EN-GB" style="font-size:11.0pt">P</span><span lang="BG" style="font-size: 11.0pt">‑</span><span lang="EN-GB" style="font-size:11.0pt">gp</span><span lang="BG" style="font-size:11.0pt">, което може да повиши или удължи техния терапевтичен ефект и нежеланите реакции. Когато се прилага едновременно с дигоксин или други субстрати на </span><span lang="EN-GB" style="font-size:11.0pt">P</span><span lang="BG" style="font-size: 11.0pt">‑</span><span lang="EN-GB" style="font-size:11.0pt">gp</span><span lang="BG" style="font-size:11.0pt"> с тесен терапевтичен индекс, като например циклоспорин, еверолимус, сиролимус или такролимус, трябва да се подхожда с повишено внимание и да се извършва нужното наблюдение.</span></p><p class="MsoCommentText"><u><span lang="BG" style="font-size:11.0pt"><span style="text-decoration:none"> </span></span></u></p><p class="MsoCommentText" style="page-break-after:avoid"><i><span lang="BG" style="font-size:11.0pt">Субстрати на </span></i><i><span lang="EN-GB" style="font-size:11.0pt">CYP</span></i><i><span lang="BG" style="font-size:11.0pt">3</span></i><i><span lang="EN-GB" style="font-size:11.0pt">A</span></i></p><p class="MsoCommentText" style="page-break-after:avoid"><i><span lang="BG" style="font-size:11.0pt"> </span></i></p><p class="MsoCommentText"><span lang="BG" style="font-size:11.0pt">Едновременното приложение с (перорален) мидазолам, който е чувствителен субстрат на CYP3A, повишава експозицията на мидазолам 1,5 пъти, което съответства на слабо инхибиране на CYP3A от ивакафтор. </span><span lang="BG" style="font-size:11.0pt">Не се налага корекция на дозата на субстрати на </span><span lang="EN-GB" style="font-size:11.0pt">CYP</span><span lang="BG" style="font-size:11.0pt">3</span><span lang="EN-GB" style="font-size: 11.0pt">A</span><span lang="EN-GB" style="font-size:11.0pt"> </span><span lang="BG" style="font-size:11.0pt">като мидазолам, алпразолам, диазепам или триазолам, когато те се прилагат едновременно с ивакафтор.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="RU">Хормонални контрацептиви</span></i></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="RU"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal"><span lang="BG">Ивакафтор е проучван с естроген/прогестерон перорални контрацептиви и е доказано, че няма значим ефект върху експозицията на пероралния контрацептив. </span><span lang="BG">Затова не се налага корекция на дозата на пероралните контрацептиви</span><span lang="BG">.</span></p><p style="margin:0in"><span lang="BG" style="font-size:11.0pt"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Педиатрична популация"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="labeltext" style="page-break-after:avoid"><u><span lang="BG" style='font-family:"Times New Roman",serif'><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal"><span lang="BG">Проучвания за взаимодействията са провеждани само при възрастни. </span></p><p class="labeltext"><u><span lang="BG" style='font-family:"Times New Roman",serif'><span style="text-decoration:none"> </span></span></u></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.6     Фертилитет, бременност и кърмене"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG"> </span></i></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Бременност "/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="labeltext" style="page-break-after:avoid"><u><span lang="BG" style='font-family:"Times New Roman",serif'><span style="text-decoration:none"> </span></span></u></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Липсват или има ограничени данни (за изхода на по-малко от 300 случая на бременност) от употребата на </span><span lang="RU" style='font-family:"Times New Roman",serif'>ивакафтор </span><span lang="BG" style='font-family:"Times New Roman",serif'>при бременни жени</span><span lang="RU" style='font-family:"Times New Roman",serif'>. </span><span lang="BG" style='font-family:"Times New Roman",serif'>Проучванията при животни не показват преки или непреки вредни ефекти, свързани с репродуктивна токсичност</span><span lang="RU" style='font-family:"Times New Roman",serif'> (</span><span lang="BG" style='font-family:"Times New Roman",serif'>вж. точка</span><span lang="RU" style='font-family: "Times New Roman",serif'> 5.3). Като </span><span lang="BG" style='font-family:"Times New Roman",serif'>предпазна мярка </span><span lang="EN-GB" style='font-family: "Times New Roman",serif'>e</span><span lang="BG" style='font-family:"Times New Roman",serif'> за предпочитане да се избягва употребата на ивакафтор по време на бременност.</span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Кърмене"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Не е известно дали ивакафтор и/или неговите метаболити се екскретират в кърмата. </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>Наличните фармакокинетични данни при животни показват екскреция на </span><span lang="BG" style='font-family:"Times New Roman",serif'>ивакафтор в млякото на лактиращи женски плъхове. Поради тази причина не може да се изключи риск за </span><span lang="BG" style='font-family:"Times New Roman",serif; color:black'>новородените/кърмачетата</span><span lang="BG" style='font-family:"Times New Roman",serif'>. </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>Трябва да се вземе решение дали да се преустанови кърменето или да се преустанови/не се приложи терапията с </span><span lang="BG" style='font-family:"Times New Roman",serif'>ивакафтор</span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>, като се вземат предвид ползата от кърменето за детето и ползата от терапията за жената</span><span lang="BG" style='font-family:"Times New Roman",serif'>.</span></p><p class="MsoNormalIndent" style="margin:0in"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Фертилитет"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormalIndent" style="margin:0in;page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal"><span lang="BG">Липсват данни за ефекта на ивакафтор върху фертилитета при хора. Ивакафтор оказва въздействие върху фертилитета при плъхове (вж. точка 5.3).</span></p><p class="MsoNormal"><span lang="BG" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.7     Ефекти върху способността за шофиране и работа с машини"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;page-break-after: avoid"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Ивакафтор</span><span lang="BG"> </span><span lang="BG">повлиява в малка степен способността за шофиране и работа с машини. Ивакафтор може да причини замаяност </span><span lang="BG">(вж. точка 4.8), ето защо пациентите, получили замаяност, трябва да бъдат посъветвани да не шофират и да на работят с машини, докато симптомите не отзвучат.</span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.8     Нежелани лекарствени реакции"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><span lang="BG"> </span></p><p class="labeltext" style="page-break-after:avoid"><u><span lang="BG" style='font-family:"Times New Roman",serif'>Резюме на профила на безопасност</span></u></p><p class="labeltext" style="page-break-after:avoid"><u><span lang="BG" style='font-family:"Times New Roman",serif'><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal"><span lang="BG">Най-честите нежелани реакции при пациентите на възраст 6 и повече години, са </span><span lang="BG">главоболие (23,9%), орофарингеална болка (22,0%), </span><span lang="BG">инфекция на горните дихателни пътища</span><span lang="BG"> (22,0%), назална конгестия (20,2%), </span><span lang="BG">коремна болка (15,6%), </span><span lang="BG">назофарингит (14,7%), </span><span lang="BG">диария (12,8%), замаяност (9,2%), обрив (12,8%) </span><span lang="BG">и бактерии в храчките (12,8%). Повишения на трансаминазите възникват при 12,8% от лекуваните с ивакафтор пациенти спрямо 11,5% от пациентите на плацебо. </span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">При пациентите на възраст от 2 до под 6 години най-честите нежелани реакции са назална конгестия (26,5%),</span><span lang="BG"> инфекция на горните дихателни пътища </span><span lang="BG">(23,5%), повишения на трансаминазите (14,7%), обрив (11,8%) и бактерии в храчките (11,8%).</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Сериозните нежелани реакции при пациентите, които са получавали ивакафтор, включват</span><span lang="BG" style='font-family:"Times New Roman",serif'> коремна болка и повишения на трансаминазите</span><span lang="BG" style='font-family:"Times New Roman",serif'> (вж. точка 4.4)</span><span lang="BG" style='font-family:"Times New Roman",serif'>.</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext" style="line-height:13.0pt;page-break-after:avoid"><u><span lang="BG" style='font-family:"Times New Roman",serif'>Табличен списък на нежеланите реакции</span></u></p><p class="labeltext" style="line-height:13.0pt;page-break-after:avoid"><u><span lang="BG" style='font-family:"Times New Roman",serif'><span style="text-decoration:  none"> </span></span></u></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Таблица 2 отразява нежеланите реакции, наблюдавани с ивакафтор в клинични изпитвания (плацебо-контролирани и неконтролирани проучвания), при които продължителността на експозицията на ивакафтор варира от 16 седмици до 144 седмици. Честотата на нежеланите реакции е дефинирана както следва: много чести (</span><span style='font-family:"Times New Roman",serif'>≥</span><span lang="BG" style='font-family:"Times New Roman",serif'>1/10); чести (</span><span style='font-family:"Times New Roman",serif'>≥</span><span lang="BG" style='font-family:"Times New Roman",serif'>1/100 до &lt;1/10); нечести (</span><span style='font-family:"Times New Roman",serif'>≥</span><span lang="BG" style='font-family:"Times New Roman",serif'>1/1 000 до &lt;1/100); редки (</span><span style='font-family: "Times New Roman",serif'>≥</span><span lang="BG" style='font-family:"Times New Roman",serif'>1/10 000 до &lt;1/1 000); много редки (&lt;1/10 000); с неизвестна честота (от наличните данни не може да бъде направена оценка). Във всяка от групите по честота нежеланите реакции са подредени по намаляваща сериозност.</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext" style="margin-top:0in;margin-right:0in;margin-bottom:6.0pt; margin-left:56.7pt;text-indent:-56.7pt;page-break-after:avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'>Таблица 2: Нежелани реакции</span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:100.0%;border-collapse:collapse;border:none" width="100%"> <thead> <tr style="page-break-inside:avoid;height:26.4pt"> <td style="width:33.32%;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:26.4pt" valign="top" width="33%"> <p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph;    page-break-after:avoid"><b><span lang="BG">Системо-органен    клас</span></b></p> </td> <td style="width:33.32%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:26.4pt" valign="top" width="33%"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><b><span lang="BG">Нежелани    реакции</span></b></p> </td> <td style="width:33.36%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:26.4pt" valign="top" width="33%"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:    avoid"><b><span lang="BG">Честота</span></b></p> </td> </tr> </thead> <tr style="page-break-inside:avoid;height:6.4pt"> <td rowspan="3" style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="33%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Инфекции   и   инфестации</span></p> </td> <td style="width:33.32%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="33%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Инфекция   на горните   дихателни   пътища </span></p> </td> <td style="width:33.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="33%"> <p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph;   page-break-after:avoid"><span lang="BG">много   чести</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:6.4pt"> <td style="width:33.32%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="33%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Назофарингит   </span></p> </td> <td style="width:33.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="33%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">много   чести</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:6.35pt"> <td style="width:33.32%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="33%"> <p class="MsoNormal"><span lang="BG">Ринит</span></p> </td> <td style="width:33.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="33%"> <p class="MsoNormal"><span lang="BG">чести</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td rowspan="2" style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Нарушения   на нервната   система</span></p> </td> <td style="width:33.32%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Главоболие</span></p> </td> <td style="width:33.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph;   page-break-after:avoid"><span lang="BG">много   чести</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal"><span lang="BG">Замаяност</span></p> </td> <td style="width:33.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal"><span lang="BG">много   чести</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:13.15pt"> <td rowspan="6" style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="33%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Нарушения   на ухото и   лабиринта</span></p> </td> <td style="width:33.32%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="33%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Болка   в ухото</span></p> </td> <td style="width:33.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="33%"> <p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph;   page-break-after:avoid"><span lang="BG">чести</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:13.15pt"> <td style="width:33.32%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="33%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Ушен   дискомфорт </span></p> </td> <td style="width:33.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="33%"> <p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph;   page-break-after:avoid"><span lang="BG">чести</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:13.15pt"> <td style="width:33.32%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="33%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Тинитус</span></p> </td> <td style="width:33.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="33%"> <p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph;   page-break-after:avoid"><span lang="BG">чести</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:13.15pt"> <td style="width:33.32%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="33%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Хиперемия   на   тъпанчевата   мембрана</span></p> </td> <td style="width:33.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="33%"> <p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph;   page-break-after:avoid"><span lang="BG">чести</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:13.15pt"> <td style="width:33.32%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="33%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Вестибуларно   нарушение </span></p> </td> <td style="width:33.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="33%"> <p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph;   page-break-after:avoid"><span lang="BG">чести</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:13.15pt"> <td style="width:33.32%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="33%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Конгестия   на ухото </span></p> </td> <td style="width:33.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="33%"> <p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph;   page-break-after:avoid"><span lang="BG">нечести</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:13.15pt"> <td rowspan="4" style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="33%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Респираторни,   гръдни и   медиастинални   нарушения</span></p> </td> <td style="width:33.32%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="33%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Орофарингеална   болка</span></p> </td> <td style="width:33.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.15pt" valign="top" width="33%"> <p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph;   page-break-after:avoid"><span lang="BG">много   чести</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:6.4pt"> <td style="width:33.32%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="33%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Назална   конгестия </span></p> </td> <td style="width:33.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="33%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">много   чести</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:6.4pt"> <td style="width:33.32%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="33%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Конгестия   на синусите </span></p> </td> <td style="width:33.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.4pt" valign="top" width="33%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">чести</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:6.35pt"> <td style="width:33.32%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="33%"> <p class="MsoNormal"><span lang="BG">Фарингеален   еритем</span></p> </td> <td style="width:33.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:6.35pt" valign="top" width="33%"> <p class="MsoNormal"><span lang="BG">чести</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:18.75pt"> <td rowspan="2" style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.75pt" valign="top" width="33%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Стомашно-чревни   нарушения</span></p> </td> <td style="width:33.32%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.75pt" valign="top" width="33%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Коремна   болка</span></p> </td> <td style="width:33.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.75pt" valign="top" width="33%"> <p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph;   page-break-after:avoid"><span lang="BG">много   чести</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:18.75pt"> <td style="width:33.32%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.75pt" valign="top" width="33%"> <p class="MsoNormal"><span lang="BG">Диария</span></p> </td> <td style="width:33.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.75pt" valign="top" width="33%"> <p class="MsoNormal"><span lang="BG">много   чести</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal"><span lang="BG">Хепатобилиарни   нарушения</span></p> </td> <td style="width:33.32%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal"><span lang="BG">Повишения   на </span><span lang="BG">трансаминазите</span></p> </td> <td style="width:33.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal"><span lang="BG">много   чести</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal"><span lang="BG">Нарушения   на кожата и   подкожната   тъкан</span></p> </td> <td style="width:33.32%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal"><span lang="BG">Обрив</span></p> </td> <td style="width:33.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal"><span lang="BG">много   чести</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td rowspan="5" style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal"><span lang="BG">Нарушения   на   възпроизводителната   система и   гърдата</span></p> </td> <td style="width:33.32%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal"><span lang="BG">Образувание   в гърдата</span></p> </td> <td style="width:33.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal"><span lang="BG">чести</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal"><span lang="BG">Възпаление   на гърдата </span></p> </td> <td style="width:33.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal"><span lang="BG">нечести</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal"><span lang="BG">Гинекомастия</span></p> </td> <td style="width:33.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal"><span lang="BG">нечести</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal"><span lang="BG">Нарушение   на гръдното   зърно</span></p> </td> <td style="width:33.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal"><span lang="BG">нечести</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Болка   в гръдното   зърно</span></p> </td> <td style="width:33.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">нечести</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal"><span lang="BG">Изследвания</span></p> </td> <td style="width:33.32%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal"><span lang="BG">Бактерии   в храчките</span></p> </td> <td style="width:33.36%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal"><span lang="BG">много   чести</span></p> </td> </tr> </table><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG">Описание на избрани нежелани реакции</span></u></p><p class="MsoNormal" style="page-break-after:avoid"><b><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></b></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG">Повишения на трансаминазите</span></i></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">По време на 48-седмичните плацебо-контролирани проучвания 1 и 2 при пациенти на възраст 6</span> <span lang="BG">и повече години честотата на максимални стойности на трансаминазите (</span><span lang="EN-GB">ALT</span><span lang="BG"> или </span><span lang="EN-GB">AST</span><span lang="BG">) &gt;</span><span lang="EN-GB"> </span><span lang="BG">8, &gt;</span><span lang="EN-GB"> </span><span lang="BG">5 или &gt;</span><span lang="EN-GB"> </span><span lang="BG">3</span><span lang="EN-GB"> x ULN</span><span lang="BG"> е съответно 3,7%; 3,7% и 8.3% при пациентите, лекувани с ивакафтор, и 1,0%; 1,9% и 8,7% при пациентите, третирани с плацебо. Двама пациенти, един на плацебо и един на ивакафтор, прекратяват окончателно лечението поради повишени трансаминази, всеки &gt;</span><span lang="EN-GB"> </span><span lang="BG">8</span><span lang="EN-GB"> x ULN</span><span lang="BG">. Нито един от лекуваните с ивакафтор пациенти не е получил повишение на трансаминазите &gt;</span><span lang="EN-GB"> </span><span lang="BG">3</span><span lang="EN-GB"> x ULN</span><span lang="BG">, асоциирано с повишен общ билирубин &gt;</span><span lang="EN-GB"> </span><span lang="BG">1,5</span><span lang="EN-GB"> x ULN</span><span lang="BG">. При пациентите, лекувани с ивакафтор, повечето повишения на трансаминазите до 5</span><span lang="EN-GB"> x ULN</span><span lang="BG"> отшумяват без прекъсване на лечението. Приложението на ивакафтор е прекъснато при повечето пациенти с повишения на трансаминазите &gt;</span><span lang="EN-GB"> </span><span lang="BG">5</span><span lang="EN-GB"> x ULN</span><span lang="BG">. Във всички случаи, където приложението е прекъснато поради повишени трансаминази и впоследствие е подновено, приложението на ивакафтор е могло да бъде подновено успешно (вж. точка</span><span lang="EN-GB"> </span><span lang="BG">4.4).</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">По време на плацебо-контролираните проучвания фаза</span><span lang="EN-GB"> </span><span lang="BG">3 (до 24</span><span lang="EN-GB"> </span><span lang="BG">седмици) на тезакафтор/ивакафтор честотата на максимални стойности на трансаминазите (</span><span lang="EN-GB">ALT</span><span lang="BG"> или </span><span lang="EN-GB">AST</span><span lang="BG">) &gt;8, &gt;5 или &gt;3</span><span lang="EN-GB"> x ULN</span><span lang="BG"> е 0,2%; 1,0% и 3,4% при пациентите, лекувани с тезакафтор/ивакафтор, и 0,4%; 1,0% и 3,4% при третираните с плацебо пациенти. Един пациент (0,2%) на терапия и 2</span><span lang="EN-GB"> </span><span lang="BG">пациента (0,4%) на плацебо спират окончателно лечението поради повишени трансаминази. При нито един пациент, лекуван с тезакафтор/ивакафтор, не се получава повишение на трансаминазите &gt;</span><span lang="EN-GB"> </span><span lang="BG">3</span><span lang="EN-GB"> x ULN</span><span lang="BG">, свързвано с повишен общ билирубин &gt;</span><span lang="EN-GB"> </span><span lang="BG">2</span><span lang="EN-GB"> x ULN</span><span lang="BG">.</span></p><p class="MsoNormal" style="margin-left:40.3pt;text-indent:-40.3pt;page-break-after: avoid"><span lang="EN-GB"> </span></p><p class="MsoNormal"><span lang="BG">По време на 24</span><span lang="EN-GB"> </span><span lang="BG">седмичното плацебо-контролирано проучване фаза</span><span lang="EN-GB"> </span><span lang="BG">3</span><span lang="BG"> </span><span lang="BG">на ивакафтор/тезакафтор/елексакафтор тези показатели са </span>1<span lang="BG">,</span>5%, 2<span lang="BG">,</span>5% <span lang="BG">и </span>7<span lang="BG">,</span>9% <span lang="BG">при пациентите, лекувани с </span><span lang="BG">ивакафтор/тезакафтор/елексакафтор, и </span>1<span lang="BG">,</span>0%, 1<span lang="BG">,</span>5%<span lang="BG"> и </span>5<span lang="BG">,</span>5% <span lang="BG">при </span><span lang="BG">третираните с плацебо пациенти</span>. <span lang="BG">Честотата на нежеланите реакции на повишение на трансаминазите е</span> 10<span lang="BG">,</span>9% <span lang="BG">при пациентите, лекувани с ивакафтор </span><span lang="BG">в комбинирана схема с ивакафтор/тезакафтор/елексакафтор,</span><span lang="BG"> </span><span lang="BG">и </span>4<span lang="BG">,</span>0% <span lang="BG">при третираните с плацебо пациенти.</span></p><p class="MsoNormal"><i><span lang="EN-GB"> </span></i></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Педиатрична популация"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal"><span lang="BG">Данните за безопасност за ивакафтор са оценени при </span><span lang="EN-GB">6 </span><span lang="BG">пациенти на възраст между 4 месеца до под 6 месеца, 11 пациенти от 6‑ до под 12‑месечна възраст, 19</span><span lang="EN-GB"> </span><span lang="BG">пациенти от 12‑ до под 24‑месечна възраст, 34</span><span lang="EN-GB"> </span><span lang="BG">пациенти между 2- и под 6-годишна възраст, 61</span><span lang="EN-GB"> </span><span lang="BG">пациенти между 6‑ и под 12-годишна възраст и 94</span><span lang="EN-GB"> </span><span lang="BG">пациенти между 12- и под 18-годишна възраст. </span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Профилът на безопасност в общи линии е сходен при педиатрични пациенти на възраст 4 и повече месеца и също съответства на този при възрастни пациенти.</span></p><p class="MsoNormal"><i><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></i></p><p class="MsoNormal"><span lang="BG">Честотата на повишенията на трансаминазите (</span><span lang="EN-GB">ALT</span><span lang="BG"> или </span><span lang="EN-GB">AST</span><span lang="BG">), наблюдавана в проучвания 2, 5 и 6, (пациенти на възраст от 6 до под 12 години), в проучване 7 (пациенти на възраст от 2 до под 6 години) и в проучване 8 (пациенти на възраст от 6 до под 24 месеца ) е описана в Таблица 3. В плацебо-контролираните проучвания ч</span><span lang="BG">естотата на случаите на повишение на трансаминазите е подобна при лечението с ивакафтор (15,0%) и плацебо (14,6%). Пиковите повишения на чернодробните функционални показатели обикновено са по-големи при педиатричните пациенти, отколкото при по-възрастните пациенти. При всички популации пиковите повишения на чернодробните функционални показатели се връщат към стойностите от изходното ниво след прекъсване, а в почти всички случаи, в които приложението е прекъснато поради повишени трансаминази и впоследствие подновено, приложението на ивакафтор е могло да бъде подновено успешно (вж. точка 4.4). Наблюдавани са случаи, показващи повторно повишаване на трансаминазите при подновяване на лечението. В проучване 7 ивакафтор е окончателно спрян при един пациент. В проучване 8 няма пациенти с повишения на общия билирубин или които да са прекъснали лечението с ивакафтор поради повишаване на трансаминазите в никоя от възрастовите кохорти </span><span lang="RU">(</span><span lang="BG">вж. точка</span><span lang="EN-GB"> </span><span lang="RU">4.4 </span><span lang="BG">за овладяване на повишените трансаминази</span><span lang="RU">).</span></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="margin-bottom:6.0pt;page-break-after:avoid"><b><span lang="BG">Таблица</span><span lang="EN-GB"> </span></b><b><span lang="BG">3</span><span lang="EN-GB">: </span></b><b><span lang="BG">Повишения на трансаминазите при пациенти на възраст от 4</span><span lang="EN-GB"> </span></b><b><span lang="BG">месеца до </span><span lang="EN-GB">&lt;</span></b><b><span lang="BG"> </span><span lang="EN-GB">12 </span></b><b><span lang="BG">години, лекувани с ивакафтор като монотерапия</span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoTableGrid" style="margin-left:6.85pt;border-collapse:collapse;border:none"> <tr style="height:28.95pt"> <td style="width:121.1pt;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:28.95pt" valign="top" width="161"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p> </td> <td style="width:49.65pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt" valign="top" width="66"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">n</span></b></p> </td> <td style="width:80.95pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">% </span></b><b><span lang="BG">пациенти   </span><span lang="EN-GB">&gt; 3 x ULN </span></b></p> </td> <td style="width:81.0pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">% </span></b><b><span lang="BG">пациенти   </span><span lang="EN-GB">&gt;5 x ULN</span></b></p> </td> <td style="width:81.0pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">% </span></b><b><span lang="BG">пациенти   </span><span lang="EN-GB">&gt; 8 x ULN</span></b></p> </td> </tr> <tr style="height:14.35pt"> <td style="width:121.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="161"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">от   </span><span lang="EN-GB">6 </span><span lang="BG">до</span><span lang="EN-GB"> &lt;12</span><span lang="BG"> години</span></p> </td> <td style="width:49.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="66"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">40</span></p> </td> <td style="width:80.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">15</span><span lang="BG">,</span><span lang="EN-GB">0%   (6)</span></p> </td> <td style="width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">2</span><span lang="BG">,</span><span lang="EN-GB">5% (1)</span></p> </td> <td style="width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">2</span><span lang="BG">,</span><span lang="EN-GB">5% (1)</span></p> </td> </tr> <tr style="height:14.35pt"> <td style="width:121.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="161"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">от   </span><span lang="EN-GB">2 </span><span lang="BG">до</span><span lang="EN-GB"> &lt;6</span><span lang="BG"> години</span></p> </td> <td style="width:49.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="66"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">34</span></p> </td> <td style="width:80.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">14</span><span lang="BG">,</span><span lang="EN-GB">7%   (5)</span></p> </td> <td style="width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">14</span><span lang="BG">,</span><span lang="EN-GB">7% (5)</span></p> </td> <td style="width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">14</span><span lang="BG">,</span><span lang="EN-GB">7%   (5)</span></p> </td> </tr> <tr style="height:14.35pt"> <td style="width:121.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="161"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">от   </span><span lang="EN-GB">12 </span><span lang="BG">до</span><span lang="EN-GB"> &lt;24</span><span lang="BG"> месеца</span></p> </td> <td style="width:49.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="66"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">18</span></p> </td> <td style="width:80.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">27</span><span lang="BG">,</span><span lang="EN-GB">8%   (5)</span></p> </td> <td style="width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">11</span><span lang="BG">,</span><span lang="EN-GB">1%   (2)</span></p> </td> <td style="width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">11</span><span lang="BG">,</span><span lang="EN-GB">1%   (2)</span></p> </td> </tr> <tr style="height:13.7pt"> <td style="width:121.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.7pt" valign="top" width="161"> <p class="MsoNormal"><span lang="BG">от </span><span lang="EN-GB">6 </span><span lang="BG">до</span><span lang="EN-GB"> &lt;12</span><span lang="BG"> месеца</span></p> </td> <td style="width:49.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt" valign="top" width="66"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">11</span></p> </td> <td style="width:80.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">9</span><span lang="BG">,</span><span lang="EN-GB">1% (1)</span></p> </td> <td style="width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">0</span><span lang="BG">,</span><span lang="EN-GB">0% (0)</span></p> </td> <td style="width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">0</span><span lang="BG">,</span><span lang="EN-GB">0% (0)</span></p> </td> </tr> <tr style="height:13.7pt"> <td style="width:121.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.7pt" valign="top" width="161"> <p class="MsoNormal"><span lang="BG">от 4</span><span lang="BG"> </span><span lang="BG">до</span><span lang="EN-GB"> &lt;</span><span lang="BG">6 месеца</span></p> </td> <td style="width:49.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt" valign="top" width="66"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">6</span></p> </td> <td style="width:80.95pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">0</span><span lang="BG">,</span><span lang="EN-GB">0% (0)</span></p> </td> <td style="width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">0</span><span lang="BG">,</span><span lang="EN-GB">0% (0)</span></p> </td> <td style="width:81.0pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.7pt" valign="top" width="108"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">0</span><span lang="BG">,</span><span lang="EN-GB">0% (0)</span></p> </td> </tr> </table><p class="MsoNormal"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Съобщаване на подозирани нежелани реакции"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal"><span lang="BG">Съобщаването на подозирани нежелани реакции след разрешаване за употреба на лекарствения продукт е важно.</span><span lang="BG"> Това позволява да продължи наблюдението на съотношението полза/риск за лекарствения продукт. От медицинските специалисти се изисква да съобщават всяка подозирана нежелана реакция чрез <span style="background:lightgrey">национална система за съобщаване, посочена в </span></span><span lang="EN-GB"><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span lang="BG" style="background:lightgrey">Приложение V</span></a></span><span lang="BG">.</span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.9     Предозиране"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="labeltext" style="page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Няма наличен специален антидот за предозирането с ивакафтор. Лечението на предозирането се състои от общи поддържащи мерки, включително проследяване на жизнените показатели, чернодробните функционални показатели и проследяване на клиничното състояние на пациента.</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="5.       ФАРМАКОЛОГИЧНИ СВОЙСТВА "/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="5.1     Фармакодинамични свойства"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG"> </span></i></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Фармакотерапевтична група: Други продукти за лечение на дихателната система,<i> <br/> </i>ATC код: </span><span lang="BG" style="color:black">R07AX02</span></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Механизъм на действие"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal"><span lang="BG">Ивакафтор е потенциатор на CFTR белтъка, т.е. <i>in vitro</i> ивакафтор повишава пропускливостта на CFTR канала, за да</span><span lang="BG"> </span><span lang="BG">се увеличи транспортът на хлорните йони при специфичните мутации, водещи до каналопатии (както са изброени в точка 4.1), характеризиращи се с намалена вероятност за отваряне на канала в сравнение с нормалния CFTR. Ивакафтор потенциира също вероятността за отваряне на </span><i><span lang="EN-GB">R</span></i><i><span lang="BG">117</span></i><i><span lang="EN-GB">H</span></i><span lang="BG">‑</span><span lang="EN-GB">CFTR</span><span lang="BG">, който има както малка </span><span lang="BG">вероятност за отваряне на канала, така и намалена амплитуда на потока в канала (проводимост). Мутацията<i> G970R </i>причинява сплайсинг дефект, водещ до наличие на</span><span lang="BG"> </span><span lang="BG">малко количество CFTR белтък на клетъчната повърхност или липсата му, което може да обясни резултатите, наблюдавани при лица с тази мутация в проучване 5 (вж. „Фармакодинамични ефекти“ и данните в „Клинична ефикасност“).</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><i><span lang="BG">In vitro</span></i><span lang="BG"> отговорите, наблюдавани при експерименти от вида „patch clamp” с един канал с използване на мембранни пачове от клетки на гризачи, експресиращи мутантни CFTR форми, не съответстват непременно на фармакодинамичния отговор <i>in vivo </i>(напр. хлорни йони в потта) или на клиничната полза. Точният механизъм, който позволява на ивакафтор да потенциира</span><span lang="BG"> активността на отваряне на нормални и някои мутантни CFTR форми в тази система, не е напълно обяснен.</span></p><p class="MsoBodyText2" style="margin-bottom:0in;line-height:normal"><span lang="BG" style="font-size:11.0pt;color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Фармакодинамични ефекти"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>В проучвания 1 и 2 при пациенти с <i>G551D </i>мутация в един алел на <i>CFTR</i> гена ивакафтор води до бързи (15 дни), съществени (средната промяна на хлорните йони в потта от изходно ниво на седмица 24 е съответно ‑48 mmol/l [95% ДИ ‑51; ‑45] и ‑54 mmol/l [95% ДИ ‑62; ‑47]) и трайни (в продължение на 48 седмици) понижения на концентрацията на хлорните йони в потта.</span></p><p class="documenttext" style="margin-bottom:0in"><u><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'><span style="text-decoration:none"> </span></span></u></p><p class="documenttext" style="margin-bottom:0in"><span lang="BG" style='font-size: 11.0pt;font-family:"Times New Roman",serif'>В проучване 5, част 1, при пациенти, които имат не-<i>G551D</i> водеща до каналопатия мутация на <i>CFTR</i> гена, лечението с ивакафтор води до бърза (15 дни) и съществена средна промяна от изходно ниво на хлорните йони в потта от ‑49 mmol/l (95% ДИ -57; -41) за 8 седмици лечение. При пациенти с <i>G970R</i>-<i>CFTR</i> мутацията обаче средната (SD) абсолютна промяна на хлорните йони в потта на седмица 8 е -6,25 (6,55) mmol/l. В част 2 на проучването се наблюдават подобни резултати като в част 1. При визитата за проследяване на 4-тата седмица (4 седмици след приключване на приложението на ивакафтор) средните стойности на хлорни йони в потта за всяка група клонят към нивата от преди лечението.</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="documenttext" style="margin-bottom:0in"><span lang="BG" style='font-size: 11.0pt;font-family:"Times New Roman",serif'>В проучване 6 при пациенти на възраст</span><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>6</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>или повече години с КФ, които имат </span><i><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'>R</span></i><i><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>117</span></i><i><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'>H</span></i><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'> мутация на </span><i><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'>CFTR</span></i><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'> гена, разликата между леченията по отношение на средната промяна на хлорните йони в потта от изходното ниво за 24-те седмици на лечение е ‑24</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'> mmol</span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>/</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>l</span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'> (95%</span><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>ДИ</span><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>‑28;</span><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>‑20). В подгрупов анализ по възраст разликата между леченията е -21,87</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'> mmol/l (95% </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>ДИ</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>: -26,46; -17,28)</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'> <span lang="BG">при пациенти на възраст 18 или повече години и </span></span><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'>‑27,63 mmol/l (95% </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>ДИ</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>: -37,16; -18,10) </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>при пациенти на възраст</span><span style='font-size: 11.0pt;font-family:"Times New Roman",serif'> 6-11</span><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>години</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>. </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>Двама пациенти на възраст</span><span style='font-size: 11.0pt;font-family:"Times New Roman",serif'> 12 </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>до</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'> 17 </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>години са включени в това проучване.</span></p><p class="documenttext" style="margin-bottom:0in"><span lang="BG" style='font-size: 11.0pt;font-family:"Times New Roman",serif'> </span></p><p class="documenttext" style="margin-bottom:0in"><span lang="BG" style='font-size: 11.0pt;font-family:"Times New Roman",serif'>В проучване 7 при пациенти на възраст от 2 до под 6 години</span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'> с водеща до каналопатия мутация в най-малко 1 алел на <i>CFTR</i> гена</span><span lang="BG" style='font-size:11.0pt; font-family:"Times New Roman",serif'>, на които е прилагано или 50 mg, или 75 mg ивакафтор два пъти дневно, средната абсолютна промяна от изходно ниво на хлорните йони в потта е ‑47 mmol/l (95% ДИ ‑58; ‑36) на седмица 24.</span></p><p class="documenttext" style="margin-bottom:0in"><span lang="BG" style='font-size: 11.0pt;font-family:"Times New Roman",serif'> </span></p><p class="documenttext" style="margin-bottom:0in"><span lang="BG" style='font-size: 11.0pt;font-family:"Times New Roman",serif'>В проучване 8 при пациенти с КФ на възраст под 24 месеца средната абсолютна промяна от изходно ниво на хлорните йони в потта е ‑65,1 mmol/l (95% ДИ ‑74,1; ‑56,0) на седмица 24. Резултатите са сходни във възрастовите кохорти от 12 до под 24 месеца, от 6 до под 12</span><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>месеца и от 4 до под 6 месеца.</span></p><p class="documenttext" style="margin-bottom:0in"><u><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'><span style="text-decoration:none"> </span></span></u></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Клинична ефикасност и безопасност"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="documenttext" style="margin-bottom:0in;page-break-after:avoid"><u><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG">Проучвания 1 и 2: проучвания при пациенти с КФ с </span></i><i><span lang="EN-GB">G</span></i><i><span lang="BG">551</span></i><i><span lang="EN-GB">D</span></i><i><span lang="EN-GB"> </span></i><i><span lang="BG">мутации, водещи до каналопатии</span></i></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG"> </span></i></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Ефикасността на ивакафтор е оценена в две рандомизирани, двойнослепи, плацебо-контролирани, многоцентрови проучвания фаза 3 на клинично стабилни пациенти с КФ, които са имали <i>G551D</i> мутация на <i>CFTR</i> гена най-малко в 1 алел и ФЕО<sub>1</sub> </span><span style='font-family:"Times New Roman",serif'>≥</span><span lang="BG" style='font-family:"Times New Roman",serif'>40% от прогнозираното. </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Пациентите и в двете проучвания са рандомизирани 1:1 да получават или 150 mg ивакафтор, или плацебо на всеки 12 часа с храна, съдържаща мазнини, в продължение на 48 седмици в допълнение към предписаната им терапия за КФ (напр. тобрамицин, дорназа алфа). Не е разрешена употребата на хипертоничен разтвор на натриев хлорид за инхалация.</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Проучване 1 оценява 161 пациенти на възраст</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>12 и повече години; 122 (75,8%) пациенти имат <i>F508del</i> мутацията във втория алел. В началото на проучването пациентите в групата на плацебо използват някои лекарствени продукти с по-висока честота</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>,</span><span lang="BG" style='font-family:"Times New Roman",serif'> отколкото групата на ивакафтор. Тези лекарства включват дорназа алфа (73,1% спрямо 65,1%), салбутамол (53,8% спрямо 42,2%), тобрамицин (44,9% спрямо 33,7%) и салметерол/флутиказон (41,0% спрямо 27,7%). На изходното ниво средният прогнозиран ФЕО<sub>1</sub> е 63,6% (диапазон: 31,6% до 98,2%), а средната възраст е 26 години (диапазон: 12 до 53 години). </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Проучване 2 оценява 52 пациенти на възраст от 6 до 11 години при скрининга. Средното (SD) телесно тегло е 30,9 (8,63) kg; 42 (80,8%) пациенти имат <i>F508del</i> мутацията във втория алел. На изходното ниво средният прогнозиран ФЕО<sub>1</sub> е 84,2% (диапазон: 44,0% до 133,8%), а средната възраст е 9 години (диапазон: 6 до 12 години); 8 (30,8%) пациенти в групата на плацебо и 4 (15,4%) пациенти в групата на ивакафтор имат ФЕО<sub>1</sub> по-малко от 70% от прогнозираното на изходно ниво. </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Първичната крайна точка за ефикасност при двете проучвания е средната абсолютна промяна спрямо изходното ниво в процента на прогнозирания ФЕО<sub>1</sub> за 24 седмици лечение. </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Разликата между лечението с ивакафтор и с плацебо по отношение на средната абсолютна промяна (95%</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>ДИ) в процента на прогнозирания ФЕО<sub>1</sub> от изходно ниво до седмица 24 е 10,6 процентни точки (8,6; 12,6) при проучване 1 и 12,5 процентни точки (6,6; 18,3) при проучване 2. Разликата между лечението с ивакафтор и с плацебо по отношение на средната относителна промяна (95%</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>ДИ) в процента на прогнозирания ФЕО<sub>1</sub> от изходно ниво до седмица 24 е 17,1% (13,9; 20,2) при проучване 1 и 15,8% (8,4; 23,2) при проучване 2. Средната промяна на ФЕО<sub>1</sub> от изходно ниво до седмица 24 (</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>l</span><span lang="BG" style='font-family:"Times New Roman",serif'>) е 0,37 </span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>l</span><span lang="BG" style='font-family:"Times New Roman",serif'> в групата на ивакафтор и 0,01 </span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>l</span><span lang="BG" style='font-family:"Times New Roman",serif'> в групата на плацебо при проучване 1 и 0,30 </span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>l</span><span lang="BG" style='font-family:"Times New Roman",serif'> в групата на ивакафтор и 0,07 </span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>l</span><span lang="BG" style='font-family:"Times New Roman",serif'> в групата на плацебо при проучване 2. И при двете проучвания подобрението на ФЕО<sub>1</sub> е с бързо начало (ден 15) и се поддържа в продължение на 48 седмици. </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Разликата в лечението между ивакафтор и плацебо за средната абсолютна промяна (95% ДИ) на процента на прогнозирания ФЕО<sub>1</sub> от изходно ниво до седмица 24 при пациенти на възраст от 12 до 17 години в проучване 1 е 11,9 процентни точки (5,9; 17,9). Разликата в лечението между ивакафтор и плацебо за средната абсолютна промяна (95% ДИ) на процента на прогнозирания ФЕО<sub>1</sub> от изходно ниво до седмица 24 при пациенти с прогнозирано на изходно ниво ФЕО<sub>1 </sub>по-голямо от 90% в проучване 2 е 6,9 процентни точки (‑3,8; 17,6).</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Резултатите за клинично значимите вторични крайни точки са дадени в Таблица </span>4<span lang="BG">.</span></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:6.0pt; margin-left:56.7pt;text-indent:-56.7pt;page-break-after:avoid"><b><span lang="BG">Таблица </span></b><b>4</b><b><span lang="BG">: Ефект на ивакафтор върху други крайни точки за ефикасност в проучванията</span></b><b><span lang="EN-GB"> </span></b><b><span lang="BG">1 и</span></b><b><span lang="EN-GB"> </span></b><b><span lang="BG">2</span></b></p><table align="left" border="0" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:100.0%;border-collapse:collapse;margin-left:7.1pt;  margin-right:7.1pt" width="100%"> <thead> <tr style="height:10.5pt"> <td style="width:27.94%;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:10.5pt" valign="top" width="27%"> <p align="left" class="tabletextcenterjustified" style="margin:0in;text-align:    left;page-break-after:avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'> </span></b></p> </td> <td colspan="2" style="width:34.38%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt" valign="top" width="34%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'>Проучване 1</span></b></p> </td> <td colspan="2" style="width:37.68%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt" valign="top" width="37%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'>Проучване 2</span></b></p> </td> </tr> <tr style="height:28.25pt"> <td style="width:27.94%;border:solid windowtext 1.0pt;    border-top:none;padding:0in 5.4pt 0in 5.4pt;height:28.25pt" valign="bottom" width="27%"> <p class="tabletextleftjustified" style="margin:0in;page-break-after:avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'>Крайна    точка</span></b></p> </td> <td style="width:19.96%;border-top:none;    border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:28.25pt" valign="bottom" width="19%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'>Разлика    в лечението<sup>a</sup></span></b></p> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'>(95% ДИ)</span></b></p> </td> <td style="width:14.42%;border-top:none;    border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:28.25pt" valign="bottom" width="14%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><b><i><span lang="BG" style='font-family:"Times New Roman",serif'>P </span></i></b><b><span lang="BG" style='font-family:"Times New Roman",serif'>стойност</span></b></p> </td> <td style="width:19.96%;border-top:none;    border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:28.25pt" valign="bottom" width="19%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'>Разлика    в лечението<sup>a</sup></span></b></p> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'>(95% ДИ)</span></b></p> </td> <td style="width:17.72%;border-top:none;    border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:28.25pt" valign="bottom" width="17%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><b><i><span lang="BG" style='font-family:"Times New Roman",serif'>P </span></i></b><b><span lang="BG" style='font-family:"Times New Roman",serif'>стойност</span></b></p> </td> </tr> </thead> <tr style="height:10.5pt"> <td colspan="5" style="width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt" valign="top" width="100%"> <p align="left" class="tabletextcenterjustified" style="margin:0in;text-align:   left;page-break-after:avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'>Средна   абсолютна   промяна   спрямо   изходното   ниво в скора   на   респираторния   домейн на CFQ-R<sup>б </sup>(точки)<sup>в</sup></span></b></p> </td> </tr> <tr style="height:18.3pt"> <td style="width:27.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="27%"> <p class="tabletextleftjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>До седмица</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>24</span></p> </td> <td style="width:19.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="19%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>8,1</span></p> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>(4,7</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>;</span><span lang="BG" style='font-family:"Times New Roman",serif'> 11,4)</span></p> </td> <td style="width:14.42%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="14%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>&lt;0,0001</span></p> </td> <td style="width:19.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="19%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>6,1</span></p> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>(‑1,4</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>;</span><span lang="BG" style='font-family:"Times New Roman",serif'> 13,5)</span></p> </td> <td style="width:17.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="17%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>0,1092</span></p> </td> </tr> <tr style="height:18.85pt"> <td style="width:27.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.85pt" valign="top" width="27%"> <p class="tabletextleftjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>До седмица</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>48</span></p> </td> <td style="width:19.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt" valign="top" width="19%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>8,6</span></p> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>(5,3</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>;</span><span lang="BG" style='font-family:"Times New Roman",serif'> 11,9)</span></p> </td> <td style="width:14.42%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt" valign="top" width="14%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>&lt;0,0001</span></p> </td> <td style="width:19.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt" valign="top" width="19%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>5,1</span></p> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>(-1,6</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>;</span><span lang="BG" style='font-family:"Times New Roman",serif'> 11,8)</span></p> </td> <td style="width:17.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt" valign="top" width="17%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>0,1354</span></p> </td> </tr> <tr style="height:9.95pt"> <td colspan="5" style="width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:9.95pt" valign="top" width="100%"> <p align="left" class="tabletextcenterjustified" style="margin:0in;text-align:   left;page-break-after:avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'>Относителен   риск за   пулмонална   екзацербация</span></b></p> </td> </tr> <tr style="height:10.5pt"> <td style="width:27.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt" valign="top" width="27%"> <p class="tabletextleftjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>До седмица</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>24</span></p> </td> <td style="width:19.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.5pt" valign="top" width="19%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>0,40</span><sup><span lang="BG" style='font-family:"Times New Roman",serif'>г</span></sup></p> </td> <td style="width:14.42%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.5pt" valign="top" width="14%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>0,0016</span></p> </td> <td style="width:19.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.5pt" valign="top" width="19%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>НА</span></p> </td> <td style="width:17.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.5pt" valign="top" width="17%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>НА</span></p> </td> </tr> <tr style="height:9.95pt"> <td style="width:27.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:9.95pt" valign="top" width="27%"> <p class="tabletextleftjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>До седмица</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>48</span></p> </td> <td style="width:19.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:9.95pt" valign="top" width="19%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>0,46<sup>г</sup></span></p> </td> <td style="width:14.42%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:9.95pt" valign="top" width="14%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>0,0012</span></p> </td> <td style="width:19.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:9.95pt" valign="top" width="19%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>НА</span></p> </td> <td style="width:17.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:9.95pt" valign="top" width="17%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>НА</span></p> </td> </tr> <tr style="height:10.5pt"> <td colspan="5" style="width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt" valign="top" width="100%"> <p align="left" class="tabletextcenterjustified" style="margin:0in;text-align:   left;page-break-after:avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'>Средна   абсолютна   промяна   спрямо   изходното   ниво в   телесното   тегло (kg)</span></b></p> </td> </tr> <tr style="height:18.85pt"> <td style="width:27.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.85pt" valign="top" width="27%"> <p class="tabletextleftjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>На седмица</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>24</span></p> </td> <td style="width:19.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt" valign="top" width="19%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>2,8</span></p> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>(1,8</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>;</span><span lang="BG" style='font-family:"Times New Roman",serif'> 3,7)</span></p> </td> <td style="width:14.42%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt" valign="top" width="14%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>&lt;0,0001</span></p> </td> <td style="width:19.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt" valign="top" width="19%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>1,9</span></p> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>(0,9</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>;</span><span lang="BG" style='font-family:"Times New Roman",serif'> 2,9)</span></p> </td> <td style="width:17.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.85pt" valign="top" width="17%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>0,0004</span></p> </td> </tr> <tr style="height:18.3pt"> <td style="width:27.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="27%"> <p class="tabletextleftjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>На седмица</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>48</span></p> </td> <td style="width:19.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="19%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>2,7<br/>   (1,3</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>;</span><span lang="BG" style='font-family:"Times New Roman",serif'> 4,1)</span></p> </td> <td style="width:14.42%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="14%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>0,0001</span></p> </td> <td style="width:19.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="19%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>2,8</span></p> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>(1,3</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>;</span><span lang="BG" style='font-family:"Times New Roman",serif'> 4,2)</span></p> </td> <td style="width:17.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="17%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>0,0002</span></p> </td> </tr> <tr style="height:13.8pt"> <td colspan="5" style="width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.8pt" valign="top" width="100%"> <p align="left" class="tabletextcenterjustified" style="margin:0in;text-align:   left;page-break-after:avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'>Средна   абсолютна   промяна спрямо   изходното   ниво в BMI (kg/m<sup>2</sup>)</span></b></p> </td> </tr> <tr style="height:18.3pt"> <td style="width:27.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="27%"> <p class="tabletextleftjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>На седмица</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>24</span></p> </td> <td style="width:19.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="19%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>0,94</span></p> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>(0,62; 1,26)</span></p> </td> <td style="width:14.42%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="14%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>&lt;0,0001</span></p> </td> <td style="width:19.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="19%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>0,81</span></p> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>(0,34; 1,28)</span></p> </td> <td style="width:17.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="17%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>0,0008</span></p> </td> </tr> <tr style="height:18.3pt"> <td style="width:27.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="27%"> <p class="tabletextleftjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>На седмица</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>48</span></p> </td> <td style="width:19.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="19%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>0,93</span></p> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>(0,48; 1,38)</span></p> </td> <td style="width:14.42%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="14%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>&lt;0,0001</span></p> </td> <td style="width:19.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="19%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>1,09</span></p> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>(0,51; 1,67)</span></p> </td> <td style="width:17.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="17%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>0,0003</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:18.3pt"> <td colspan="5" style="width:100.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="100%"> <p align="left" class="tabletextcenterjustified" style="margin:0in;text-align:   left;page-break-after:avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'>Средна   промяна   спрямо   изходното   ниво в z-скорове   </span></b></p> </td> </tr> <tr style="page-break-inside:avoid;height:18.3pt"> <td style="width:27.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="27%"> <p class="tabletextleftjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>Тегло-за-възрастта:</span></p> <p class="tabletextleftjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>z-скор   на седмица</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>48<sup>д</sup></span></p> </td> <td style="width:19.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="19%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>0,33</span></p> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>(0,04; 0,62)</span></p> </td> <td style="width:14.42%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="14%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>0,0260</span></p> </td> <td style="width:19.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="19%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>0,39</span></p> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>(0,24; 0,53)</span></p> </td> <td style="width:17.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:18.3pt" valign="top" width="17%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>&lt;0,0001</span></p> </td> </tr> <tr style="height:29.05pt"> <td style="width:27.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:29.05pt" valign="top" width="27%"> <p class="tabletextleftjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>BMI   за-възрастта:   </span></p> <p class="tabletextleftjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>z-скор   на седмица</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>48<sup>д</sup></span><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p> </td> <td style="width:19.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:29.05pt" valign="top" width="19%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>0,33</span></p> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>(0,002; 0,65)</span></p> </td> <td style="width:14.42%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:29.05pt" valign="top" width="14%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>0,0490</span></p> </td> <td style="width:19.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:29.05pt" valign="top" width="19%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>0,45</span></p> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>(0,26; 0,65)</span></p> </td> <td style="width:17.72%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:29.05pt" valign="top" width="17%"> <p class="tabletextcenterjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>&lt;0,0001</span></p> </td> </tr> </table><p class="tablefootnote" style="margin-top:6.0pt;page-break-after:avoid"><span lang="BG" style='font-size:9.0pt;font-family:"Times New Roman",serif;color:white'>ДИ: доверителен интервал; НА: не е анализирано поради ниската честота на събитията </span></p><p class="tablefootnote" style="page-break-after:avoid"><sup><span lang="BG" style='font-size:9.0pt;font-family:"Times New Roman",serif'>a        </span></sup><span lang="BG" style='font-size:9.0pt;font-family:"Times New Roman",serif'>Разлика в лечението = ефект на ивакафтор – ефект на плацебо</span></p><p class="MsoNormal" style="margin-left:13.5pt;text-indent:-13.5pt;page-break-after: avoid"><sup><span lang="BG" style="font-size:9.0pt">б</span></sup><span lang="BG" style="font-size:9.0pt"> </span><span lang="BG" style="font-size: 9.0pt">CFQ-R: </span><span lang="BG" style="font-size:9.0pt">Въпросник за кистозна фиброза – актуализиран (</span><span lang="BG" style="font-size:9.0pt">Cystic Fibrosis Questionnaire-Revised) е специфичен за заболяването, начин за измерване на качеството на живот във връзка със здравето при КФ.</span></p><p class="tablefootnote" style="margin-left:14.2pt;text-indent:-14.2pt; page-break-after:avoid"><sup><span lang="BG" style='font-size:9.0pt;font-family: "Times New Roman",serif'>в</span></sup><span lang="BG" style='font-size: 9.0pt;font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-size:9.0pt;font-family:"Times New Roman",serif'>Данните от проучване 1 са събрани от CFQ-R</span><span lang="BG" style='font-size:9.0pt;font-family:"Times New Roman",serif'> за възрастни/юноши и </span><span lang="BG" style='font-size:9.0pt;font-family:"Times New Roman",serif'>CFQ-R за деца на възраст от </span><span lang="BG" style='font-size:9.0pt;font-family:"Times New Roman",serif'>12 до 13</span><span lang="EN-GB" style='font-size:9.0pt;font-family: "Times New Roman",serif'> </span><span lang="BG" style='font-size:9.0pt; font-family:"Times New Roman",serif'>години; </span><span lang="BG" style='font-size:9.0pt;font-family:"Times New Roman",serif'>Данните от проучване </span><span lang="BG" style='font-size:9.0pt;font-family:"Times New Roman",serif'>2</span><span lang="BG" style='font-size:9.0pt;font-family:"Times New Roman",serif'> са получени от CFQ-R за деца от 6- до 11-годишна възраст.</span></p><p class="tablefootnote" style="page-break-after:avoid"><sup><span lang="BG" style='font-size:9.0pt;font-family:"Times New Roman",serif'>г        </span></sup><span lang="BG" style='font-size:9.0pt;font-family:"Times New Roman",serif'>Коефициент на риска за времето до първата пулмонална екзацербация</span></p><p class="MsoNormal"><sup><span lang="BG" style="font-size:9.0pt">д        </span></sup><span lang="BG" style="font-size:9.0pt">При лица под 20-годишна възраст (CDC таблици на растежа)</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG">Проучване</span></i><i><span lang="EN-GB"> </span></i><i><span lang="BG">5: проучване при пациенти с КФ с не-G551D водещи до каналопатии мутации</span></i></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG"> </span></i></p><p class="MsoNormal"><span lang="BG">Проучване</span><span lang="EN-GB"> </span><span lang="BG">5 е фаза 3, в две части, рандомизирано, двойносляпо, плацебо-контролирано, кръстосано проучване (част 1), последвано от 16-седмичен период на открито разширено проучване (част 2) за оценка на ефикасността и безопасността на ивакафтор при пациенти с КФ на възраст 6 и повече години, които имат <i>G970R</i> или не‑<i>G551D</i> водеща до каналопатия мутация на <i>CFTR</i> гена (<i>G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P</i> или <i>G1349D</i>). </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>В част 1 пациентите са рандомизирани 1:1 да получават или 150 mg ивакафтор, или плацебо на всеки 12 часа с храна, съдържаща мазнини, в продължение на 8 седмици в допълнение към тяхната предписана терапия за КФ и преминават на другото лечение за вторите 8 седмици след период на очистване</span><span lang="BG" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>от 4 до 8 седмици. Използването на хипертоничен солен разтвор за инхалиране не е разрешено. В част 2 всички пациенти получават ивакафтор, както е показано в част 1, за още 16 седмици. Продължителността на непрекъснатото лечение с ивакафтор е 24 седмици за пациентите, рандомизирани в част</span><span lang="EN-GB" style='font-family: "Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>1 на последователност на лечението плацебо/ивакафтор, и 16 седмици за пациентите, рандомизирани в част</span><span lang="EN-GB" style='font-family: "Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>1 на последователност на лечението ивакафтор/плацебо.</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Включени са </span><span lang="RU" style='font-family:"Times New Roman",serif'>39</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>пациенти (средна възраст 23 години) с прогнозиран ФЕО<sub>1</sub> на изходно ниво<sub> </sub></span><span style='font-family:"Times New Roman",serif'>≥</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>40% (среден прогнозиран ФЕО<sub>1</sub> 78% [диапазон: 43% до 119%]). Шестдесет и два процента (24/39) от тях са носители на мутацията <i>F508del</i>-<i>CFTR</i> във втория алел. Общо 36 пациенти продължават в част 2 (18 на всяка последователност на лечението).</span></p><p class="MsoNormal"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal"><span lang="BG">В част 1 на проучване 5 средният </span><span lang="BG">процент на прогнозирания ФЕО<sub>1</sub> на изходно ниво при пациентите, третирани с плацебо, е 79,3%, а за пациентите, лекувани с ивакафтор, тази стойност е 76,4%. Средната обща стойност след изходното ниво е съответно 76,0% и 83,7%. Средната абсолютна промяна от изходно ниво до седмица 8 на процента на прогнозирания ФЕО<sub>1</sub> (първична крайна точка за ефикасност) е 7,5% в периода на ивакафтор и ‑3,2% в периода на плацебо. Наблюдаваната разлика в лечението (95% ДИ) между ивакафтор и плацебо е 10,7% (7,3; 14,1) (<i>P</i> &lt; 0,0001).</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Ефектът на ивакафтор при общата популация от проучване 5 (включително вторичните крайни точки абсолютна промяна в BMI [индекс на телесната маса] на 8 -та седмица от лечението и абсолютната промяна в скора на респираторния домейн на CFQ-R през 8 -те седмици на лечение) и по индивидуална мутация (абсолютна промяна на хлорните йони в потта и в процента на прогнозирания ФЕО<sub>1</sub> на седмица 8) е показан в Таблица 4. Въз основа на клиничните (процент на прогнозирания ФЕО<sub>1</sub>) и фармакодинамичните (хлорните йони в потта) отговори на ивакафтор не е възможно да се установи ефикасността при пациенти с <i>G970R</i> мутацията.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:6.0pt; margin-left:56.7pt;text-indent:-56.7pt;page-break-after:avoid"><b><span lang="BG">Таблица </span></b><b>5</b><b><span lang="BG">: Ефект на ивакафтор върху променливите за ефикасност в общата популация и за специфични <i>CFTR</i> мутации</span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:454.9pt;margin-left:.5pt;border-collapse:collapse;border:none" width="607"> <tr> <td colspan="2" style="width:151.6pt;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="BG">Абсолютна   промяна в процента   на   прогнозирания   ФЕО<sub>1</sub></span></b></p> </td> <td colspan="2" style="width:151.65pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid;text-autospace:none"><b><span lang="BG" style="color:black">BMI</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid;text-autospace:none"><b><span lang="BG" style="color:black">(kg/m</span></b><b><sup><span lang="BG" style='font-family:"Times New Roman Bold",serif;color:black'>2</span></sup></b><b><span lang="BG" style="color:black">)</span></b></p> </td> <td style="width:151.65pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="BG">Скор на   респираторния   домейн на CFQ-R   (точки)</span></b></p> </td> </tr> <tr> <td colspan="2" style="width:151.6pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="BG">През седмица</span></b><b><span lang="EN-GB"> </span></b><b><span lang="BG">8</span></b></p> </td> <td colspan="2" style="width:151.65pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid;text-autospace:none"><b><span lang="BG" style="color:black">На   седмица</span></b><b><span lang="EN-GB" style="color:black"> </span></b><b><span lang="BG" style="color:black">8</span></b></p> </td> <td style="width:151.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="BG">През седмица</span></b><b><span lang="EN-GB"> </span></b><b><span lang="BG">8</span></b></p> </td> </tr> <tr> <td colspan="5" style="width:454.9pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="607"> <p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><span lang="BG" style="color:black">Всички   пациенти (</span><span style="color:black">N</span><span lang="BG" style="color:black">=39)</span></p> <p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><span lang="BG" style="color:black">Резултати,   показани   като средна (95%</span><span lang="EN-GB" style="color:black"> </span><span lang="BG" style="color:black">ДИ)   промяна от   изходно   ниво за   пациентите,   лекувани с   ивакафтор,   спрямо </span><span lang="BG">третир<span style="color:black">аните с   плацебо:</span></span></p> </td> </tr> <tr> <td colspan="2" style="width:151.6pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG" style="color:black">10,7 (7,3</span><span lang="EN-GB" style="color:black">;</span><span lang="BG" style="color:black"> 14,1)</span></p> </td> <td colspan="2" style="width:151.65pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG" style="color:black">0,66 (0,34; 0,99)</span></p> </td> <td style="width:151.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="202"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG" style="color:black">9,6 (4,5</span><span lang="EN-GB" style="color:black">;</span><span lang="BG" style="color:black"> 14,7)</span></p> </td> </tr> <tr style="height:15.65pt"> <td colspan="5" style="width:455.4pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.65pt" valign="top" width="607"> <p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><b><span lang="BG" style="color:black">Пациенти,   групирани   според вида   мутация (n)</span></b></p> <p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><span lang="BG" style="color:black">Резултати,   показани   като средна   (минимум, максимум)   промяна от   изходно   ниво за   пациентите,   лекувани с   ивакафтор,   на седмица</span><span lang="EN-GB" style="color:black"> </span><span lang="BG" style="color:black">8*:</span></p> </td> </tr> <tr style="height:15.65pt"> <td rowspan="2" style="width:79.55pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.65pt" valign="top" width="106"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid;text-autospace:none"><b><span lang="BG" style="color:black">Мутация   (n)</span></b></p> <p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><b><span lang="BG" style="color:black"> </span></b></p> </td> <td colspan="2" style="width:187.9pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.65pt" valign="top" width="251"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid;text-autospace:none"><b><span lang="BG">Абсолютна   промяна</span></b><b><span lang="BG">   на хлорните   йони в потта <span style="color:black">(mmol/</span></span></b><b><span style="color:black">l</span></b><b><span lang="BG" style="color:black">)</span></b></p> </td> <td colspan="2" style="width:187.95pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.65pt" valign="top" width="251"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid;text-autospace:none"><b><span lang="BG">Абсолютна   промяна</span></b><b><span lang="BG">   в процента   на   прогнозирания   ФЕО<sub>1</sub> (процентни   точки)</span></b></p> </td> </tr> <tr style="height:15.65pt"> <td colspan="2" style="width:187.9pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.65pt" valign="top" width="251"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid;text-autospace:none"><b><span lang="BG" style="color:black">На   седмица</span></b><b><span lang="EN-GB" style="color:black"> </span></b><b><span lang="BG" style="color:black">8</span></b></p> </td> <td colspan="2" style="width:187.95pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.65pt" valign="top" width="251"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid;text-autospace:none"><b><span lang="BG" style="color:black">На   седмица</span></b><b><span lang="EN-GB" style="color:black"> </span></b><b><span lang="BG" style="color:black">8</span></b></p> </td> </tr> <tr style="height:103.5pt"> <td style="width:79.55pt;border-top:none;border-left:   solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:   none;padding:0in 5.4pt 0in 5.4pt;height:103.5pt" valign="top" width="106"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid;text-autospace:none"><i><span lang="BG" style="color:black">G1244E</span></i><span lang="BG" style="color:black"> (5)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><i><span lang="BG">G1349D</span></i><span lang="BG"> (2)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><i><span lang="BG">G178R</span></i><span lang="BG"> (5)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><i><span lang="BG">G551S</span></i><span lang="BG"> (2)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><i><span lang="BG">G970R</span><sup><span lang="EN-GB"></span></sup></i><span lang="BG"> (4)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><i><span lang="BG">S1251N </span></i><span lang="BG">(8)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><i><span lang="BG">S1255P</span></i><span lang="BG"> (2)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><i><span lang="BG">S549N</span></i><span lang="BG"> (6)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid;text-autospace:none"><i><span lang="BG">S549R</span></i><span lang="BG">   (4)</span></p> </td> <td colspan="2" style="width:187.9pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:103.5pt" valign="top" width="251"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">-55 (-75; -34)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">-80 (-82; -79)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">-53 (-65; -35)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">-68<sup>†</sup> </span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">-6 (-16; -2)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">-54 (-84; -7)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">-78 (-82; -74)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">-74 (-93; -53)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">-61</span><sup><span lang="EN-GB">††</span></sup><span lang="BG"> (-71; -54)</span></p> </td> <td colspan="2" style="width:187.95pt;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:103.5pt" valign="top" width="251"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">8 (-1; 18)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">20 (3; 36)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">8 (-1; 18)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">3<sup>†</sup></span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">3 (-1; 5)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">9 (-20; 21)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">3 (-1; 8)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">11 (-2; 20)</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">5 (-3; 13)</span></p> </td> </tr> <tr height="0"> <td style="border:none" width="106"></td> <td style="border:none" width="96"></td> <td style="border:none" width="154"></td> <td style="border:none" width="48"></td> <td style="border:none" width="203"></td> </tr> </table><p class="MsoNormal" style="margin-top:6.0pt;page-break-after:avoid"><sup><span lang="BG" style="font-size:9.0pt">*</span></sup><span lang="BG" style="font-size: 9.0pt">     Статистическо тестване не е извършено поради малкия брой индивидуални мутации.</span></p><p class="MsoNormal" style="margin-left:13.5pt;text-indent:-13.5pt;page-break-after: avoid"><b><sup><span lang="BG" style="font-size:9.0pt;color:black">†</span></sup></b><span lang="BG" style="font-size:9.0pt"> </span><span lang="BG" style="font-size: 9.0pt">Отразява резултатите от един пациент с мутацията <i>G551S</i> с данни от времевата точка на 8-та седмица.</span></p><p class="MsoNormal" style="margin-left:13.5pt;text-indent:-13.5pt;page-break-after: avoid"><b><sup><span lang="BG" style="font-size:9.0pt;color:black">††</span></sup></b><b><span lang="BG" style="font-size:9.0pt;color:black"> </span></b><span lang="BG" style="font-size:9.0pt">n=3 за анализа на абсолютната промяна на хлорните йони в потта.</span></p><p class="labeltext" style="margin-left:13.7pt;text-align:justify;text-justify: inter-ideograph;text-indent:-13.7pt"><sup><span style='font-size:9.0pt; font-family:"Times New Roman",serif'>#</span></sup><span style='font-size:9.0pt; font-family:"Times New Roman",serif'> </span><span style='font-size:9.0pt; font-family:"Times New Roman",serif'>Причинява сплайсинг дефект, водещ до </span><span lang="BG" style='font-size:9.0pt;font-family:"Times New Roman",serif'>наличие на</span><span style='font-size:9.0pt;font-family:"Times New Roman",serif'> малко количество CFTR белтък на клетъчната повърхност </span><span lang="BG" style='font-size:9.0pt;font-family:"Times New Roman",serif'>или липсата му</span><span lang="BG" style='font-size:9.0pt;font-family:"Times New Roman",serif'>.</span></p><p class="labeltext" style="text-align:justify;text-justify:inter-ideograph"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>В част 2 от проучване 5 средната (SD) абсолютна промяна на процента на прогнозирания ФЕО<sub>1</sub> след 16 седмици (пациенти, рандомизирани на последователността на лечението ивакафтор/плацебо в част 1) на непрекъснато лечение с ивакафтор е 10,4% (13,2%). При визитата за проследяване 4 седмици след приключване на приложението на ивакафтор средната (SD) абсолютна промяна на процента на прогнозирания ФЕО<sub>1</sub> в част 2, седмица 16, е ‑5,9% (9,4%). За пациентите, рандомизирани на последователността на лечението плацебо/ивакафтор в част 1, има допълнителна средна (</span><span style='font-family: "Times New Roman",serif'>SD</span><span lang="BG" style='font-family:"Times New Roman",serif'>) промяна от 3,3% (9,3%) на процента на прогнозирания ФЕО<sub>1</sub> след 16</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>допълнителни седмици лечение с ивакафтор. При визитата за проследяване 4 седмици след приключване на приложението на ивакафтор средната (SD) абсолютна промяна на процента на прогнозирания ФЕО<sub>1</sub> от част 2, седмица 16, е</span><span style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>‑7,4% (5,5%).<u> </u></span></p><p class="labeltext"><u><span lang="BG" style='font-family:"Times New Roman",serif'><span style="text-decoration:none"> </span></span></u></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="BG" style='font-family:"Times New Roman",serif'>Проучване 3: проучване при пациенти с КФ с F508del мутацията на CFTR гена</span></i></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="BG" style='font-family:"Times New Roman",serif'> </span></i></p><p class="MsoNormal"><span lang="BG">Проучване 3 (част</span><span lang="EN-GB"> </span><span lang="BG">A) е 16-седмично, с рандомизиране 4:1, двойносляпо, плацебо-контролирано, паралелно-групово проучване фаза 2 на </span><span lang="BG">ивакафтор (150 mg на всеки 12 часа) при 140 пациенти с КФ на възраст 12 и повече години, които са хомозиготни за мутацията <i>F508del</i> на <i>CFTR</i> гена и са имали ФЕО1 </span><span lang="EN-GB">≥</span><span lang="BG">40% от прогнозирания</span><span lang="BG">.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Средната абсолютна промяна от изходно ниво до седмица 16 в процента на прогнозирания ФЕО<sub>1</sub> (първична крайна точка за ефикасност) е 1,5 процентни точки в групата на ивакафтор и</span><span lang="EN-GB"> </span><span lang="BG">‑0,2 процентни точки в групата на плацебо. Изчислената разлика в лечението за ивакафтор спрямо плацебо е 1,7 процентни точки (95%</span><span lang="EN-GB"> </span><span lang="BG">ДИ</span><span lang="EN-GB"> </span><span lang="BG">‑0,6; 4,1). Тази разлика не е статистически значима (<i>P</i>=0,15). </span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG">Проучване 4: открито разширено проучване</span></i></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG"> </span></i></p><p class="MsoNormal"><span lang="BG" style="color:black">В проучване 4 пациенти, които са завършили лечението в проучвания</span><span lang="EN-GB" style="color:black"> </span><span lang="BG" style="color:black">1 и 2 с плацебо, преминават на ивакафтор, а пациентите на ивакафтор продължават да го получават за най-малко 96 седмици, т.е. продължителността на лечението с ивакафтор е най-малко 96 седмици за пациентите в групата на плацебо/ивакафтор и най-малко 144 седмици за пациентите в групата на ивакафтор/ивакафтор.</span></p><p class="MsoNormal"><span lang="BG" style="color:black"> </span></p><p class="MsoNormal"><span lang="BG" style="color:black">Сто четиридесет и четири (144) пациенти от проучване</span><span lang="EN-GB" style="color:black"> </span><span lang="BG" style="color:black">1 са прехвърлени в проучване 4, 67 в групата на плацебо/ивакафтор и 77 в групата на ивакафтор/ивакафтор. Четиридесет и осем (48) пациенти от проучване 2 са прехвърлени в проучване</span><span lang="EN-GB" style="color:black"> </span><span lang="BG" style="color:black">4, 22 в групата на плацебо/ивакафтор и 26 в групата на ивакафтор/ивакафтор.</span></p><p class="MsoNormal"><span lang="BG" style="color:black"> </span></p><p class="MsoNormal"><span lang="BG">Таблица</span><span lang="EN-GB"> </span>6<span lang="BG"> показва резултатите от средната (SD) абсолютна промяна в процента на прогнозирания ФЕО<sub>1</sub> и за двете групи пациенти. За пациентите от групата на плацебо/ивакафтор процентът на прогнозирания ФЕО<sub>1</sub> на изходно ниво е този от проучване 4, а за пациентите от групата на ивакафтор/ивакафтор стойността на изходно ниво е тази от проучвания 1 и 2.</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif; color:black'> </span></p><p class="labeltext" style="margin-bottom:6.0pt;page-break-after:avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'>Таблица </span></b><b><span style='font-family:"Times New Roman",serif'>6</span></b><b><span lang="BG" style='font-family:"Times New Roman",serif'>: Ефект на ивакафтор върху процента на прогнозирания ФЕО<sub>1</sub></span></b><span lang="BG" style='font-family: "Times New Roman",serif'> </span><b><span lang="BG" style='font-family:"Times New Roman",serif'>в проучване 4</span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="border-collapse:collapse;border:none"> <tr> <td style="width:99.85pt;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="133"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Първоначално   проучване и   група за   лечение</span></b></p> </td> <td style="width:143.45pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="191"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="BG">Продължителност   на   лечението с   ивакафтор (седмици)</span></b></p> </td> <td colspan="2" style="width:209.85pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="280"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="BG">Абсолютна   промяна от   изходно   ниво в процента   на   прогнозирания   ФЕО<sub>1 </sub>(процентни   точки)</span></b></p> </td> </tr> <tr> <td style="width:99.85pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="133"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG"> </span></b></p> </td> <td style="width:143.45pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="191"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="BG"> </span></b></p> </td> <td style="width:67.0pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="BG">N</span></b></p> </td> <td style="width:142.85pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="190"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="BG">Средно (SD)</span></b></p> </td> </tr> <tr> <td colspan="4" style="width:453.15pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="604"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Проучване</span></b><b><span lang="EN-GB"> </span></b><b><span lang="BG">1</span></b></p> </td> </tr> <tr> <td style="width:99.85pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="133"> <p class="MsoNormal" style="margin-left:28.35pt;page-break-after:avoid"><b><span lang="BG">Ивакафтор</span></b></p> </td> <td style="width:143.45pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" width="191"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">48<sup>*</sup></span></p> </td> <td style="width:67.0pt;border-top:none;border-left:none;border-bottom:   solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">77</span></p> </td> <td style="width:142.85pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" width="190"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">9,4 (8,3)</span></p> </td> </tr> <tr> <td style="width:99.85pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="133"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG"> </span></b></p> </td> <td style="width:143.45pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" width="191"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">144</span></p> </td> <td style="width:67.0pt;border-top:none;border-left:none;border-bottom:   solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">72</span></p> </td> <td style="width:142.85pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" width="190"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">9,4 (10,8)</span></p> </td> </tr> <tr> <td style="width:99.85pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="133"> <p class="MsoNormal" style="margin-left:28.35pt;page-break-after:avoid"><b><span lang="BG">Плацебо</span></b></p> </td> <td style="width:143.45pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" width="191"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">0<sup>*</sup></span></p> </td> <td style="width:67.0pt;border-top:none;border-left:none;border-bottom:   solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">67</span></p> </td> <td style="width:142.85pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" width="190"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">-1,2 (7,8)<sup><span style="color:#1F497D">†</span></sup></span></p> </td> </tr> <tr> <td style="width:99.85pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="133"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG"> </span></b></p> </td> <td style="width:143.45pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" width="191"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">96</span></p> </td> <td style="width:67.0pt;border-top:none;border-left:none;border-bottom:   solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">55</span></p> </td> <td style="width:142.85pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" width="190"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">9,5 (11,2)</span></p> </td> </tr> <tr> <td colspan="4" style="width:453.15pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="604"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Проучване</span></b><b><span lang="EN-GB"> </span></b><b><span lang="BG">2</span></b></p> </td> </tr> <tr> <td style="width:99.85pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="133"> <p class="MsoNormal" style="margin-left:28.35pt;page-break-after:avoid"><b><span lang="BG">Ивакафтор</span></b></p> </td> <td style="width:143.45pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" width="191"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">48<sup>*</sup></span></p> </td> <td style="width:67.0pt;border-top:none;border-left:none;border-bottom:   solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">26</span></p> </td> <td style="width:142.85pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" width="190"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">10,2 (15,7)</span></p> </td> </tr> <tr> <td style="width:99.85pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="133"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG"> </span></b></p> </td> <td style="width:143.45pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" width="191"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">144</span></p> </td> <td style="width:67.0pt;border-top:none;border-left:none;border-bottom:   solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">25</span></p> </td> <td style="width:142.85pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" width="190"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">10,3 (12,4)</span></p> </td> </tr> <tr> <td style="width:99.85pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="133"> <p class="MsoNormal" style="margin-left:28.35pt;page-break-after:avoid"><b><span lang="BG">Плацебо</span></b></p> </td> <td style="width:143.45pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" width="191"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">0<sup>*</sup></span></p> </td> <td style="width:67.0pt;border-top:none;border-left:none;border-bottom:   solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">22</span></p> </td> <td style="width:142.85pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" width="190"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">-0,6 (10,1)<sup><span style="color:#1F497D">†</span></sup></span></p> </td> </tr> <tr> <td style="width:99.85pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="133"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG"> </span></b></p> </td> <td style="width:143.45pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" width="191"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">96</span></p> </td> <td style="width:67.0pt;border-top:none;border-left:none;border-bottom:   solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt" width="89"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">21</span></p> </td> <td style="width:142.85pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" width="190"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="BG">10,5 (11,5)</span></p> </td> </tr> </table><p class="MsoNormal" style="margin-top:6.0pt;margin-right:0in;margin-bottom:0in; margin-left:9.05pt;margin-bottom:.0001pt;text-indent:-9.05pt;page-break-after: avoid"><sup><span lang="BG" style="font-size:9.0pt">*</span></sup><span lang="BG" style="font-size:9.0pt">   Лечението се извършва по време на заслепено, контролирано, 48-седмично проучване фаза</span><span lang="EN-GB" style="font-size:9.0pt"> </span><span lang="BG" style="font-size:9.0pt">3.</span></p><p class="MsoNormal"><sup><span lang="BG" style="font-size:9.0pt">†</span></sup><span lang="BG" style="font-size:9.0pt">  Промяна от изходно ниво на предишното проучване след 48</span><span lang="EN-GB" style="font-size:9.0pt"> </span><span lang="BG" style="font-size:9.0pt">седмици лечение с плацебо.</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif; color:black'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif; color:black'>Когато средната (SD) абсолютна промяна в процента на прогнозирания ФЕО<sub>1</sub> бъде сравнена на изходно ниво при проучване</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="RU" style='font-family:"Times New Roman",serif'>4</span><span lang="RU" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="RU" style='font-family:"Times New Roman",serif'>за пациентите в групата на ивакафтор/ивакафтор (</span><span style='font-family:"Times New Roman",serif'>n</span><span lang="RU" style='font-family:"Times New Roman",serif'>=72), които са п</span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>рехвърлени от проучване</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>1, средната (SD) абсолютна промяна в процента на прогнозирания ФЕО<sub>1</sub> е 0,0% (9,05), докато за пациентите в групата на ивакафтор/ивакафтор (n=25), прехвърлени от проучване</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>2, тази цифра е 0,6% (9,1). Това показва, че пациентите в групата на ивакафтор/ивакафтор запазват подобрението, наблюдавано на седмица</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>48 от първоначалното проучване (ден</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>0 до седмица</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>48), в процента на прогнозирания ФЕО<sub>1</sub> до седмица</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>144. Няма допълнителни подобрения в проучване</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>4 (седмица</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>48 до седмица</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>144).</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif; color:black'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif; color:black'>За пациентите в групата на плацебо/ивакафтор от проучване</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>1 честотата на пулмоналните екзацербации</span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>на годишна база е по-висока в първоначалното проучване, когато пациентите са на плацебо (1,34 събития/година), отколкото при последващото проучване</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>4, когато пациентите са прехвърлени на ивакафтор (0,48</span><span lang="EN-GB" style='font-family:"Times New Roman",serif; color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif; color:black'>събития/година от ден</span><span lang="EN-GB" style='font-family: "Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>1 до седмица</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>48 и 0,67</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>събития/година от седмица</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>48 до 96). За пациентите в групата на ивакафтор/ивакафтор от проучване</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>1 честотата на пулмоналните екзацербации на годишна база е 0,57</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>събития/година от ден</span><span lang="EN-GB" style='font-family: "Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>1 до седмица</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>48, когато пациентите са на ивакафтор. Когато те са прехвърлени в проучване</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>4, честотата на пулмоналните екзацербации на годишна база е 0,91</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>събития/година от ден</span><span lang="EN-GB" style='font-family: "Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>1 до седмица</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>48 и 0,77</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>събития/година от седмица 48 до 96.</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif; color:black'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif; color:black'>За пациенти</span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>те</span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>, прехвърлени от проучване</span><span lang="EN-GB" style='font-family:"Times New Roman",serif;color:black'> </span><span lang="BG" style='font-family:"Times New Roman",serif;color:black'>2, броят на събитията е като цяло малък.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG">Проучване</span></i><i><span lang="EN-GB"> </span></i><i><span lang="BG">6: проучване при пациенти с КФ с </span></i><i>R</i><i><span lang="BG">117</span></i><i>H</i><i><span lang="BG"> мутация на </span></i><i>CFTR</i><i><span lang="BG"> гена </span></i></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">В проучване 6 са оценени 69</span> <span lang="BG">пациенти на възраст 6</span> <span lang="BG">и повече години; 53 (76,8%) пациенти имат мутацията </span><i>F</i><i><span lang="BG">508</span></i><i>del</i> <span lang="BG">във втория алел. Потвърденият </span><i>R</i><i><span lang="BG">117</span></i><i>H</i><i> </i><span lang="BG">поли-</span>T<span lang="BG"> вариант е <i>5</i></span><i>T</i><i> </i><span lang="BG">при 38 пациенти </span><span lang="BG">и <i>7</i></span><i>T</i><span lang="BG"> при 16 пациенти</span><span lang="BG">. На изходното ниво средният прогнозиран ФЕО<sub>1</sub> е 73% (диапазон: 32,5% до 105,5%), а средната възраст е 31 години (диапазон: 6 до 68 години). Средната абсолютна промяна от изходното ниво до седмица 24 в процента на прогнозирания ФЕО<sub>1</sub> (първична крайна точка за ефикасност) е 2,57 процентни точки в групата на ивакафтор и 0,46 процентни точки в групата на плацебо. Изчислената разлика в лечението за ивакафтор спрямо плацебо е 2,1 процентни точки (95% ДИ</span><span lang="EN-GB"> </span><span lang="BG">‑1,1;</span><span lang="EN-GB"> </span><span lang="BG">5,4).</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Предварително планиран подгрупов анализ е проведен при пациенти на 18 и повече години (26</span><span lang="EN-GB"> </span><span lang="BG">пациенти на плацебо и 24 на ивакафтор). Лечението с ивакафтор води до средна абсолютна промяна в процента на прогнозирания ФЕО<sub>1</sub> до седмица</span> <span lang="BG">24 с 4,5</span> <span lang="BG">процентни точки в групата на ивакафтор спрямо ‑0,46</span> <span lang="BG">процентни точки в групата на плацебо. Изчислената разлика в лечението за ивакафтор спрямо плацебо е 5,0 процентни точки (95%</span><span lang="EN-GB"> </span><span lang="BG">ДИ</span><span lang="EN-GB"> </span><span lang="BG">1,1;</span><span lang="EN-GB"> </span><span lang="BG">8,8).</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">В подгрупов анализ при пациенти с потвърден </span><i>R</i><i><span lang="BG">117</span></i><i>H</i><i><span lang="BG">-5</span></i><i>T</i><i> </i><span lang="BG">генетичен вариант разликата в </span><span lang="BG">средната абсолютна промяна от изходно ниво до седмица </span><span lang="BG">24 в процента на прогнозирания ФЕО<sub>1</sub> между ивакафтор и плацебо е 5,3% (95% ДИ</span><span lang="EN-GB"> </span><span lang="BG">1,3;</span><span lang="EN-GB"> </span><span lang="BG">9,3). При пациентите с потвърден </span><i>R</i><i><span lang="BG">117</span></i><i>H</i><i><span lang="BG">-7</span></i><i>T</i><i> </i><span lang="BG">генетичен вариант </span><span lang="BG">разликата в лечението между ивакафтор и плацебо е </span><span lang="BG">0,2% (95% ДИ</span><span lang="EN-GB"> </span><span lang="BG">‑8,1;</span><span lang="EN-GB"> </span><span lang="BG">8,5).</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">При вторичните променливи за ефикасност не се наблюдават разлики между леченията с ивакафтор спрямо плацебо по отношение на абсолютната промяна от изходно ниво в </span><span lang="EN-GB">BMI</span><span lang="BG"> на седмица 24 или времето до първата пулмонална екзацербация. Наблюдавани са разлики между леченията по отношение на абсолютната промяна в скора на респираторния домейн на<b> </b></span><span lang="EN-GB">CFQ</span><span lang="BG">‑</span><span lang="EN-GB">R</span><span lang="EN-GB"> </span><span lang="BG">до седмица 24 (разликата между лечението с ивакафтор спрямо плацебо е 8,4 [95%</span><span lang="EN-GB"> </span><span lang="BG">ДИ 2,2; 14,6] точки) и на средната промяна от изходното ниво на хлорните йони в потта (вж. „Фармакодинамични ефекти“).</span></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG"> </span></i></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG">Проучване</span></i><i><span lang="EN-GB"> </span></i><i><span lang="BG">7: проучване при педиатрични пациенти с КФ на възраст от</span></i><i><span lang="EN-GB"> </span></i><i><span lang="BG">2 до под 6</span></i><i><span lang="EN-GB"> </span></i><i><span lang="BG">години с </span></i><i><span lang="EN-GB">G</span></i><i><span lang="BG">551</span></i><i><span lang="EN-GB">D</span></i><i><span lang="BG"> или друга водеща до каналопатия мутация</span></i></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG"> </span></i></p><p class="MsoNormal"><span lang="BG">Фармакокинетичният профил, безопасността и ефикасността на ивакафтор при 34</span><span lang="EN-GB"> </span><span lang="BG">пациенти на възраст от</span><span lang="EN-GB"> </span><span lang="BG">2 до под 6</span><span lang="EN-GB"> </span><span lang="BG">години с КФ, които имат </span><i><span lang="EN-GB">G</span></i><i><span lang="BG">551</span></i><i><span lang="EN-GB">D</span></i><span lang="BG">, </span><i><span lang="EN-GB">G</span></i><i><span lang="BG">1244</span></i><i><span lang="EN-GB">E</span></i><span lang="BG">, </span><i><span lang="EN-GB">G</span></i><i><span lang="BG">1349</span></i><i><span lang="EN-GB">D</span></i><span lang="BG">, </span><i><span lang="EN-GB">G</span></i><i><span lang="BG">178</span></i><i><span lang="EN-GB">R</span></i><span lang="BG">, </span><i><span lang="EN-GB">G</span></i><i><span lang="BG">551</span></i><i><span lang="EN-GB">S</span></i><span lang="BG">, </span><i><span lang="EN-GB">S</span></i><i><span lang="BG">1251</span></i><i><span lang="EN-GB">N</span></i><span lang="BG">, </span><i><span lang="EN-GB">S</span></i><i><span lang="BG">1255</span></i><i><span lang="EN-GB">P</span></i><span lang="BG">, </span><i><span lang="EN-GB">S</span></i><i><span lang="BG">549</span></i><i><span lang="EN-GB">N</span></i><i><span lang="EN-GB"> </span></i><span lang="BG">или </span><i><span lang="EN-GB">S</span></i><i><span lang="BG">549</span></i><i><span lang="EN-GB">R</span></i><span lang="BG"> мутация в </span><i><span lang="EN-GB">CFTR</span></i><span lang="BG"> гена, са оценени при едно 24‑седмично неконтролирано проучване с ивакафтор (пациентите с тегло под 14</span><span lang="EN-GB"> kg</span><span lang="BG"> получават ивакафтор 50</span><span lang="EN-GB"> mg</span><span lang="BG">, а пациентите с тегло 14</span><span lang="EN-GB"> kg</span><span lang="BG"> или повече получават ивакафтор 75</span><span lang="EN-GB"> mg</span><span lang="BG">). Ивакафтор е прилаган перорално на всеки 12</span><span lang="EN-GB"> </span><span lang="BG">часа с храна, съдържаща мазнини, в добавка към предписаните им терапии за КФ.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Пациентите в проучване</span><span lang="EN-GB"> </span><span lang="BG">7 са на възраст от</span><span lang="EN-GB"> </span><span lang="BG">2 до под 6</span><span lang="EN-GB"> </span><span lang="BG">години (средна възраст 3</span><span lang="EN-GB"> </span><span lang="BG">години). Двадесет и шест пациенти от общо включените 34 (76,5%) имат </span><i><span lang="EN-GB">CFTR</span></i><span lang="BG"> генотип </span><i><span lang="EN-GB">G</span></i><i><span lang="BG">551</span></i><i><span lang="EN-GB">D</span></i><i><span lang="BG">/</span></i><i><span lang="EN-GB">F</span></i><i><span lang="BG">508</span></i><i><span lang="EN-GB">del</span></i><i><span lang="BG">,</span></i><span lang="BG"> а само 2</span><span lang="EN-GB"> </span><span lang="BG">пациенти имат не-</span><i><span lang="EN-GB">G</span></i><i><span lang="BG">551</span></i><i><span lang="EN-GB">D</span></i><span lang="BG"> мутация (</span><i><span lang="EN-GB">S</span></i><i><span lang="BG">549</span></i><i><span lang="EN-GB">N</span></i><span lang="BG">). Средното количество (</span><span lang="EN-GB">SD</span><span lang="BG">) хлорни йони в потта на изходно ниво (</span><span lang="EN-GB">n</span><span lang="BG">=25) е 97,88</span><span lang="EN-GB"> mmol</span><span lang="BG">/</span><span lang="EN-GB">l</span><span lang="BG"> (14,00). Средната стойност (</span><span lang="EN-GB">SD</span><span lang="BG">) на фекална еластаза‑1 на изходно ниво (</span><span lang="EN-GB">n</span><span lang="BG">=27) е 28</span><span lang="EN-GB"> </span><span lang="BG">µ</span><span lang="EN-GB">g</span><span lang="BG">/</span><span lang="EN-GB">g </span><span lang="BG">(95).</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Първичната крайна точка за безопасност е оценена през седмица</span><span lang="EN-GB"> </span><span lang="BG">24 (вж. точка 4.8). Оценените вторични и експлораторни крайни точки за ефикасност са абсолютна промяна от изходно ниво на хлорните йони в потта за 24</span><span lang="EN-GB"> </span><span lang="BG">седмици лечение, абсолютна промяна от изходно ниво на теглото, индекса на телесната маса (</span><span lang="EN-GB">BMI</span><span lang="BG">) и ръста (подкрепени от </span><span lang="EN-GB">z</span><span lang="BG">‑скорове за теглото, </span><span lang="EN-GB">BMI</span><span lang="BG"> и ръста) на 24</span><span lang="EN-GB"> </span><span lang="BG">седмици от лечението и измервания на функцията на панкреаса като например фекална еластаза‑1. Има данни за процента на прогнозирания </span><span lang="EN-GB">FEV</span><sub><span lang="BG">1</span></sub><span lang="BG"> (експлораторна крайна точка) за 3</span><span lang="EN-GB"> </span><span lang="BG">пациенти в групата на ивакафтор 50</span><span lang="EN-GB"> mg</span><span lang="BG"> и 17</span><span lang="EN-GB"> </span><span lang="BG">пациенти в групата на доза 75</span><span lang="EN-GB"> mg</span><span lang="BG">.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Средната (</span>SD<span lang="BG">) обща (комбинирано за двете групи с приложение на ивакафтор) абсолютна промяна от изходно ниво в </span>BMI<span lang="BG"> на седмица</span> <span lang="BG">24 е 0,32</span> kg<span lang="BG">/</span>m<sup><span lang="BG">2</span></sup><span lang="BG"> (0,54), а средната (</span>SD<span lang="BG">) обща промяна в </span>z<span lang="BG">‑скора за </span>BMI <span lang="BG">за възрастта е 0,37 (0,42). Средната (</span>SD<span lang="BG">) обща промяна в </span>z<span lang="BG">‑скора за ръст за възрастта е ‑0,01 (0,33). Средната (</span>SD<span lang="BG">) обща промяна от изходно ниво във фекалната еластаза‑1 (</span>n<span lang="BG">=27) е 99,8</span> <span lang="BG">µ</span>g<span lang="BG">/</span>g<span lang="BG"> (138,4). Шест</span><span lang="EN-GB"> </span><span lang="BG">пациенти с начални нива под 200 </span>μg<span lang="BG">/</span>g<span lang="BG"> постигат, на седмица</span><span lang="EN-GB"> </span><span lang="BG">24, ниво ≥</span> <span lang="BG">200</span><span lang="EN-GB"> </span>μg<span lang="BG">/</span>g<span lang="BG">. Средната (</span>SD<span lang="BG">) обща промяна в процента на прогнозирания </span>FEV<sub><span lang="BG">1</span></sub><span lang="BG"> от изходно ниво на седмица</span> <span lang="BG">24 (експлораторна крайна точка) е 1,8 (17,81). </span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="RU">Проучване</span></i><i><span lang="EN-GB"> </span></i><i><span lang="RU">8: проучване </span></i><i><span lang="BG">при</span></i><i><span lang="BG"> </span></i><i><span lang="BG">педиатрични</span></i><i><span lang="BG"> </span></i><i><span lang="RU">пациенти </span></i><i><span lang="RU">с КФ </span></i><i><span lang="RU">на възраст под 24</span></i><i><span lang="EN-GB"> </span></i><i><span lang="RU">месеца</span></i></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="RU"> </span></i></p><p class="documenttext" style="margin-bottom:0in"><span lang="BG" style='font-size: 11.0pt;font-family:"Times New Roman",serif'>Фармакокинетичният профил</span><span lang="RU" style='font-size:11.0pt;font-family:"Times New Roman",serif'>, безопасност</span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>та и </span><span lang="RU" style='font-size:11.0pt;font-family:"Times New Roman",serif'>ефикасност</span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>та на ивакафтор при </span><span lang="RU" style='font-size:11.0pt;font-family: "Times New Roman",serif'>пациенти с КФ на възраст от 6 до под 24</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'> </span><span lang="RU" style='font-size:11.0pt;font-family:"Times New Roman",serif'>месеца </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>са оценени в завършена кохорта от</span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'> </span><span lang="RU" style='font-size:11.0pt;font-family:"Times New Roman",serif'>пациенти </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>в едно продължаващо</span><span lang="RU" style='font-size:11.0pt;font-family:"Times New Roman",serif'> 24‑</span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>седмично</span><span lang="RU" style='font-size:11.0pt;font-family:"Times New Roman",serif'>, </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>открито клинично </span><span lang="RU" style='font-size:11.0pt;font-family:"Times New Roman",serif'>проучване </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>фаза 3 при </span><span lang="RU" style='font-size:11.0pt;font-family: "Times New Roman",serif'>пациенти на възраст под 24</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'> </span><span lang="RU" style='font-size:11.0pt;font-family:"Times New Roman",serif'>месеца (</span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>п</span><span lang="RU" style='font-size:11.0pt;font-family:"Times New Roman",serif'>роучване</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'> </span><span lang="RU" style='font-size:11.0pt;font-family:"Times New Roman",serif'>8).</span></p><p class="MsoNormal"><span lang="RU"> </span></p><p class="MsoNormal"><span lang="BG">В част Б от п</span><span lang="RU">роучване</span><span lang="EN-GB"> </span><span lang="RU">8 </span><span lang="BG">са включени </span><span lang="RU">19</span><span lang="EN-GB"> </span><span lang="RU">пациенти на възраст от 12 до под 24</span><span lang="EN-GB"> </span><span lang="RU">месеца (</span><span lang="BG">средна възраст</span><span lang="RU"> 15</span><span lang="BG">,</span><span lang="RU">2</span><span lang="EN-GB"> </span><span lang="RU">месеца </span><span lang="BG">на изходно ниво</span><span lang="RU">), </span><span lang="BG">като </span><span lang="RU">18</span><span lang="EN-GB"> </span><span lang="RU">пациенти </span><span lang="BG">завършват </span><span lang="RU">24‑</span><span lang="BG">седмичния период на лечение, 11 пациенти на възраст от 6 до под 12 месеца (средна възраст 9,0</span><span lang="EN-GB"> </span><span lang="BG">месеца на изходно ниво), като всичките 11 пациенти завършват 24-седмичния период на лечение, и 6 пациенти на възраст от 4 месеца до под 6 месеца (средна възраст 4,5 месеца на изходното ниво), като всичките 6 пациенти завършват 24-седмичния период на лечение</span><span lang="RU">. Пациенти</span><span lang="BG">те получават ивакафтор 25 </span><span lang="EN-GB">mg</span><span lang="RU">, 50</span><span lang="EN-GB"> mg</span><span lang="EN-GB"> </span><span lang="BG">или</span><span lang="RU"> 75</span><span lang="EN-GB"> mg</span><span lang="EN-GB"> </span><span lang="BG">в зависимост от възрастта и теглото им при всяка визита от </span><span lang="RU">проучване</span><span lang="BG">то </span><span lang="RU">(</span><span lang="BG">вж. точка </span><span lang="RU">4.2). </span><span lang="BG">Ивакафтор е прилаган перорално на всеки</span><span lang="RU"> 12</span><span lang="EN-GB"> </span><span lang="BG">часа с храна, съдържаща мазнини. Пациентите продължават своите предписани стандартни терапии за КФ</span><span lang="RU">.</span></p><p class="MsoNormal"><span lang="RU"> </span></p><p class="MsoNormal"><span lang="BG">В част Б от п</span><span lang="RU">роучване</span><span lang="EN-GB"> </span><span lang="RU">8 </span><span lang="BG">първичната крайна точка за </span><span lang="RU">безопасност </span><span lang="BG">е оценена в продължение на </span><span lang="RU">24</span><span lang="EN-GB"> </span><span lang="RU">седмици (</span><span lang="BG">вж. точка</span><span lang="EN-GB"> </span><span lang="RU">4.8). Вторичните крайни точки са оценка на фармакокинетиката</span><span lang="BG"> и абсолютната промяна от изходно ниво на хлорните йони в потта в продължение на </span><span lang="RU">24</span><span lang="BG">‑</span><span lang="RU">седми</span><span lang="BG">чното лечение </span><span lang="RU">(</span><span lang="BG">вж. „Фармакодинамични ефекти“</span><span lang="RU">). </span><span lang="BG">Третичните</span><span lang="BG"> </span><span lang="RU">крайни точки </span><span lang="BG">включват мерки за </span><span lang="RU">ефикасност</span><span lang="RU"> </span><span lang="BG">като ф</span><span lang="RU">екална еластаза‑1 и </span><span lang="BG">параметри на растежа</span><span lang="RU">. </span></p><p class="MsoNormal"><span lang="RU"> </span></p><p class="tabletextleftjustified" style="margin:0in"><span lang="BG" style='font-family:"Times New Roman",serif'>При</span><span lang="RU" style='font-family:"Times New Roman",serif'> пациентите </span><span lang="BG" style='font-family:"Times New Roman",serif'>на възраст от 4 до под 24 месеца</span><span lang="RU" style='font-family:"Times New Roman",serif'>, за които са известни стойностите и на изходно ниво, и на седмица 24, с</span><span lang="BG" style='font-family:"Times New Roman",serif'>редните </span><span lang="RU" style='font-family:"Times New Roman",serif'>(</span><span style='font-family:"Times New Roman",serif'>SD</span><span lang="RU" style='font-family:"Times New Roman",serif'>) </span><span lang="BG" style='font-family:"Times New Roman",serif'>z-скорове за тегло за възрастта, ръст за възрастта и тегло за ръста са дадени в Таблица </span><span style='font-family:"Times New Roman",serif'>7</span><span lang="RU" style='font-family:"Times New Roman",serif'>.</span></p><p class="MsoNormal"><span lang="RU"> </span></p><p class="MsoNormal" style="margin-top:0in;margin-right:0in;margin-bottom:6.0pt; margin-left:56.7pt;text-indent:-56.7pt;page-break-after:avoid"><b><span lang="RU">Таблица </span></b><b>7</b><b><span lang="RU">: Ефект на ивакафтор върху параметрите на растежа при пациенти на </span></b><b><span lang="BG">възраст от 4 до под </span></b><b><span lang="BG">24</span></b><b><span lang="BG"> месеца със стойности на изходно ниво и на седмица 24</span></b></p><table border="1" cellpadding="0" cellspacing="0" class="TableGrid1" style="width:450.9pt;border-collapse:collapse;border:none" width="601"> <tr> <td rowspan="2" style="width:120.25pt;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" width="160"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Параметър</span></b></p> </td> <td rowspan="2" style="width:60.65pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="81"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="BG">Брой   пациенти</span></b></p> </td> <td colspan="2" style="width:1.75in;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" width="168"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="BG">Изходно   ниво</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB"> </span></b></p> </td> <td colspan="2" style="width:2.0in;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" width="192"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="BG">Абсолютна   промяна на   седмица </span></b><b><span lang="EN-GB">24</span></b></p> </td> </tr> <tr> <td style="width:58.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="78"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="BG">Средна   стойност</span></b><b><span lang="EN-GB">(SD)</span></b></p> </td> <td style="width:67.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="BG">Медиана</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">(min, max)</span></b></p> </td> <td style="width:1.0in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="96"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="BG">Средна   стойност </span></b><b><span lang="EN-GB">(SD)</span></b></p> </td> <td style="width:1.0in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="96"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="BG">Медиана</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB">(min, max)</span></b></p> </td> </tr> <tr> <td style="width:120.25pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="160"> <p class="tabletextleftjustified" style="margin:0in;page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>z-скор   тегло-за-възрастта</span></p> </td> <td style="width:60.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="81"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">35</span></p> </td> <td style="width:58.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="78"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">0</span><span lang="BG">,17</span><span lang="EN-GB"> (0</span><span lang="BG">,85</span><span lang="EN-GB">)</span></p> </td> <td style="width:67.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">0,2</span><span lang="BG">0</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">[-1</span><span lang="BG">,92;</span><span lang="EN-GB">   1</span><span lang="BG">,</span><span lang="EN-GB">79]</span></p> </td> <td style="width:1.0in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="96"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">0,</span><span lang="BG">3</span><span lang="EN-GB">3</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">(0,</span><span lang="BG">53</span><span lang="EN-GB">)</span></p> </td> <td style="width:1.0in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="96"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">0,</span><span lang="BG">26</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">[-0</span><span lang="BG">,</span><span lang="EN-GB">54</span><span lang="BG">;</span><span lang="EN-GB"> 1</span><span lang="BG">,</span><span lang="EN-GB">63]</span></p> </td> </tr> <tr> <td style="width:120.25pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="160"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">z-скор   ръст-за-възрастта</span></p> </td> <td style="width:60.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="81"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">34</span></p> </td> <td style="width:58.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="78"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">0</span><span lang="BG">,06</span><span lang="EN-GB"> (</span><span lang="BG">1,03</span><span lang="EN-GB">) </span></p> </td> <td style="width:67.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">0</span><span lang="BG">,</span><span lang="EN-GB">1</span><span lang="BG">2</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">[-1</span><span lang="BG">,99;</span><span lang="BG"> </span><span lang="BG">2,79</span><span lang="EN-GB">]</span></p> </td> <td style="width:1.0in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="96"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">0,</span><span lang="BG">32</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">(0,9</span><span lang="BG">2</span><span lang="EN-GB">)</span></p> </td> <td style="width:1.0in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="96"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">0</span><span lang="BG">,</span><span lang="EN-GB">4</span><span lang="BG">7</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB">[-1</span><span lang="BG">,</span><span lang="EN-GB">81;   3</span><span lang="BG">,</span><span lang="EN-GB">38]</span></p> </td> </tr> <tr> <td style="width:120.25pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="160"> <p class="MsoNormal"><span lang="BG">z-скор тегло   за ръста</span></p> </td> <td style="width:60.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="81"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">34</span></p> </td> <td style="width:58.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="78"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB" style="color:black">0</span><span lang="BG" style="color:black">,24</span><span lang="EN-GB" style="color:black"> (</span><span lang="BG" style="color:black">1</span><span lang="EN-GB" style="color:black">,</span><span lang="BG" style="color:black">01</span><span lang="EN-GB" style="color:black">)</span></p> </td> <td style="width:67.5pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="90"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB" style="color:black">0</span><span lang="BG" style="color:black">,26</span></p> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB" style="color:black">[-1</span><span lang="BG" style="color:black">,72</span><span lang="EN-GB" style="color:black">; 2</span><span lang="BG" style="color:black">,</span><span lang="EN-GB" style="color:black">16]</span></p> </td> <td style="width:1.0in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="96"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB" style="color:black">0,</span><span lang="BG" style="color:black">24</span></p> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB" style="color:black">(0,9</span><span lang="BG" style="color:black">8</span><span lang="EN-GB" style="color:black">)</span></p> </td> <td style="width:1.0in;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="96"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB" style="color:black">0</span><span lang="BG" style="color:black">,2</span><span lang="EN-GB" style="color:black">9</span></p> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB" style="color:black">[-2</span><span lang="BG" style="color:black">,</span><span lang="EN-GB" style="color:black">04</span><span lang="BG" style="color:black">;</span><span lang="EN-GB" style="color:black"> 2</span><span lang="BG" style="color:black">,</span><span lang="EN-GB" style="color:black">22]</span></p> </td> </tr> </table><p class="MsoNormal"><span lang="EN-GB"> </span></p><p class="documenttext" style="margin-bottom:0in"><span lang="BG" style='font-size: 11.0pt;font-family:"Times New Roman",serif'>При</span><span lang="RU" style='font-size:11.0pt;font-family:"Times New Roman",serif'> пациентите</span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'> на възраст от 4 до под 24 месеца</span><span lang="RU" style='font-size:11.0pt;font-family:"Times New Roman",serif'>, за които са известни стойностите и </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>на изходно ниво, </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>и</span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'> </span><span lang="RU" style='font-size:11.0pt;font-family:"Times New Roman",serif'>на </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>седмица</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'> </span><span lang="RU" style='font-size:11.0pt;font-family:"Times New Roman",serif'>24, 18 пациенти са с панкреатична недостатъчност</span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'> на изходно ниво (дефинирана като </span><span lang="RU" style='font-size:11.0pt; font-family:"Times New Roman",serif'>фекална еластаза-1 &lt;200</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'> </span><span lang="RU" style='font-size:11.0pt;font-family:"Times New Roman",serif'>µ</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>g</span><span lang="RU" style='font-size:11.0pt;font-family:"Times New Roman",serif'>/</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>g</span><span lang="RU" style='font-size:11.0pt;font-family:"Times New Roman",serif'>) </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>със средни</span><span lang="RU" style='font-size:11.0pt;font-family:"Times New Roman",serif'> (</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>SD</span><span lang="RU" style='font-size:11.0pt;font-family:"Times New Roman",serif'>) </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>стойности на </span><span lang="RU" style='font-size:11.0pt;font-family:"Times New Roman",serif'>фекалната еластаза-1 </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>на изходно ниво </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>и на седмица</span><span style='font-size: 11.0pt;font-family:"Times New Roman",serif'> </span><span lang="RU" style='font-size:11.0pt;font-family:"Times New Roman",serif'>24 съответно 25</span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>,</span><span lang="RU" style='font-size:11.0pt;font-family:"Times New Roman",serif'>5 µ</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>g</span><span lang="RU" style='font-size:11.0pt;font-family:"Times New Roman",serif'>/</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>g</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'> <span lang="RU">(27,6) </span></span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>и </span><span lang="RU" style='font-size:11.0pt;font-family:"Times New Roman",serif'>253,6 µ</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>g</span><span lang="RU" style='font-size:11.0pt;font-family:"Times New Roman",serif'>/</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>g</span><span lang="RU" style='font-size:11.0pt;font-family:"Times New Roman",serif'> (128</span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>,</span><span lang="RU" style='font-size:11.0pt;font-family:"Times New Roman",serif'>3) (</span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>средна</span><span lang="RU" style='font-size:11.0pt;font-family:"Times New Roman",serif'> [</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>SD</span><span lang="RU" style='font-size:11.0pt;font-family:"Times New Roman",serif'>] абсолютна промяна 228</span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>,</span><span lang="RU" style='font-size:11.0pt;font-family:"Times New Roman",serif'>41 µ</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>g</span><span lang="RU" style='font-size:11.0pt;font-family:"Times New Roman",serif'>/</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>g</span><span lang="RU" style='font-size:11.0pt;font-family:"Times New Roman",serif'> [128</span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>,</span><span lang="RU" style='font-size:11.0pt;font-family:"Times New Roman",serif'>3]). </span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>Резултатите са сходни във възрастовите кохорти от 12 до под 24 месеца, от 6 до под 12 месеца и от 4 месеца до под 6 месеца.</span></p><p class="MsoNormal"><span lang="BG" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Педиатрична популация"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal"><span lang="BG">Европейската агенция по лекарствата отлага задължението за предоставяне на резултатите от проучванията с </span><span lang="EN-GB">Kalydeco</span><span lang="EN-GB"> </span><span lang="BG">в една или повече подгрупи на педиатричната популация с кистозна фиброза (вж. точка 4.2 за информация относно употреба в педиатрията).</span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.2     Фармакокинетични свойства"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal"><span lang="BG">Фармакокинетиката на ивакафтор е сходна при здрави възрастни доброволци и пациенти с КФ.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">След пероралното приложение на единична доза от 150 mg на здрави доброволци след хранене средните стойности (±SD) за AUC и C<sub>max</sub> са съответно 10</span><span lang="EN-GB"> </span><span lang="BG">600 (5260) ng*час/m</span><span lang="EN-GB">l</span><span lang="BG"> и 768 (233) ng/m</span><span lang="EN-GB">l</span><span lang="BG">. След приложение на всеки 12 часа стационарните плазмени концентрации на ивакафтор се достигат между ден 3 до ден 5, със съотношение на кумулиране от 2,2 до 2,9.</span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Абсорбция"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="labeltextheading"><u><span lang="BG" style='font-family:"Times New Roman",serif; font-style:normal'><span style="text-decoration:none"> </span></span></u></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>След многократно перорално приложение на ивакафтор експозицията на ивакафтор обикновено нараства с дозата от 25 mg на всеки 12 часа до 450 mg на всеки 12 часа. Експозицията на ивакафтор нараства приблизително 2,5 до 4 пъти, когато се дава с храна, съдържаща мазнини. Ето защо ивакафтор трябва да се прилага с храна, съдържаща мазнини. Медианата (диапазона) на t<sub>max</sub> е приблизително 4,0 (3,0; 6,0) часа след хранене.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Гранулите ивакафтор (2</span><span lang="EN-GB"> x </span><span lang="BG">75</span><span lang="EN-GB"> mg</span><span lang="BG"> сашета) имат подобна бионаличност, както и таблетката от 150</span><span lang="EN-GB"> mg</span><span lang="BG">, когато се дават със съдържаща мазнини храна на здрави възрастни. Средното геометрично съотношение по метода на най-малките квадрати (90%</span><span lang="EN-GB"> </span><span lang="BG">ДИ) за гранулите в сравнение с таблетките е 0,951 (0,839; 1,08) за </span><span lang="EN-GB">AUC</span><sub><span lang="BG">0-</span></sub><sub><span lang="EN-GB" style="font-family:SimSun">∞</span></sub><span lang="BG"> и 0,918 (0,750; 1,12) за </span><span lang="EN-GB">C<sub>max</sub></span><span lang="BG">. Ефектът на храната върху абсорбцията на ивакафтор е сходен за двете лекарствени форми, т.е. таблетки и гранули.</span></p><p class="MsoNormal"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Разпределение"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Ивакафтор се свързва приблизително 99% с плазмените белтъци, основно с алфа-1-кисел гликопротеин и албумин. Ивакафтор не се свързва с човешките еритроцити.</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>След перорално приложение на ивакафтор 150 mg на всеки 12 часа в продължение на 7 дни при здрави доброволци след хранене средният (±SD) привиден обем на разпределение е 353 (122) </span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>l</span><span lang="BG" style='font-family:"Times New Roman",serif'>.</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Биотрансформация"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="labeltext" style="page-break-after:avoid"><i><u><span lang="BG" style='font-family:"Times New Roman",serif'><span style="text-decoration:none"> </span></span></u></i></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Ивакафтор се метаболизира в значителна степен при хора. <i>In</i></span><i><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span></i><i><span lang="BG" style='font-family:"Times New Roman",serif'>vitro</span></i><span lang="BG" style='font-family:"Times New Roman",serif'> и <i>in</i></span><i><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span></i><i><span lang="BG" style='font-family:"Times New Roman",serif'>vivo</span></i><span lang="BG" style='font-family:"Times New Roman",serif'> данните показват, че ивакафтор се метаболизира основно чрез CYP3A. M1 и M6 са двата основни метаболита на ивакафтор при хора. M1 притежава приблизително една шеста от мощта на ивакафтор и се счита за фармакологично активен. M6 притежава по-малко от една петдесета от мощта на ивакафтор и не се счита за фармакологично активен.</span></p><p class="MsoNormal"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Ефектът, който се получава върху експозицията на ивакафтор при </span><span lang="FR" style='font-family:"Times New Roman",serif'>CYP3A4*22 </span><span lang="BG" style='font-family:"Times New Roman",serif'>хетерозиготен генотип, е подобен на този, който се получава при едновременното приложение на слаб инхибитор на </span><span lang="FR" style='font-family:"Times New Roman",serif'>CYP3A4</span><span lang="BG" style='font-family:"Times New Roman",serif'>, което няма клинична значимост. Не се счита за необходимо да се коригира дозата на ивакафтор. Ефектът се очаква да бъде по-силно изразен при пациентите с </span><span lang="FR" style='font-family:"Times New Roman",serif'>CYP3A4*22 </span><span lang="BG" style='font-family:"Times New Roman",serif'>хомозиготен генотип. Липсват обаче данни за такива пациенти.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Елиминиране"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>След перорално приложение при здрави доброволци основната част от ивакафтор (87,8%) се елиминира с фецеса след метаболитно преобразуване. На основните метаболити M1 и M6 се пада приблизително 65% от общата елиминирана доза: 22% като M1 и 43% като M6. Има незначителна екскреция с урината на ивакафтор като непроменено изходно вещество. Привидният терминален полуживот е приблизително 12 часа след приложение на единична доза след хранене. Привидният клирънс (CL/F) на ивакафтор е сходен при здрави лица и пациенти с КФ. Средната стойност (±SD) на CL/F за единична доза 150 mg е 17,3 (8,4) </span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>l</span><span lang="BG" style='font-family:"Times New Roman",serif'>/час при здрави лица.</span></p><p class="MsoNormal"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Линейност/нелинейност"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="labeltext" style="page-break-after:avoid"><u><span lang="BG" style='font-family:"Times New Roman",serif'><span style="text-decoration:none"> </span></span></u></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Фармакокинетиката на ивакафтор обикновено е линейна по отношение на времето или дозата</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>,</span><span lang="BG" style='font-family:"Times New Roman",serif'> варираща от 25 mg до 250 mg.</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext" style="page-break-after:avoid"><u><span lang="BG" style='font-family:"Times New Roman",serif'>Специални популации</span></u></p><p class="labeltext" style="page-break-after:avoid"><u><span lang="BG" style='font-family:"Times New Roman",serif'><span style="text-decoration:none"> </span></span></u></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="BG" style='font-family:"Times New Roman",serif'>Чернодробно увреждане</span></i></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="BG" style='font-family:"Times New Roman",serif'> </span></i></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>След единична доза от 150 mg ивакафтор възрастните пациенти с умерено нарушена чернодробна функция (клас B по Child-Pugh, скор 7 до 9) имат сходна стойност на C<sub>max</sub> на ивакафтор, (средна стойност [±SD] от 735 [331] ng/m</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>l</span><span lang="BG" style='font-family:"Times New Roman",serif'>), но приблизително двукратно увеличение на AUC<sub>0-</sub></span><sub><span style="font-family:SimSun">∞</span></sub><span style='font-family:"Times New Roman",serif'> <span lang="BG">на ивакафтор (средна стойност [±SD] от 16 800 [6140] ng*час/m</span></span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>l</span><span lang="BG" style='font-family:"Times New Roman",serif'>), в сравнение със здрави лица, съответстващи демографски. Симулации за прогнозиране на експозицията в стационарно състояние на ивакафтор показват, че чрез намаляване на дозата от 150 mg на всеки 12 часа на 150 mg веднъж дневно възрастните с умерено чернодробно увреждане биха имали сравними стойности на C<sub>min</sub> в стационарно състояние с тези, получени с доза от 150 mg на всеки 12 часа при възрастни без чернодробно увреждане. Въз основа на тези резултати се препоръчва изменена схема с </span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>Kalydeco</span><span lang="BG" style='font-family:"Times New Roman",serif'> като монотерапия при пациенти с умерено чернодробно увреждане (вж. точка 4.2).</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Въздействието на тежко чернодробно увреждане (клас C по Child-Pugh, скор 10 до 15)</span><span lang="BG" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>върху фармакокинетиката на ивакафтор не е проучено. Величината на повишението на експозицията при тези пациенти е неизвестна, но се очаква да е по-висока, отколкото се наблюдава при пациенти с умерено чернодробно увреждане. Затова употребата на </span><span style='font-family:"Times New Roman",serif'>ивакафтор </span><span lang="BG" style='font-family:"Times New Roman",serif'>при пациенти с тежко чернодробно увреждане не се препоръчва, освен ако ползите не надвишават рисковете (вж. точка 4.2 и точка</span><span lang="EN-GB" style='font-family: "Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>4.4).</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Не се счита, че е необходимо коригиране на дозата при пациенти с леко чернодробно увреждане.</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="BG" style='font-family:"Times New Roman",serif'>Бъбречно увреждане</span></i></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="BG" style='font-family:"Times New Roman",serif'> </span></i></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Не са провеждани фармакокинетични проучвания с ивакафтор при пациенти с бъбречно увреждане. При едно фармакокинетично проучване при хора има минимално елиминиране на ивакафтор и неговите метаболити в урината (само 6,6% от общата радиоактивност се открива в урината). Има незначителна екскреция с урината на ивакафтор като непроменено изходно вещество (по-малко от 0,01% след единична перорална доза от 500 mg). </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Не се препоръчва корекция на дозата при леко и умерено бъбречно увреждане. Препоръчва се обаче повишено внимание при приложение на ивакафтор на пациенти с тежко бъбречно увреждане (креатининов клирънс по-нисък или равен на 30 m</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>l</span><span lang="BG" style='font-family:"Times New Roman",serif'>/min) или терминална бъбречна недостатъчност (вж. точка 4.2 и</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>4.4). </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="BG" style='font-family:"Times New Roman",serif'>Расова принадлежност</span></i></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="BG" style='font-family:"Times New Roman",serif'> </span></i></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Расовата принадлежност няма клинично значим ефект върху ФК на ивакафтор при пациенти от бялата (</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>n</span><span lang="BG" style='font-family:"Times New Roman",serif'>=379) и останалите раси (</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'>n</span><span lang="BG" style='font-family:"Times New Roman",serif'>=29) въз основа на популационен ФК анализ.</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="BG" style='font-family:"Times New Roman",serif'>Пол</span></i></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Фармакокинетичните параметри на ивакафтор са подобни при мъжете и при жените.</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="BG" style='font-family:"Times New Roman",serif'>Старческа възраст</span></i></p><p class="labeltext" style="page-break-after:avoid"><i><span lang="BG" style='font-family:"Times New Roman",serif'> </span></i></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Клиничните проучвания на ивакафтор като монотерапия не включват достатъчен брой пациенти на възраст 65</span><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>и повече години, за да се определи дали фармакокинетичните параметри са подобни на тези при по-младите възрастни.</span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="labeltextheading"><span lang="BG" style='font-family:"Times New Roman",serif'>Педиатрична популация</span></p><p class="labeltextheading"><span lang="BG" style='font-family:"Times New Roman",serif'> </span></p><p class="MsoNormal"><span lang="BG">Прогнозираната експозиция на ивакафтор, основаваща се на наблюдаваните концентрации на ивакафтор при проучвания фаза</span><span lang="EN-GB"> </span><span lang="BG">2 и фаза</span><span lang="EN-GB"> </span><span lang="BG">3, определена с използване на популационен ФК анализ, е представена по възрастови групи в Таблица</span> 8<span lang="BG">.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-bottom:6.0pt;page-break-after:avoid"><b><span lang="BG">Таблица</span></b><b> 8</b><b><span lang="BG">: Средна (</span></b><b>SD</b><b><span lang="BG">) експозиция на ивакафтор по възрастови групи</span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="border-collapse:collapse;border:none"> <thead> <tr style="page-break-inside:avoid;height:23.9pt"> <td style="width:140.1pt;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="187"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Възрастова    група</span></b></p> </td> <td style="width:127.55pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="170"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Доза    </span></b></p> </td> <td style="width:92.4pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="123"> <p class="MsoNormal" style="page-break-after:avoid"><b>C<sub>min, ss</sub>    (ng/ml)</b></p> </td> <td style="width:92.4pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="123"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">AUC<sub>τ,    ss</sub></span></b><b> (</b><b><span lang="BG">ng*час</span></b><b>/ml)</b></p> </td> </tr> </thead> <tr style="page-break-inside:avoid;height:23.9pt"> <td style="width:140.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="187"> <p class="labeltext" style="page-break-after:avoid"><span lang="RU" style='font-family:"Times New Roman",serif'>4- до   под 6-месечни</span></p> <p class="labeltext" style="page-break-after:avoid"><span lang="RU" style='font-family:"Times New Roman",serif'>(≥5</span><span style='font-family:"Times New Roman",serif'> kg</span><span lang="RU" style='font-family:"Times New Roman",serif'>)</span></p> </td> <td style="width:127.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="170"> <p class="MsoNormal"><span lang="BG">2</span><span lang="EN-GB">5 mg </span><span lang="BG">на всеки   12 часа</span></p> </td> <td style="width:92.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="123"> <p class="MsoNormal"><span lang="BG">371 (183)</span></p> </td> <td style="width:92.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="123"> <p class="MsoNormal"><span lang="BG">6480 (2520)</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:23.9pt"> <td style="width:140.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="187"> <p class="labeltext" style="page-break-after:avoid"><span lang="RU" style='font-family:"Times New Roman",serif'>6- до   под 12-месечни</span></p> <p class="labeltext" style="page-break-after:avoid"><span lang="RU" style='font-family:"Times New Roman",serif'>(5</span><span style='font-family:   "Times New Roman",serif'> kg</span><span style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>до</span><span lang="RU" style='font-family:"Times New Roman",serif'> &lt;7</span><span style='font-family:"Times New Roman",serif'> kg</span><span lang="RU" style='font-family:"Times New Roman",serif'>)</span><sup><span style='font-family:"Times New Roman",serif'>*</span></sup></p> </td> <td style="width:127.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="170"> <p class="MsoNormal"><span lang="BG">2</span><span lang="EN-GB">5 mg </span><span lang="BG">на всеки   12 часа</span></p> </td> <td style="width:92.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="123"> <p class="MsoNormal"><span lang="BG">336</span></p> </td> <td style="width:92.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="123"> <p class="MsoNormal"><span lang="BG">5410</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:23.9pt"> <td style="width:140.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="187"> <p class="labeltext" style="page-break-after:avoid"><span lang="RU" style='font-family:"Times New Roman",serif'>6- до   под 12-месечни</span></p> <p class="labeltext" style="page-break-after:avoid"><span lang="RU" style='font-family:"Times New Roman",serif'>(7</span><span style='font-family:   "Times New Roman",serif'> kg</span><span style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>до</span><span lang="RU" style='font-family:"Times New Roman",serif'> &lt;14</span><span style='font-family:"Times New Roman",serif'> kg</span><span lang="RU" style='font-family:"Times New Roman",serif'>)</span></p> </td> <td style="width:127.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="170"> <p class="MsoNormal"><span lang="EN-GB">50 mg </span><span lang="BG">на   всеки 12 часа</span></p> </td> <td style="width:92.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="123"> <p class="MsoNormal"><span lang="BG">508 (252)</span></p> </td> <td style="width:92.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="123"> <p class="MsoNormal"><span lang="BG">9140 (4200)</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:23.9pt"> <td style="width:140.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="187"> <p class="labeltext" style="page-break-after:avoid"><span lang="RU" style='font-family:"Times New Roman",serif'>12</span><span lang="BG" style='font-family:"Times New Roman",serif'>- до   под 24‑месечни</span></p> <p class="MsoNormal"><span lang="RU">(7</span><span lang="EN-GB"> kg</span><span lang="EN-GB"> </span><span lang="BG">до</span><span lang="RU"> &lt;14</span><span lang="EN-GB"> kg</span><span lang="RU">)</span></p> </td> <td style="width:127.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="170"> <p class="MsoNormal"><span lang="EN-GB">50 mg </span><span lang="BG">на   всеки 12 часа</span></p> </td> <td style="width:92.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="123"> <p class="MsoNormal"><span lang="EN-GB">440 (212)</span></p> </td> <td style="width:92.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="123"> <p class="MsoNormal"><span lang="EN-GB">9050 (3050)</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:23.9pt"> <td style="width:140.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="187"> <p class="labeltext" style="page-break-after:avoid"><span lang="RU" style='font-family:"Times New Roman",serif'>12</span><span lang="BG" style='font-family:"Times New Roman",serif'>- до   под 24‑месечни</span></p> <p class="MsoNormal"><span lang="RU">(≥14</span><span lang="EN-GB"> kg</span><span lang="EN-GB"> </span><span lang="BG">до</span><span lang="RU"> &lt;25</span><span lang="EN-GB"> kg</span><span lang="RU">)</span></p> </td> <td style="width:127.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="170"> <p class="MsoNormal"><span lang="EN-GB">75 mg </span><span lang="BG">на   всеки 12 часа</span></p> </td> <td style="width:92.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="123"> <p class="MsoNormal"><span lang="EN-GB">451 (125)</span></p> </td> <td style="width:92.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="123"> <p class="MsoNormal"><span lang="EN-GB">9600 (1800)</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:23.9pt"> <td style="width:140.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="187"> <p class="MsoNormal">2<span lang="BG">- до</span>   5-годишни</p> <p class="MsoNormal">(&lt;14 kg)</p> </td> <td style="width:127.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="170"> <p class="MsoNormal">50 mg <span lang="BG">на   всеки 12 часа</span></p> </td> <td style="width:92.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="123"> <p class="MsoNormal">577 (317)</p> </td> <td style="width:92.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="123"> <p class="MsoNormal">10500 (4260)</p> </td> </tr> <tr style="page-break-inside:avoid;height:23.9pt"> <td style="width:140.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="187"> <p class="MsoNormal"><span lang="RU">2- </span><span lang="BG">до</span><span lang="RU"> 5-годишни</span></p> <p class="MsoNormal"><span lang="RU">(≥14</span> kg <span lang="BG">до</span><span lang="RU"> &lt;25</span> kg<span lang="RU">)</span></p> </td> <td style="width:127.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="170"> <p class="MsoNormal">75 mg <span lang="BG">на   всеки 12 часа</span></p> </td> <td style="width:92.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="123"> <p class="MsoNormal">629 (296)</p> </td> <td style="width:92.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="123"> <p class="MsoNormal">11300 (3820)</p> </td> </tr> <tr style="page-break-inside:avoid;height:23.9pt"> <td style="width:140.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="187"> <p class="MsoNormal"><span lang="RU">6- </span><span lang="BG">до</span><span lang="RU"> 11-годишни</span><span lang="EN-GB"> <sup>†</sup></span></p> <p class="MsoNormal"><span lang="RU">(≥14</span> kg<span lang="RU">   до &lt;25</span> kg<span lang="RU">)</span></p> </td> <td style="width:127.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="170"> <p class="MsoNormal">75 mg <span lang="BG">на   всеки 12 часа</span></p> </td> <td style="width:92.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="123"> <p class="MsoNormal">641 (329)</p> </td> <td style="width:92.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.9pt" valign="top" width="123"> <p class="MsoNormal">10760 (4470)</p> </td> </tr> <tr style="page-break-inside:avoid;height:23.15pt"> <td style="width:140.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.15pt" valign="top" width="187"> <p class="MsoNormal">6- <span lang="BG">до</span>   11-годишни <sup>†</sup></p> <p class="MsoNormal">(<span lang="RU">≥</span>25 kg)</p> </td> <td style="width:127.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.15pt" valign="top" width="170"> <p class="MsoNormal">150 mg <span lang="BG">на   всеки 12 часа</span></p> </td> <td style="width:92.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.15pt" valign="top" width="123"> <p class="MsoNormal">958 (546)</p> </td> <td style="width:92.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.15pt" valign="top" width="123"> <p class="MsoNormal">15300 (7340)</p> </td> </tr> <tr style="page-break-inside:avoid;height:24.75pt"> <td style="width:140.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:24.75pt" valign="top" width="187"> <p class="MsoNormal">12- <span lang="BG">до</span>   17-годишни</p> </td> <td style="width:127.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:24.75pt" valign="top" width="170"> <p class="MsoNormal">150 mg <span lang="BG">на   всеки 12 часа</span></p> </td> <td style="width:92.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:24.75pt" valign="top" width="123"> <p class="MsoNormal">564 (242)</p> </td> <td style="width:92.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:24.75pt" valign="top" width="123"> <p class="MsoNormal">9240 (3420)</p> </td> </tr> <tr style="page-break-inside:avoid;height:23.15pt"> <td style="width:140.1pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.15pt" valign="top" width="187"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Възрастни</span>   (≥18<span lang="BG">-годишни</span>)</p> </td> <td style="width:127.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.15pt" valign="top" width="170"> <p class="MsoNormal" style="page-break-after:avoid">150 mg<span lang="BG">   на всеки   12 часа</span></p> </td> <td style="width:92.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.15pt" valign="top" width="123"> <p class="MsoNormal" style="page-break-after:avoid">701 (317)</p> </td> <td style="width:92.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:23.15pt" valign="top" width="123"> <p class="MsoNormal" style="page-break-after:avoid">10700 (4100)</p> </td> </tr> </table><p class="MsoNormal" style="margin-top:6.0pt;margin-right:0in;margin-bottom:0in; margin-left:14.2pt;margin-bottom:.0001pt;text-indent:-14.2pt;page-break-after: avoid"><span lang="RU" style="font-size:9.0pt">*</span><span style="font-size: 9.0pt"> </span><span lang="BG" style="font-size:9.0pt">Стойности въз основа на данни от един единствен пациент; стандартни отклонения не се съобщават.</span></p><p class="MsoNormal" style="margin-left:14.2pt;text-indent:-14.2pt"><span style="font-size:9.0pt">†    </span><span lang="BG" style="font-size:9.0pt">Експозициите при</span><span lang="RU" style="font-size:9.0pt"> 6‑ </span><span lang="BG" style="font-size:9.0pt">до</span><span lang="RU" style="font-size:9.0pt"> 11‑годишните </span><span lang="BG" style="font-size:9.0pt">са</span><span lang="RU" style="font-size:9.0pt"> прогнози</span><span lang="BG" style="font-size:9.0pt"> въз основа на симулации от популационния ФК модел с използване на данни, получени за тази възрастова група</span><span lang="RU" style="font-size:9.0pt">.</span></p><p class="labeltext"><u><span lang="BG" style='font-family:"Times New Roman",serif'><span style="text-decoration:none"> </span></span></u></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.3     Предклинични данни за безопасност"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Неклиничните данни не показват особен риск за хора на базата на конвенционалните фармакологични проучвания за безопасност</span><span lang="BG">, проучвания за токсичност при многократно прилагане, генотоксичност и канцерогенен потенциал.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG">Бременност и фертилитет</span></u></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Ивакафтор се свързва с леки понижения на теглото на семенните мехурчета, понижение на индекса на общия фертилитет и броя на бременностите при женските, чифтосани с третирани мъжки, и със значими намаления на броя на жълтите тела и на имплантационните места с последващо намаление на средния брой на малките в поколението и средния брой жизнеспособни ембриони за поколение при третираните женски. Нивото без наблюдавани нежелани ефекти (</span><span lang="EN-GB" style="color:black;background:white">No</span><span lang="EN-GB" style="color:black;background:white"> </span><span lang="EN-GB" style="color: black;background:white">Observed</span><span lang="EN-GB" style="color:black; background:white"> </span><span lang="EN-GB" style="color:black;background:white">Adverse</span><span lang="EN-GB" style="color:black;background:white"> </span><span lang="EN-GB" style="color:black;background:white">Effect</span><span lang="EN-GB" style="color:black;background:white"> </span><span lang="EN-GB" style="color: black;background:white">Level</span><span lang="BG">, </span><span lang="EN-GB">NOAEL</span><span lang="BG">) при находките за фертилитета дава ниво на експозиция приблизително 4</span><span lang="EN-GB"> </span><span lang="BG">пъти системната експозиция на ивакафтор и неговите метаболити, когато се прилага като монотерапия с ивакафтор на възрастни хора при максималната препоръчителна доза за хора (</span><span lang="BG" style="color:black">МПДХ</span><span lang="BG">).</span><span lang="BG"> Преминаване на</span><span lang="BG"> </span><span lang="BG">ивакафтор</span><span lang="BG"> </span><span lang="BG">през плацентата е наблюдавано при бременни плъхове и зайци</span><span lang="BG">.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG">Пери- и постнатално развитие </span></u></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Ивакафтор понижава </span><span lang="BG">индексите за преживяемост и лактация</span><span lang="BG"> и причинява </span><span lang="BG">намаление на телесното тегло на малките. </span><span lang="EN-GB">NOAEL</span><span lang="EN-GB"> </span><span lang="BG">за жизнеспособността и растежа при потомството</span><span lang="BG"> дава ниво на експозиция приблизително 3</span><span lang="EN-GB"> </span><span lang="BG">пъти системната експозиция на ивакафтор и неговите метаболити, когато се прилага като монотерапия с ивакафтор на възрастни хора при МПДХ. </span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="BG">Проучвания при ювенилни животни</span></u></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Находки на катаракта се наблюдават при ювенилни плъхове, третирани след раждането от ден</span><span lang="EN-GB"> </span><span lang="BG">7‑ми до 35‑ти при нива на експозиция на ивакафтор 0,22 пъти </span><span lang="BG" style="color:black">МПДХ</span><span lang="BG"> на базата на системната експозиция на ивакафтор и неговите метаболити, когато се прилага като монотерапия с ивакафтор. Тази находка не е наблюдавана при фетуси, получени от плъхове майки, третирани с ивакафтор, в гестационни дни от 7‑ми до 17‑ти, при малки с експозиция на ивакафтор чрез погълнатото мляко до ден 20‑ти след раждането, при 7‑седмични плъхове или при 3,5‑ до 5‑месечни кучета, третирани с ивакафтор. Потенциалната значимост на тези находки при хората е неизвестна.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="6.       ФАРМАЦЕВТИЧНИ ДАННИ"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="6.1     Списък на помощните вещества"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG"> </span></i></p><p class="MsoNormal"><span lang="BG">Силициев диоксид, колоиден безводен</span></p><p class="MsoNormal"><span lang="BG">Кроскармелоза натрий</span></p><p class="MsoNormal"><span lang="BG">Хипромелозен ацетат сукцинат</span></p><p class="MsoNormal"><span lang="BG">Лактоза монохидрат</span></p><p class="MsoNormal"><span lang="BG">Магнезиев стеарат</span></p><p class="MsoNormal"><span lang="BG">Манитол</span></p><p class="MsoNormal"><span lang="BG">Захароза </span></p><p class="MsoNormal"><span lang="BG">Натриев лаурилсулфат (Е487)</span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.2     Несъвместимости"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Неприложимо</span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.3     Срок на годност"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">3 години</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Доказано е, че след като се смеси, сместа е стабилна в продължение на един час.</span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.4     Специални условия на съхранение"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;page-break-after: avoid"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Този лекарствен продукт не изисква специални условия на съхранение.</span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.5     Вид и съдържание на опаковката"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Гранулите са опаковани в саше от биаксиално ориентиран полиетилен терефталат/полиетилен/фолио /полиетилен </span><span lang="BG">(</span><span lang="EN-GB">BOPET</span><span lang="BG">/</span><span lang="EN-GB">PE</span><span lang="BG">/</span><span lang="EN-GB">Foil</span><span lang="BG">/</span><span lang="EN-GB">PE</span><span lang="BG">).</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Опаковка от 56 сашета (съдържа 4 индивидуални карти тип „портфейл“, всяка с по 14 сашета) </span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.6     Специални предпазни мерки при изхвърляне и работа"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG"> </span></i></p><p class="MsoNormal"><span lang="BG">Неизползваният лекарствен продукт или отпадъчните материали от него трябва да се изхвърлят в съответствие с местните изисквания</span><span lang="BG">.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="7.       ПРИТЕЖАТЕЛ НА РАЗРЕШЕНИЕТО ЗА УПОТРЕБА"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Vertex</span><span lang="EN-GB"> </span><span lang="EN-GB">Pharmaceuticals</span><span lang="BG"> (</span><span lang="EN-GB">Ireland</span><span lang="BG">) </span><span lang="EN-GB">Limited</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">28-32 Pembroke Street Upper</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Dublin 2, D02 EK84</span></p><p class="MsoNormal"><span lang="EN-GB">Ирландия</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="8.       НОМЕР(А) НА РАЗРЕШЕНИЕТО ЗА УПОТРЕБА "/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><i><span lang="BG"> </span></i></p><p class="MsoNormal"><span lang="BG">EU<span style="color:black">/1/12/782/003</span></span></p><p class="MsoNormal"><span lang="EN-GB">EU/1/12/782/004</span></p><p class="MsoNormal"><span lang="EN-GB">EU/1/12/782/006</span></p><p class="MsoNormal"><span lang="EN-GB"> </span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="9.       ДАТА НА ПЪРВО РАЗРЕШАВАНЕ/ПОДНОВЯВАНЕ НА РАЗРЕШЕНИЕТО ЗА УПОТРЕБА"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Дата на първо разрешаване: 23 </span><span lang="BG">юли 2012 г.</span></p><p class="MsoNormal"><span lang="BG">Дата на последно подновяване: 28 април </span><span lang="BG">2017 </span><span lang="BG">г.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="10.     ДАТА НА АКТУАЛИЗИРАНЕ НА ТЕКСТА"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Подробна информация за този лекарствен продукт е предоставена на уебсайта на Европейската агенция по лекарствата</span><span lang="BG"> </span><span lang="EN-GB"><a href="http://www.emea.europa.eu"><span lang="BG">http://www.ema.europa.eu</span></a></span><span lang="BG" style="color:blue">.</span></p><b><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'><br clear="all" style="page-break-before:always"/> </span></b><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'><br clear="all" style="page-break-before:always"/> </span>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
	
</section>
							<!-- sections can repeat as necessary -->
						</Composition>
					</resource>
				</entry>
				
			</Bundle>
		</resource>
	</entry>
</Bundle>